Anti-tumor effect potentiator using a biphenyl compound

MDE20200341A1Undetermined Publication Date: 2020-05-31TAIHO PHARMA CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
MDE20200341T
Authority / Receiving Office
MD · MD
Patent Type
Applications
Current Assignee / Owner
Priority Date
2017-05-26
Filing Date
2018-05-25
Publication Date
2020-05-31

AI Technical Summary

Technical Problem

Current treatments for intractable cancers such as small cell lung cancer and acute myeloid leukemia are ineffective, and there is a need for new therapeutic mechanisms that target LSD1, an enzyme involved in histone methylation and gene regulation, as its abnormalities contribute to cancer development and progression.

Method used

A biphenyl compound or its salt, represented by a specific general formula, is combined with another antitumor agent to enhance antitumor effects by inhibiting LSD1, demonstrating synergistic effects in preclinical models.

Benefits of technology

The combination of the biphenyl compound with other antitumor agents shows excellent antitumor effects while potentially reducing side effects, offering a new therapeutic approach for cancers with poor prognosis.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

An anti-cancer agent containing a biphenyl compound represented by general formula (I) [wherein ring A, ring B, R1 to R6, l, m and n are as defined in the description] and having a LSD1-inhibiting activity or a salt thereof and another anti-tumor agent which are administered in combination.
Need to check novelty before this filing date? Find Prior Art

Description

Antitumor effect enhancer using novel biphenyl compounds

[0001] The present invention relates to an antitumor agent comprising a biphenyl compound or a salt thereof in combination with another antitumor agent, and an agent for enhancing the antitumor effect of another antitumor agent.

[0002] Histone methylation is one of the epigenetic mechanisms that regulates gene expression and regulates various processes such as cell maintenance, proliferation, and differentiation.

[0003] LSD1 (KDM1A), one of the enzymes that regulates histone methylation, is a FAD (flavin adenine dinucleotide)-dependent histone demethylase that primarily demethylates the fourth lysine residue (K4) and the ninth lysine residue (K9) of histone H3 (Non-Patent Document 1). By exerting this function, LSD1 is thought to positively or negatively regulate the transcription of various genes and control stem cell self-renewal and cell differentiation in various normal tissues.

[0004] It is generally believed that abnormalities in cellular self-renewal and differentiation lead to cellular carcinogenesis. Therefore, dysregulation of LSD1, which plays a key role in this process, may be a cause of cellular carcinogenesis. Indeed, numerous reports have documented the overexpression of LSD1 and its correlation with prognosis in various types of solid cancers and hematological cancers (Non-Patent Document 2). Furthermore, LSD1 inhibition has been reported to induce cell differentiation, inhibit proliferation, and exert in vivo antitumor effects in cell lines and non-clinical models derived from several cancer types (Non-Patent Documents 3 and 4), strongly suggesting that LSD1 is one of the important target molecules for cancer therapy. These cancers in which LSD1 is involved, such as small cell lung cancer (SCLC) and acute myeloid leukemia (AML), have extremely short survival times, and existing treatment methods have not provided satisfactory therapeutic effects.

[0005] Based on the above, it is expected that drugs that inhibit LSD1 will provide an effective treatment method based on a new mechanism for intractable cancers for which no treatment currently exists.

[0006] Furthermore, since LSD1 is involved in the programs and functions of nerve cells, it has been reported that it could also be a target for the treatment of diseases other than cancer, such as neurological diseases such as Alzheimer's disease, Huntington's disease, and Rett syndrome (Non-Patent Document 2), as well as herpes virus infections (Non-Patent Document 5) and sickle cell disease (Non-Patent Document 6), in which the involvement of LSD1 function has been suggested.

[0007] Several reports have shown that LSD1 inhibitors combined with other antitumor agents have antitumor effects. For example, the combination of the LSD1 inhibitor SP2509 and the histone deacetylase inhibitor panobinostat has antitumor effects against acute myeloid leukemia (Non-Patent Document 7). Furthermore, the combination of the LSD1 inhibitor INCB059872 and all-trans retinoic acid (ATRA) has antitumor effects against acute myeloid leukemia (Non-Patent Document 8).

[0008] Biochim. Biophys. Acta, 1829(10), P. 981-986 (2013) Epigenomics, 7(4), P. 609-626 (2015) Cancer Cell, 21(4), P. 473-487 (2012) Cancer Cell, 28(1), P. 57-69 (2015) Sci. Transl. Med. , 6 (265), 265ra169 (2014) Nat. Med. , 19(3), P. 291-294 (2013) Leukemia, 28(11), P. 2155-2164 (2014) Cancer Res. , 74 (14 Suppl) Abstract 4696 (2016)

[0009] An object of the present invention is to provide a method for enhancing the antitumor effect of a compound or a salt thereof that strongly inhibits LSD1.

[0010] As a result of intensive investigations aimed at solving the above-mentioned problems, the present inventors have found that a compound represented by the following general formula (I) or a salt thereof has an excellent effect of enhancing the antitumor effect when used in combination with another compound having an antitumor effect (another antitumor agent), and have thus completed the present invention.

[0011] That is, the present invention provides the following aspects: 1. A compound represented by the following general formula (I):

[0012]

[0013] [wherein ring A is a monocyclic, bridged or spirocyclic 4-14 membered nitrogen-containing saturated heterocyclic group having 1 to 3 nitrogen atoms, 0 to 1 sulfur atom and 0 to 2 oxygen atoms as heteroatoms, ring B is a monocyclic or bicyclic 5-14 membered unsaturated heterocyclic group which may be substituted with a monocyclic or bicyclic 5-14 membered unsaturated hydrocarbon group or an oxo group and has 0 to 4 nitrogen atoms, 0 to 2 sulfur atoms and 0 to 3 oxygen atoms as heteroatoms, and at least one nitrogen atom, sulfur atom or oxygen atom, R1 is a nitro group or a cyano group, R2 is a halogen atom, R3 is an amino group, a mono- or di(C1-C6 alkyl)amino group, a (C3-C7 cycloalkyl)amino group or a C1-C6 alkyl group, R4 represents a halogen atom, a nitro group, a cyano group, a carboxy group, an optionally substituted C1-C8 alkyl group, an optionally substituted C2-C6 alkenyl group, an optionally substituted C1-C6 alkoxy group, an optionally substituted C3-C7 cycloalkyl group, a mono- or di(C1-C6 alkyl)amino group, or an optionally substituted carbamoyl group; When at least one R4 is a substituted C1-C8 alkyl group, a substituted C2-C6 alkenyl group, a substituted C1-C6 alkoxy group, a substituted C3-C7 cycloalkyl group, or a substituted carbamoyl group, the substituent is a halogen atom, a carboxy group, a C1-C6 alkoxy group, a hydroxyl group, a C1-C6 alkyl group optionally having a hydroxyl group as a substituent, a monocyclic 5- to 10-membered unsaturated hydrocarbon group, a carbamoyl group optionally having a C1-C6 alkyl group or a monocyclic 5- to 10-membered unsaturated hydrocarbon group as a substituent, a (C2-C7 acyl)oxy group, an amino group optionally having a C1-C6 alkyl group or a C2-C7 acyl group as a substituent, a C3-C7 cycloalkyl group optionally having a hydroxyl group as a substituent, or a (C1-C6 alkoxy)(C1-C6 alkyl) group. When a plurality of such substituents are present, they may be the same or different.R5 and R6 may be the same or different and represent a hydrogen atom or a C1-C6 alkyl group, or R5 and R6 may combine to form an oxo group or a thioxo group; when R5 and R6 are the same or different and represent a hydrogen atom or a C1-C6 alkyl group, at least one of R5 and R6 is a hydrogen atom; 1 represents an integer of 0 to 2; m represents an integer of 0 to 2; and n represents an integer of 0 to 5. When 1 is 2, two R2s may be the same or different. When m is 2, two R3s may be the same or different. When n is 2 to 5, two to five R4s may be the same or different. An antitumor agent characterized by administering a biphenyl compound represented by the formula (I) or a salt thereof in combination with another antitumor agent.

[0014] Item 2. The antitumor agent according to Item 1, wherein the biphenyl compound satisfies the following condition in general formula (I): Ring A is a pyrrolidinyl group, a piperidinyl group, a piperazinyl group, an azepanyl group, a diazepanyl group,

[0015]

[0016] , 2,7-diazaspiro[3.4]octanyl group, 3,7-diazaspiro[3.4]octanyl group, 2,7-diazaspiro[3.5]nonanyl group, 2,8-diazaspiro[3.5]nonanyl group, 3,7-diazaspiro[3.5]nonanyl group, 3,8-diazaspiro[4.4]nonanyl group, 3,8-diazaspiro[4.5]decanyl group, or 9-oxa-diazaspiro[3.5]nonanyl group; Ring B is a phenyl group, a naphthyl group, a pyridyl group, a pyrazolopyridyl group, a pyrazolopyrimidinyl group, an indolyl group, an indolinyl group, a 2-oxo-indolinyl group, an indazolyl group, a benzimidazolyl group, a benzisoxazolyl group, a benzothiazolyl group, a benzotriazolyl group, an imidazopyridinyl group, a quinolinyl group, an isoquinolinyl group, a quinazolinyl group, a quinoxalinyl group, a phthalazinyl group, a 2-oxo-2,3-dihydrobenzo[d]oxazolyl group, a 1,3-dihydroisobenzofuranyl group, a dihydrobenzoxazinyl group, a benzodioxolyl group, a dihydrobenzodioxinyl group, or a 2-oxo-2,a 3-dihydrobenzo[d]thiazolyl group, R1 is a nitro group or a cyano group, R2 is a fluorine atom, R2 is located on the phenyl group at the ortho position relative to R1, R3 is an amino group, a methylamino group, an ethylamino group, an isopropylamino group, a dimethylamino group, a cyclobutylamino group, or a methyl group (when a plurality of R3s are present, the R3s may be the same or different), and R4 is a fluorine atom, a chlorine atom, a bromine atom, an iodine atom, a nitro group, a cyano group, a carboxy group, a methyl group, an ethyl group, an n-propyl group, an isopropyl group, a tert-butyl group, a difluoromethyl group, a trifluoromethyl group, a fluoroethyl group, an aminoethyl group, a hydroxymethyl group, a hydroxyethyl group, a hydroxypropyl group, a hydroxydimethylethyl group, a hydroxymethylpropyl group, a hydroxymethylbutyl group, a hydroxyethylbutyl group, a carboxymethyl group, a carbamoylmethyl group, a methylcarbamoylmethyl group, a dimethylcarbamoylmethyl group, an acetylaminoethyl group, a methoxy ethyl group, hydroxycyclopropylmethyl group, hydroxycyclopropylethyl group, hydroxycyclobutylmethyl group, methylcarbonyloxyethyl group, isobutenyl group, methoxy group, hydroxypropoxy group, cyclopropyl group, hydroxymethylcyclopropyl group, methoxymethylcyclopropyl group, hydroxycyclopropylcyclopropyl group, phenylcarbamoylcyclopropyl group, benzyloxy group, dimethylamino group, carbamoyl group, methylcarbamoyl group, or dimethylcarbamoyl group (when there are multiple R4s, those R4s may be the same or different); R5 and R6 may be the same or different and represent a hydrogen atom or a C1-C6 alkyl group, or R5 and R6 may combine to form an oxo group or a thioxo group; when R5 and R6 are the same or different and represent a hydrogen atom or a C1-C6 alkyl group, at least one of R5 and R6 is a hydrogen atom; and n represents an integer of 0 to 3. When n is 2 or 3, 2 or 3 R4 may be the same or different.

[0017] Item 3. The antitumor agent according to Item 1 or 2, wherein the biphenyl compound is selected from the following (1) to (7):(1) 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile (2) 4-[5-[(3-endo)-3-amino-8-azabicyclo[3.2.1]octane-8-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile (3) 5'-((1S,2S,4R)-rel-2-amino-7-azabicyclo[2.2.1]heptane-7-carbonyl)-2",3-difluoro-4"-(2-hydroxy-2-methylpropyl)-[1,1':2',1"-terphenyl]-4-carbonitrile-isomer-B (4) 5'-((1S,2S,4R)-rel-2-amino-7-azabicyclo[2.2.1]heptane-7-carbonyl)-2'-(6,7-difluoro-1-(2-hydroxy-2-methylpropyl)-1H-benzo[d][1,2,3]triazol-5-yl)-3-fluoro-[1,1'-biphenyl]-4-carbonitrile-isomer-B (5) 5'-((1S,2S,4R)-rel-2-amino-7-azabicyclo[2.2.1]heptane-7-carbonyl)-2'-(1-(2-ethyl-2-hydroxybutyl)-6,7-difluoro-1H-benzo[d][1,2,3]triazol-5-yl)-3-fluoro-[1,1'-biphenyl]-4-carbonitrile-isomer-X (6) 5'-((1S,2S,4R)-rel-2-amino-7-azabicyclo[2.2.1]heptane-7-carbonyl)-2'-(7-bromo-6-fluoro-1-(2-hydroxy-2-methylpropyl)-1H-benzo[d][1,2,3]triazol-5-yl)-3-fluoro-[1,1'-biphenyl]-4-carbonitrile-isomer-X (7) 5'-(((1S,2S,4R)-rel-2-amino-7-azabicyclo[2.2.1]heptan-7-yl)methyl)-2'-(6,7-difluoro-1-(2-hydroxy-2-methylpropyl)-1H-benzo[d][1,2,3]triazol-5-yl)-3-fluoro-[1,1'-biphenyl]-4-carbonitrile-isomer-X.

[0018] Item 4. The antitumor agent according to any one of Items 1 to 3, wherein the other antitumor agent is at least one selected from antimetabolites, antitumor antibiotics, molecular targeted drugs, platinum-based drugs, and plant alkaloid-based drugs.

[0019] Item 5. The antitumor agent according to any one of Items 1 to 3, wherein the other antitumor agent is at least one selected from the group consisting of cytarabine, azacitidine, decitabine, guadecitabine, daunorubicin, tretinoin (ATRA), RG7388, carboplatin, cisplatin, paclitaxel, irinotecan (SN-38), and etoposide.

[0020] Item 6. A compound represented by the following general formula (I):

[0021]

[0022] [wherein ring A is a monocyclic, bridged or spirocyclic 4-14 membered nitrogen-containing saturated heterocyclic group having 1 to 3 nitrogen atoms, 0 to 1 sulfur atom and 0 to 2 oxygen atoms as heteroatoms, ring B is a monocyclic or bicyclic 5-14 membered unsaturated heterocyclic group which may be substituted with a monocyclic or bicyclic 5-14 membered unsaturated hydrocarbon group or an oxo group and has 0 to 4 nitrogen atoms, 0 to 2 sulfur atoms and 0 to 3 oxygen atoms as heteroatoms, and at least one nitrogen atom, sulfur atom or oxygen atom, R1 is a nitro group or a cyano group, R2 is a halogen atom, R3 is an amino group, a mono- or di(C1-C6 alkyl)amino group, a (C3-C7 cycloalkyl)amino group or a C1-C6 alkyl group, R4 represents a halogen atom, a nitro group, a cyano group, a carboxy group, an optionally substituted C1-C8 alkyl group, an optionally substituted C2-C6 alkenyl group, an optionally substituted C1-C6 alkoxy group, an optionally substituted C3-C7 cycloalkyl group, a mono- or di(C1-C6 alkyl)amino group, or an optionally substituted carbamoyl group; When at least one R4 is a substituted C1-C8 alkyl group, a substituted C2-C6 alkenyl group, a substituted C1-C6 alkoxy group, a substituted C3-C7 cycloalkyl group, or a substituted carbamoyl group, the substituent is a halogen atom, a carboxy group, a C1-C6 alkoxy group, a hydroxyl group, a C1-C6 alkyl group optionally having a hydroxyl group as a substituent, a monocyclic 5- to 10-membered unsaturated hydrocarbon group, a carbamoyl group optionally having a C1-C6 alkyl group or a monocyclic 5- to 10-membered unsaturated hydrocarbon group as a substituent, a (C2-C7 acyl)oxy group, an amino group optionally having a C1-C6 alkyl group or a C2-C7 acyl group as a substituent, a C3-C7 cycloalkyl group optionally having a hydroxyl group as a substituent, or a (C1-C6 alkoxy)(C1-C6 alkyl) group. When a plurality of such substituents are present, they may be the same or different.R5 and R6 may be the same or different and represent a hydrogen atom or a C1-C6 alkyl group, or R5 and R6 may combine to form an oxo group or a thioxo group; when R5 and R6 are the same or different and represent a hydrogen atom or a C1-C6 alkyl group, at least one of R5 and R6 is a hydrogen atom; 1 represents an integer of 0 to 2; m represents an integer of 0 to 2; and n represents an integer of 0 to 5. When 1 is 2, two R2s may be the same or different. When m is 2, two R3s may be the same or different. When n is 2 to 5, two to five R4s may be the same or different.

[0023] Item 7. An antitumor agent containing a biphenyl compound or a salt thereof for treating a cancer patient who has been administered another antitumor agent, wherein the biphenyl compound is represented by the following general formula (I):

[0024]

[0025] [wherein ring A is a monocyclic, bridged or spirocyclic 4-14 membered nitrogen-containing saturated heterocyclic group having 1 to 3 nitrogen atoms, 0 to 1 sulfur atom and 0 to 2 oxygen atoms as heteroatoms, ring B is a monocyclic or bicyclic 5-14 membered unsaturated heterocyclic group which may be substituted with a monocyclic or bicyclic 5-14 membered unsaturated hydrocarbon group or an oxo group and has 0 to 4 nitrogen atoms, 0 to 2 sulfur atoms and 0 to 3 oxygen atoms as heteroatoms, and at least one nitrogen atom, sulfur atom or oxygen atom, R1 is a nitro group or a cyano group, R2 is a halogen atom, R3 is an amino group, a mono- or di(C1-C6 alkyl)amino group, a (C3-C7 cycloalkyl)amino group or a C1-C6 alkyl group, R4 represents a halogen atom, a nitro group, a cyano group, a carboxy group, an optionally substituted C1-C8 alkyl group, an optionally substituted C2-C6 alkenyl group, an optionally substituted C1-C6 alkoxy group, an optionally substituted C3-C7 cycloalkyl group, a mono- or di(C1-C6 alkyl)amino group, or an optionally substituted carbamoyl group; When at least one R4 is a substituted C1-C8 alkyl group, a substituted C2-C6 alkenyl group, a substituted C1-C6 alkoxy group, a substituted C3-C7 cycloalkyl group, or a substituted carbamoyl group, the substituent is a halogen atom, a carboxy group, a C1-C6 alkoxy group, a hydroxyl group, a C1-C6 alkyl group optionally having a hydroxyl group as a substituent, a monocyclic 5- to 10-membered unsaturated hydrocarbon group, a carbamoyl group optionally having a C1-C6 alkyl group or a monocyclic 5- to 10-membered unsaturated hydrocarbon group as a substituent, a (C2-C7 acyl)oxy group, an amino group optionally having a C1-C6 alkyl group or a C2-C7 acyl group as a substituent, a C3-C7 cycloalkyl group optionally having a hydroxyl group as a substituent, or a (C1-C6 alkoxy)(C1-C6 alkyl) group. When a plurality of such substituents are present, they may be the same or different.R5 and R6 may be the same or different and represent a hydrogen atom or a C1-C6 alkyl group, or R5 and R6 may combine to form an oxo group or a thioxo group; when R5 and R6 are the same or different and represent a hydrogen atom or a C1-C6 alkyl group, at least one of R5 and R6 is a hydrogen atom; 1 represents an integer of 0 to 2; m represents an integer of 0 to 2; and n represents an integer of 0 to 5. When 1 is 2, two R2s may be the same or different. When m is 2, two R3s may be the same or different. When n is 2 to 5, two to five R4s may be the same or different.

[0026] Item 8. An antitumor agent comprising a biphenyl compound or a salt thereof in combination with another antitumor agent, wherein the biphenyl compound is a compound represented by the following general formula (I):

[0027]

[0028] [wherein ring A is a monocyclic, bridged or spirocyclic 4-14 membered nitrogen-containing saturated heterocyclic group having 1 to 3 nitrogen atoms, 0 to 1 sulfur atom and 0 to 2 oxygen atoms as heteroatoms, ring B is a monocyclic or bicyclic 5-14 membered unsaturated heterocyclic group which may be substituted with a monocyclic or bicyclic 5-14 membered unsaturated hydrocarbon group or an oxo group and has 0 to 4 nitrogen atoms, 0 to 2 sulfur atoms and 0 to 3 oxygen atoms as heteroatoms, and at least one nitrogen atom, sulfur atom or oxygen atom, R1 is a nitro group or a cyano group, R2 is a halogen atom, R3 is an amino group, a mono- or di(C1-C6 alkyl)amino group, a (C3-C7 cycloalkyl)amino group or a C1-C6 alkyl group, R4 represents a halogen atom, a nitro group, a cyano group, a carboxy group, an optionally substituted C1-C8 alkyl group, an optionally substituted C2-C6 alkenyl group, an optionally substituted C1-C6 alkoxy group, an optionally substituted C3-C7 cycloalkyl group, a mono- or di(C1-C6 alkyl)amino group, or an optionally substituted carbamoyl group; When at least one R4 is a substituted C1-C8 alkyl group, a substituted C2-C6 alkenyl group, a substituted C1-C6 alkoxy group, a substituted C3-C7 cycloalkyl group, or a substituted carbamoyl group, the substituent is a halogen atom, a carboxy group, a C1-C6 alkoxy group, a hydroxyl group, a C1-C6 alkyl group optionally having a hydroxyl group as a substituent, a monocyclic 5- to 10-membered unsaturated hydrocarbon group, a carbamoyl group optionally having a C1-C6 alkyl group or a monocyclic 5- to 10-membered unsaturated hydrocarbon group as a substituent, a (C2-C7 acyl)oxy group, an amino group optionally having a C1-C6 alkyl group or a C2-C7 acyl group as a substituent, a C3-C7 cycloalkyl group optionally having a hydroxyl group as a substituent, or a (C1-C6 alkoxy)(C1-C6 alkyl) group. When a plurality of such substituents are present, they may be the same or different.R5 and R6 may be the same or different and represent a hydrogen atom or a C1-C6 alkyl group, or R5 and R6 may combine to form an oxo group or a thioxo group; when R5 and R6 are the same or different and represent a hydrogen atom or a C1-C6 alkyl group, at least one of R5 and R6 is a hydrogen atom, 1 represents an integer of 0 to 2, m represents an integer of 0 to 2, and n represents an integer of 0 to 5. When 1 is 2, two R2s may be the same or different. When m is 2, two R3s may be the same or different. When n is 2 to 5, two to five R4s may be the same or different.

[0029] Item 9. A compound represented by the following general formula (I): [wherein ring A is a monocyclic, bridged or spirocyclic 4-14 membered nitrogen-containing saturated heterocyclic group having 1 to 3 nitrogen atoms, 0 to 1 sulfur atom and 0 to 2 oxygen atoms as heteroatoms, ring B is a monocyclic or bicyclic 5-14 membered unsaturated heterocyclic group which may be substituted with a monocyclic or bicyclic 5-14 membered unsaturated hydrocarbon group or an oxo group and has 0 to 4 nitrogen atoms, 0 to 2 sulfur atoms and 0 to 3 oxygen atoms as heteroatoms, and at least one nitrogen atom, sulfur atom or oxygen atom, R1 is a nitro group or a cyano group, R2 is a halogen atom, R3 is an amino group, a mono- or di(C1-C6 alkyl)amino group, a (C3-C7 cycloalkyl)amino group or a C1-C6 alkyl group, R4 represents a halogen atom, a nitro group, a cyano group, a carboxy group, an optionally substituted C1-C8 alkyl group, an optionally substituted C2-C6 alkenyl group, an optionally substituted C1-C6 alkoxy group, an optionally substituted C3-C7 cycloalkyl group, a mono- or di(C1-C6 alkyl)amino group, or an optionally substituted carbamoyl group; When at least one R4 is a substituted C1-C8 alkyl group, a substituted C2-C6 alkenyl group, a substituted C1-C6 alkoxy group, a substituted C3-C7 cycloalkyl group, or a substituted carbamoyl group, the substituent is a halogen atom, a carboxy group, a C1-C6 alkoxy group, a hydroxyl group, a C1-C6 alkyl group optionally having a hydroxyl group as a substituent, a monocyclic 5- to 10-membered unsaturated hydrocarbon group, a carbamoyl group optionally having a C1-C6 alkyl group or a monocyclic 5- to 10-membered unsaturated hydrocarbon group as a substituent, a (C2-C7 acyl)oxy group, an amino group optionally having a C1-C6 alkyl group or a C2-C7 acyl group as a substituent, a C3-C7 cycloalkyl group optionally having a hydroxyl group as a substituent, or a (C1-C6 alkoxy)(C1-C6 alkyl) group. When a plurality of such substituents are present, they may be the same or different.R5 and R6 may be the same or different and represent a hydrogen atom or a C1-C6 alkyl group, or R5 and R6 may combine to form an oxo group or a thioxo group; when R5 and R6 are the same or different and represent a hydrogen atom or a C1-C6 alkyl group, at least one of R5 and R6 is a hydrogen atom; 1 represents an integer of 0 to 2; m represents an integer of 0 to 2; and n represents an integer of 0 to 5. When 1 is 2, two R2s may be the same or different. When m is 2, two R3s may be the same or different. When n is 2 to 5, two to five R4s may be the same or different. A pharmaceutical composition for preventing and / or treating a tumor, comprising a biphenyl compound represented by the formula (I) or a salt thereof, and another antitumor agent.

[0030] Item 10. A biphenyl compound or a salt thereof for enhancing the antitumor effect of another antitumor agent, the biphenyl compound or a salt thereof being represented by the following general formula (I): [wherein ring A is a monocyclic, bridged or spirocyclic 4-14 membered nitrogen-containing saturated heterocyclic group having 1 to 3 nitrogen atoms, 0 to 1 sulfur atom and 0 to 2 oxygen atoms as heteroatoms, ring B is a monocyclic or bicyclic 5-14 membered unsaturated heterocyclic group which may be substituted with a monocyclic or bicyclic 5-14 membered unsaturated hydrocarbon group or an oxo group and has 0 to 4 nitrogen atoms, 0 to 2 sulfur atoms and 0 to 3 oxygen atoms as heteroatoms, and at least one nitrogen atom, sulfur atom or oxygen atom, R1 is a nitro group or a cyano group, R2 is a halogen atom, R3 is an amino group, a mono- or di(C1-C6 alkyl)amino group, a (C3-C7 cycloalkyl)amino group or a C1-C6 alkyl group, R4 represents a halogen atom, a nitro group, a cyano group, a carboxy group, an optionally substituted C1-C8 alkyl group, an optionally substituted C2-C6 alkenyl group, an optionally substituted C1-C6 alkoxy group, an optionally substituted C3-C7 cycloalkyl group, a mono- or di(C1-C6 alkyl)amino group, or an optionally substituted carbamoyl group; When at least one R4 is a substituted C1-C8 alkyl group, a substituted C2-C6 alkenyl group, a substituted C1-C6 alkoxy group, a substituted C3-C7 cycloalkyl group, or a substituted carbamoyl group, the substituent is a halogen atom, a carboxy group, a C1-C6 alkoxy group, a hydroxyl group, a C1-C6 alkyl group optionally having a hydroxyl group as a substituent, a monocyclic 5- to 10-membered unsaturated hydrocarbon group, a carbamoyl group optionally having a C1-C6 alkyl group or a monocyclic 5- to 10-membered unsaturated hydrocarbon group as a substituent, a (C2-C7 acyl)oxy group, an amino group optionally having a C1-C6 alkyl group or a C2-C7 acyl group as a substituent, a C3-C7 cycloalkyl group optionally having a hydroxyl group as a substituent, or a (C1-C6 alkoxy)(C1-C6 alkyl) group. When a plurality of such substituents are present, they may be the same or different.R5 and R6 may be the same or different and represent a hydrogen atom or a C1-C6 alkyl group, or R5 and R6 may combine to form an oxo group or a thioxo group; when R5 and R6 are the same or different and represent a hydrogen atom or a C1-C6 alkyl group, at least one of R5 and R6 is a hydrogen atom; 1 represents an integer of 0 to 2; m represents an integer of 0 to 2; and n represents an integer of 0 to 5. When 1 is 2, two R2s may be the same or different. When m is 2, two R3s may be the same or different. When n is 2 to 5, two to five R4s may be the same or different.] A biphenyl compound or a salt thereof.

[0031] Item 11. Use of a biphenyl compound or a salt thereof for enhancing the antitumor effect of another antitumor agent, the biphenyl compound being represented by the following general formula (I): [wherein ring A is a monocyclic, bridged or spirocyclic 4-14 membered nitrogen-containing saturated heterocyclic group having 1 to 3 nitrogen atoms, 0 to 1 sulfur atom and 0 to 2 oxygen atoms as heteroatoms, ring B is a monocyclic or bicyclic 5-14 membered unsaturated heterocyclic group which may be substituted with a monocyclic or bicyclic 5-14 membered unsaturated hydrocarbon group or an oxo group and has 0 to 4 nitrogen atoms, 0 to 2 sulfur atoms and 0 to 3 oxygen atoms as heteroatoms, and at least one nitrogen atom, sulfur atom or oxygen atom, R1 is a nitro group or a cyano group, R2 is a halogen atom, R3 is an amino group, a mono- or di(C1-C6 alkyl)amino group, a (C3-C7 cycloalkyl)amino group or a C1-C6 alkyl group, R4 represents a halogen atom, a nitro group, a cyano group, a carboxy group, an optionally substituted C1-C8 alkyl group, an optionally substituted C2-C6 alkenyl group, an optionally substituted C1-C6 alkoxy group, an optionally substituted C3-C7 cycloalkyl group, a mono- or di(C1-C6 alkyl)amino group, or an optionally substituted carbamoyl group; When at least one R4 is a substituted C1-C8 alkyl group, a substituted C2-C6 alkenyl group, a substituted C1-C6 alkoxy group, a substituted C3-C7 cycloalkyl group, or a substituted carbamoyl group, the substituent is a halogen atom, a carboxy group, a C1-C6 alkoxy group, a hydroxyl group, a C1-C6 alkyl group optionally having a hydroxyl group as a substituent, a monocyclic 5- to 10-membered unsaturated hydrocarbon group, a carbamoyl group optionally having a C1-C6 alkyl group or a monocyclic 5- to 10-membered unsaturated hydrocarbon group as a substituent, a (C2-C7 acyl)oxy group, an amino group optionally having a C1-C6 alkyl group or a C2-C7 acyl group as a substituent, a C3-C7 cycloalkyl group optionally having a hydroxyl group as a substituent, or a (C1-C6 alkoxy)(C1-C6 alkyl) group. When a plurality of such substituents are present, they may be the same or different.R5 and R6 may be the same or different and represent a hydrogen atom or a C1-C6 alkyl group, or R5 and R6 may combine to form an oxo group or a thioxo group; when R5 and R6 are the same or different and represent a hydrogen atom or a C1-C6 alkyl group, at least one of R5 and R6 is a hydrogen atom; 1 represents an integer of 0 to 2; m represents an integer of 0 to 2; and n represents an integer of 0 to 5. When 1 is 2, two R2s may be the same or different. When m is 2, two R3s may be the same or different. When n is 2 to 5, two to five R4s may be the same or different.] Use of a biphenyl compound represented by the formula (I) or a salt thereof.

[0032] Item 12. Use of a biphenyl compound or a salt thereof for producing an agent for enhancing the antitumor effect of another antitumor agent, the biphenyl compound being represented by the following general formula (I): [wherein ring A is a monocyclic, bridged or spirocyclic 4-14 membered nitrogen-containing saturated heterocyclic group having 1 to 3 nitrogen atoms, 0 to 1 sulfur atom and 0 to 2 oxygen atoms as heteroatoms, ring B is a monocyclic or bicyclic 5-14 membered unsaturated heterocyclic group which may be substituted with a monocyclic or bicyclic 5-14 membered unsaturated hydrocarbon group or an oxo group and has 0 to 4 nitrogen atoms, 0 to 2 sulfur atoms and 0 to 3 oxygen atoms as heteroatoms, and at least one nitrogen atom, sulfur atom or oxygen atom, R1 is a nitro group or a cyano group, R2 is a halogen atom, R3 is an amino group, a mono- or di(C1-C6 alkyl)amino group, a (C3-C7 cycloalkyl)amino group or a C1-C6 alkyl group, R4 represents a halogen atom, a nitro group, a cyano group, a carboxy group, an optionally substituted C1-C8 alkyl group, an optionally substituted C2-C6 alkenyl group, an optionally substituted C1-C6 alkoxy group, an optionally substituted C3-C7 cycloalkyl group, a mono- or di(C1-C6 alkyl)amino group, or an optionally substituted carbamoyl group; When at least one R4 is a substituted C1-C8 alkyl group, a substituted C2-C6 alkenyl group, a substituted C1-C6 alkoxy group, a substituted C3-C7 cycloalkyl group, or a substituted carbamoyl group, the substituent is a halogen atom, a carboxy group, a C1-C6 alkoxy group, a hydroxyl group, a C1-C6 alkyl group optionally having a hydroxyl group as a substituent, a monocyclic 5- to 10-membered unsaturated hydrocarbon group, a carbamoyl group optionally having a C1-C6 alkyl group or a monocyclic 5- to 10-membered unsaturated hydrocarbon group as a substituent, a (C2-C7 acyl)oxy group, an amino group optionally having a C1-C6 alkyl group or a C2-C7 acyl group as a substituent, a C3-C7 cycloalkyl group optionally having a hydroxyl group as a substituent, or a (C1-C6 alkoxy)(C1-C6 alkyl) group. When a plurality of such substituents are present, they may be the same or different.R5 and R6 may be the same or different and represent a hydrogen atom or a C1-C6 alkyl group, or R5 and R6 may combine to form an oxo group or a thioxo group; when R5 and R6 are the same or different and represent a hydrogen atom or a C1-C6 alkyl group, at least one of R5 and R6 is a hydrogen atom; 1 represents an integer of 0 to 2; m represents an integer of 0 to 2; and n represents an integer of 0 to 5. When 1 is 2, two R2s may be the same or different. When m is 2, two R3s may be the same or different. When n is 2 to 5, two to five R4s may be the same or different.] Use of a biphenyl compound represented by the formula (I) or a salt thereof.

[0033] Item 13. A compound represented by the following general formula (I): [wherein ring A is a monocyclic, bridged or spirocyclic 4-14 membered nitrogen-containing saturated heterocyclic group having 1 to 3 nitrogen atoms, 0 to 1 sulfur atom and 0 to 2 oxygen atoms as heteroatoms, ring B is a monocyclic or bicyclic 5-14 membered unsaturated heterocyclic group which may be substituted with a monocyclic or bicyclic 5-14 membered unsaturated hydrocarbon group or an oxo group and has 0 to 4 nitrogen atoms, 0 to 2 sulfur atoms and 0 to 3 oxygen atoms as heteroatoms, and at least one nitrogen atom, sulfur atom or oxygen atom, R1 is a nitro group or a cyano group, R2 is a halogen atom, R3 is an amino group, a mono- or di(C1-C6 alkyl)amino group, a (C3-C7 cycloalkyl)amino group or a C1-C6 alkyl group, R4 represents a halogen atom, a nitro group, a cyano group, a carboxy group, an optionally substituted C1-C8 alkyl group, an optionally substituted C2-C6 alkenyl group, an optionally substituted C1-C6 alkoxy group, an optionally substituted C3-C7 cycloalkyl group, a mono- or di(C1-C6 alkyl)amino group, or an optionally substituted carbamoyl group; When at least one R4 is a substituted C1-C8 alkyl group, a substituted C2-C6 alkenyl group, a substituted C1-C6 alkoxy group, a substituted C3-C7 cycloalkyl group, or a substituted carbamoyl group, the substituent is a halogen atom, a carboxy group, a C1-C6 alkoxy group, a hydroxyl group, a C1-C6 alkyl group optionally having a hydroxyl group as a substituent, a monocyclic 5- to 10-membered unsaturated hydrocarbon group, a carbamoyl group optionally having a C1-C6 alkyl group or a monocyclic 5- to 10-membered unsaturated hydrocarbon group as a substituent, a (C2-C7 acyl)oxy group, an amino group optionally having a C1-C6 alkyl group or a C2-C7 acyl group as a substituent, a C3-C7 cycloalkyl group optionally having a hydroxyl group as a substituent, or a (C1-C6 alkoxy)(C1-C6 alkyl) group. When a plurality of such substituents are present, they may be the same or different.R5 and R6 may be the same or different and represent a hydrogen atom or a C1-C6 alkyl group, or R5 and R6 may combine to form an oxo group or a thioxo group; when R5 and R6 are the same or different and represent a hydrogen atom or a C1-C6 alkyl group, at least one of R5 and R6 is a hydrogen atom; 1 represents an integer of 0 to 2; m represents an integer of 0 to 2; and n represents an integer of 0 to 5. When 1 is 2, two R2s may be the same or different. When m is 2, two R3s may be the same or different. When n is 2 to 5, two to five R4s may be the same or different. A method for preventing and / or treating a tumor, comprising the step of administering to a patient a therapeutically and / or prophylactically effective amount of a biphenyl compound represented by the formula (I) or a salt thereof in combination with another antitumor agent.

[0034] Item 14. A compound represented by the following general formula (I): [wherein ring A is a monocyclic, bridged or spirocyclic 4-14 membered nitrogen-containing saturated heterocyclic group having 1 to 3 nitrogen atoms, 0 to 1 sulfur atom and 0 to 2 oxygen atoms as heteroatoms, ring B is a monocyclic or bicyclic 5-14 membered unsaturated heterocyclic group which may be substituted with a monocyclic or bicyclic 5-14 membered unsaturated hydrocarbon group or an oxo group and has 0 to 4 nitrogen atoms, 0 to 2 sulfur atoms and 0 to 3 oxygen atoms as heteroatoms, and at least one nitrogen atom, sulfur atom or oxygen atom, R1 is a nitro group or a cyano group, R2 is a halogen atom, R3 is an amino group, a mono- or di(C1-C6 alkyl)amino group, a (C3-C7 cycloalkyl)amino group or a C1-C6 alkyl group, R4 represents a halogen atom, a nitro group, a cyano group, a carboxy group, an optionally substituted C1-C8 alkyl group, an optionally substituted C2-C6 alkenyl group, an optionally substituted C1-C6 alkoxy group, an optionally substituted C3-C7 cycloalkyl group, a mono- or di(C1-C6 alkyl)amino group, or an optionally substituted carbamoyl group; When at least one R4 is a substituted C1-C8 alkyl group, a substituted C2-C6 alkenyl group, a substituted C1-C6 alkoxy group, a substituted C3-C7 cycloalkyl group, or a substituted carbamoyl group, the substituent is a halogen atom, a carboxy group, a C1-C6 alkoxy group, a hydroxyl group, a C1-C6 alkyl group optionally having a hydroxyl group as a substituent, a monocyclic 5- to 10-membered unsaturated hydrocarbon group, a carbamoyl group optionally having a C1-C6 alkyl group or a monocyclic 5- to 10-membered unsaturated hydrocarbon group as a substituent, a (C2-C7 acyl)oxy group, an amino group optionally having a C1-C6 alkyl group or a C2-C7 acyl group as a substituent, a C3-C7 cycloalkyl group optionally having a hydroxyl group as a substituent, or a (C1-C6 alkoxy)(C1-C6 alkyl) group. When a plurality of such substituents are present, they may be the same or different.R5 and R6 may be the same or different and represent a hydrogen atom or a C1-C6 alkyl group, or R5 and R6 may combine to form an oxo group or a thioxo group; when R5 and R6 are the same or different and represent a hydrogen atom or a C1-C6 alkyl group, at least one of R5 and R6 is a hydrogen atom; 1 represents an integer of 0 to 2; m represents an integer of 0 to 2; and n represents an integer of 0 to 5. When 1 is 2, two R2s may be the same or different. When m is 2, two R3s may be the same or different. When n is 2 to 5, two to five R4s may be the same or different.

[0035] Item 15. A compound represented by the following general formula (I): [wherein ring A is a monocyclic, bridged or spirocyclic 4-14 membered nitrogen-containing saturated heterocyclic group having 1 to 3 nitrogen atoms, 0 to 1 sulfur atom and 0 to 2 oxygen atoms as heteroatoms, ring B is a monocyclic or bicyclic 5-14 membered unsaturated heterocyclic group which may be substituted with a monocyclic or bicyclic 5-14 membered unsaturated hydrocarbon group or an oxo group and has 0 to 4 nitrogen atoms, 0 to 2 sulfur atoms and 0 to 3 oxygen atoms as heteroatoms, and at least one nitrogen atom, sulfur atom or oxygen atom, R1 is a nitro group or a cyano group, R2 is a halogen atom, R3 is an amino group, a mono- or di(C1-C6 alkyl)amino group, a (C3-C7 cycloalkyl)amino group or a C1-C6 alkyl group, R4 represents a halogen atom, a nitro group, a cyano group, a carboxy group, an optionally substituted C1-C8 alkyl group, an optionally substituted C2-C6 alkenyl group, an optionally substituted C1-C6 alkoxy group, an optionally substituted C3-C7 cycloalkyl group, a mono- or di(C1-C6 alkyl)amino group, or an optionally substituted carbamoyl group; When at least one R4 is a substituted C1-C8 alkyl group, a substituted C2-C6 alkenyl group, a substituted C1-C6 alkoxy group, a substituted C3-C7 cycloalkyl group, or a substituted carbamoyl group, the substituent is a halogen atom, a carboxy group, a C1-C6 alkoxy group, a hydroxyl group, a C1-C6 alkyl group optionally having a hydroxyl group as a substituent, a monocyclic 5- to 10-membered unsaturated hydrocarbon group, a carbamoyl group optionally having a C1-C6 alkyl group or a monocyclic 5- to 10-membered unsaturated hydrocarbon group as a substituent, a (C2-C7 acyl)oxy group, an amino group optionally having a C1-C6 alkyl group or a C2-C7 acyl group as a substituent, a C3-C7 cycloalkyl group optionally having a hydroxyl group as a substituent, or a (C1-C6 alkoxy)(C1-C6 alkyl) group. When a plurality of such substituents are present, they may be the same or different.R5 and R6 may be the same or different and represent a hydrogen atom or a C1-C6 alkyl group, or R5 and R6 may combine to form an oxo group or a thioxo group; when R5 and R6 are the same or different and represent a hydrogen atom or a C1-C6 alkyl group, at least one of R5 and R6 is a hydrogen atom; 1 represents an integer of 0 to 2; m represents an integer of 0 to 2; and n represents an integer of 0 to 5. When 1 is 2, two R2s may be the same or different. When m is 2, two R3s may be the same or different. When n is 2 to 5, two to five R4s may be the same or different. A method for enhancing an antitumor effect, comprising the step of administering a therapeutically and / or prophylactically effective amount of a biphenyl compound represented by the following formula (I):

[0036] Item 16. A product comprising a biphenyl compound or a salt thereof and another antitumor agent as a combined preparation for simultaneous, sequential, or interval use in preventing and / or treating tumors, wherein the biphenyl compound is represented by the following general formula (I): [wherein ring A is a monocyclic, bridged or spirocyclic 4-14 membered nitrogen-containing saturated heterocyclic group having 1 to 3 nitrogen atoms, 0 to 1 sulfur atom and 0 to 2 oxygen atoms as heteroatoms, ring B is a monocyclic or bicyclic 5-14 membered unsaturated heterocyclic group which may be substituted with a monocyclic or bicyclic 5-14 membered unsaturated hydrocarbon group or an oxo group and has 0 to 4 nitrogen atoms, 0 to 2 sulfur atoms and 0 to 3 oxygen atoms as heteroatoms, and at least one nitrogen atom, sulfur atom or oxygen atom, R1 is a nitro group or a cyano group, R2 is a halogen atom, R3 is an amino group, a mono- or di(C1-C6 alkyl)amino group, a (C3-C7 cycloalkyl)amino group or a C1-C6 alkyl group, R4 represents a halogen atom, a nitro group, a cyano group, a carboxy group, an optionally substituted C1-C8 alkyl group, an optionally substituted C2-C6 alkenyl group, an optionally substituted C1-C6 alkoxy group, an optionally substituted C3-C7 cycloalkyl group, a mono- or di(C1-C6 alkyl)amino group, or an optionally substituted carbamoyl group; When at least one R4 is a substituted C1-C8 alkyl group, a substituted C2-C6 alkenyl group, a substituted C1-C6 alkoxy group, a substituted C3-C7 cycloalkyl group, or a substituted carbamoyl group, the substituent is a halogen atom, a carboxy group, a C1-C6 alkoxy group, a hydroxyl group, a C1-C6 alkyl group optionally having a hydroxyl group as a substituent, a monocyclic 5- to 10-membered unsaturated hydrocarbon group, a carbamoyl group optionally having a C1-C6 alkyl group or a monocyclic 5- to 10-membered unsaturated hydrocarbon group as a substituent, a (C2-C7 acyl)oxy group, an amino group optionally having a C1-C6 alkyl group or a C2-C7 acyl group as a substituent, a C3-C7 cycloalkyl group optionally having a hydroxyl group as a substituent, or a (C1-C6 alkoxy)(C1-C6 alkyl) group. When a plurality of such substituents are present, they may be the same or different.R5 and R6 may be the same or different and represent a hydrogen atom or a C1-C6 alkyl group, or R5 and R6 may combine to form an oxo group or a thioxo group; when R5 and R6 are the same or different and represent a hydrogen atom or a C1-C6 alkyl group, at least one of R5 and R6 is a hydrogen atom; 1 represents an integer of 0 to 2; m represents an integer of 0 to 2; and n represents an integer of 0 to 5. When 1 is 2, the two R2s may be the same or different. When m is 2, the two R3s may be the same or different. When n is 2 to 5, the two to five R4s may be the same or different.]

[0037] Item 17. A compound represented by the following general formula (I): [wherein ring A is a monocyclic, bridged or spirocyclic 4-14 membered nitrogen-containing saturated heterocyclic group having 1 to 3 nitrogen atoms, 0 to 1 sulfur atom and 0 to 2 oxygen atoms as heteroatoms, ring B is a monocyclic or bicyclic 5-14 membered unsaturated heterocyclic group which may be substituted with a monocyclic or bicyclic 5-14 membered unsaturated hydrocarbon group or an oxo group and has 0 to 4 nitrogen atoms, 0 to 2 sulfur atoms and 0 to 3 oxygen atoms as heteroatoms, and at least one nitrogen atom, sulfur atom or oxygen atom, R1 is a nitro group or a cyano group, R2 is a halogen atom, R3 is an amino group, a mono- or di(C1-C6 alkyl)amino group, a (C3-C7 cycloalkyl)amino group or a C1-C6 alkyl group, R4 represents a halogen atom, a nitro group, a cyano group, a carboxy group, an optionally substituted C1-C8 alkyl group, an optionally substituted C2-C6 alkenyl group, an optionally substituted C1-C6 alkoxy group, an optionally substituted C3-C7 cycloalkyl group, a mono- or di(C1-C6 alkyl)amino group, or an optionally substituted carbamoyl group; When at least one R4 is a substituted C1-C8 alkyl group, a substituted C2-C6 alkenyl group, a substituted C1-C6 alkoxy group, a substituted C3-C7 cycloalkyl group, or a substituted carbamoyl group, the substituent is a halogen atom, a carboxy group, a C1-C6 alkoxy group, a hydroxyl group, a C1-C6 alkyl group optionally having a hydroxyl group as a substituent, a monocyclic 5- to 10-membered unsaturated hydrocarbon group, a carbamoyl group optionally having a C1-C6 alkyl group or a monocyclic 5- to 10-membered unsaturated hydrocarbon group as a substituent, a (C2-C7 acyl)oxy group, an amino group optionally having a C1-C6 alkyl group or a C2-C7 acyl group as a substituent, a C3-C7 cycloalkyl group optionally having a hydroxyl group as a substituent, or a (C1-C6 alkoxy)(C1-C6 alkyl) group. When a plurality of such substituents are present, they may be the same or different.R5 and R6 may be the same or different and represent a hydrogen atom or a C1-C6 alkyl group, or R5 and R6 may combine to form an oxo group or a thioxo group; when R5 and R6 are the same or different and represent a hydrogen atom or a C1-C6 alkyl group, at least one of R5 and R6 is a hydrogen atom; 1 represents an integer of 0 to 2; m represents an integer of 0 to 2; and n represents an integer of 0 to 5. When 1 is 2, two R2s may be the same or different. When m is 2, two R3s may be the same or different. When n is 2 to 5, two to five R4s may be the same or different.] A combination of a biphenyl compound represented by the formula (I) or a salt thereof with another antitumor agent.

[0038] According to the present invention, it is possible to perform cancer treatment that exhibits excellent antitumor effects while suppressing the onset of side effects.

[0039] In the present invention, the LSD1 inhibitor that exhibits excellent synergistic effects with other antitumor agents is a biphenyl compound represented by the following general formula (I) or a salt thereof.

[0040] (In the formula, ring A, ring B, R1 to R6, l, m, and n are as defined above.)

[0041] Unless otherwise specified in the present specification, examples of the "substituent" include a halogen atom, a hydroxyl group, a cyano group, a nitro group, an alkyl group, a hydroxyalkyl group, a halogenoalkyl group, a cycloalkyl group, a hydroxycycloalkyl group, a cycloalkyl-alkyl group, an aralkyl group, an alkenyl group, an alkynyl group, an alkoxy group, a halogenoalkoxy group, a cycloalkoxy group, a cycloalkyl-alkoxy group, an unsaturated hydrocarbon ring-alkoxy group, an alkylthio group, a cycloalkyl-alkylthio group, an amino group, a mono- or dialkylamino group, a cycloalkylamino group, a cycloalkyl-alkylamino group, an acyl group, an acyloxy group, an oxo group, a carboxyl group, an alkoxycarbonyl group, an aralkyloxycarbonyl group, a carbamoyl group which may have an unsaturated hydrocarbon ring group as a substituent, a saturated or unsaturated heterocyclic group, an unsaturated hydrocarbon ring group (such as an aromatic hydrocarbon group), a saturated heterocyclic oxy group, and the like. When the substituent is present, the number of the substituent is typically one, two, or three.

[0042] In the present specification, the term "halogen atom" includes a fluorine atom, a chlorine atom, a bromine atom, an iodine atom, etc., and is preferably a fluorine atom, a chlorine atom, a bromine atom or an iodine atom, and more preferably a fluorine atom or a chlorine atom.

[0043] In the present specification, the "alkyl group" may be either a straight-chain or branched-chain group, and examples thereof include C1-C6 alkyl groups such as a methyl group, ethyl group, n-propyl group, isopropyl group, n-butyl group, isobutyl group, sec-butyl group, tert-butyl group, n-pentyl group, isopentyl group, tert-pentyl group, and n-hexyl group.

[0044] In the present specification, examples of a "hydroxyalkyl group" include the alkyl groups listed above that have at least one hydroxyl group (e.g., one or two). Specific examples include a hydroxymethyl group, a 2-hydroxyethyl group, a 1-hydroxyethyl group, a 3-hydroxypropyl group, a 2-hydroxypropyl group, a 1-methyl-2-hydroxyethyl group, a 4-hydroxybutyl group, a 2,2-dimethyl-2-hydroxyethyl group, a 5-hydroxypentyl group, a 3,3-dimethyl-3-hydroxypropyl group, a 6-hydroxyhexyl group, a dihydroxymethyl group, a 1,2-dihydroxyethyl group, a 2,3-dihydroxypropyl group, a 3,4-dihydroxybutyl group, a 4,5-dihydroxypentyl group, and a 5,6-dihydroxyhexyl group, with a hydroxyalkyl group having one hydroxyl group being preferred.

[0045] In the present specification, the "halogenoalkyl group" refers to a linear or branched alkyl group having 1 to 6 carbon atoms and having 1 to 13 halogen atoms (halogeno-C1-C6 alkyl group), and examples thereof include a halogeno-C1-C6 alkyl group such as a fluoromethyl group, a difluoromethyl group, a trifluoromethyl group, a trichloromethyl group, a fluoroethyl group, a 1,1,1-trifluoroethyl group, a monofluoro-n-propyl group, a perfluoro-n-propyl group, and a perfluoroisopropyl group, and preferably a halogeno-C1-C4 alkyl group, and more preferably a halogeno-C1-C4 alkyl group having 1 to 7 halogen atoms.

[0046] In the present specification, specific examples of the "cycloalkyl group" include C3-C7 cycloalkyl groups such as cyclopropyl group, cyclobutyl group, cyclopentyl group, cyclohexyl group, and cycloheptyl group.

[0047] As used herein, examples of a "hydroxycycloalkyl group" include the above-listed C3-C7 cycloalkyl groups having at least one hydroxyl group (e.g., one or two). Specific examples include a 1-hydroxycyclopropyl group, a 2-hydroxycyclopropyl group, a 1-hydroxycyclobutyl group, a 3-hydroxycyclobutyl group, a 1-hydroxycyclopentyl group, a 3,4-dihydroxycyclopentyl group, a 1-hydroxycyclohexyl group, a 4-hydroxycyclohexyl group, and a 1-hydroxycycloheptyl group, and preferably a hydroxycycloalkyl group having one hydroxyl group.

[0048] As used herein, the term "cycloalkyl-alkyl group" includes C3-C7 cycloalkyl-substituted C1-C4 alkyl groups such as cyclopropylmethyl group, cyclobutylmethyl group, cyclopentylmethyl group, cyclohexylmethyl group, and cycloheptylmethyl group.

[0049] In this specification, examples of the "aralkyl group" include C7-C13 aralkyl groups such as benzyl, phenethyl, naphthylmethyl, and fluorenylmethyl.

[0050] As used herein, the term "alkenyl group" refers to an unsaturated hydrocarbon group which may be straight-chained, branched-chained, or cyclic and has at least one double bond (for example, one or two), and examples thereof include C2-C6 alkenyl groups such as vinyl, allyl, 1-propenyl, 2-methyl-2-propenyl, isopropenyl, 1-butenyl, 2-butenyl, 3-butenyl, isobutenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 2-methyl-2-butenyl, 3-methyl-2-butenyl, 5-hexenyl, 1-cyclopentenyl, 1-cyclohexenyl, and 3-methyl-3-butenyl.

[0051] As used herein, the term "alkynyl group" refers to an unsaturated hydrocarbon group which may be straight-chained, branched-chained, or cyclic and has at least one triple bond (e.g., one or two), and examples thereof include C2-C6 alkynyl groups such as ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl, and 1-methyl-2-propynyl.

[0052] In the present specification, the "alkoxy group" may be either a straight-chain or branched-chain alkoxy group, and examples thereof include C1-C6 alkoxy groups such as a methoxy group, ethoxy group, n-propoxy group, isopropoxy group, n-butoxy group, isobutoxy group, sec-butoxy group, tert-butoxy group, pentyloxy group, isopentyloxy group, and hexyloxy group.

[0053] In the present specification, the term "halogenoalkoxy group" refers to a linear or branched alkoxy group having 1 to 6 carbon atoms and 1 to 13 halogen atoms (halogeno C1-C6 alkoxy group), and examples thereof include halogeno C1-C6 alkoxy groups such as a fluoromethoxy group, a difluoromethoxy group, a trifluoromethoxy group, a trichloromethoxy group, a fluoroethoxy group, a 1,1,1-trifluoroethoxy group, a monofluoro-n-propoxy group, a perfluoro-n-propoxy group, and a perfluoro-isopropoxy group, preferably a halogeno C1-C4 alkoxy group, and more preferably a halogeno C1-C4 alkoxy group having 1 to 7 halogen atoms.

[0054] As used herein, the term "cycloalkoxy group" includes C3-C7 cycloalkoxy groups such as cyclopropoxy group, cyclobutoxy group, cyclopentyloxy group, cyclohexyloxy group, and cycloheptyloxy group.

[0055] As used herein, the term "cycloalkyl-alkoxy group" includes C3-C7 cycloalkyl-substituted C1-C4 alkoxy groups such as cyclopropylmethoxy group, cyclobutylmethoxy group, cyclopentylmethoxy group, cyclohexylmethoxy group, and cycloheptylmethoxy group.

[0056] As used herein, the "alkylthio group" may be either a straight-chain or branched-chain alkylthio group, and examples thereof include C1-C6 alkylthio groups such as a methylthio group, an ethylthio group, an n-propylthio group, an isopropylthio group, an n-butylthio group, an isobutylthio group, a tert-butylthio group, an n-pentylthio group, an isopentylthio group, and a hexylthio group.

[0057] As used herein, examples of the "cycloalkyl-alkylthio group" include C3-C7 cycloalkyl-substituted C1-C4 alkylthio groups such as a cyclopropylmethylthio group, a cyclobutylmethylthio group, a cyclopentylmethylthio group, a cyclohexylmethylthio group, and a cycloheptylmethylthio group.

[0058] As used herein, examples of the "monoalkylamino group" include amino groups mono-substituted with a straight-chain or branched C1-C6 alkyl group, such as a methylamino group, ethylamino group, n-propylamino group, isopropylamino group, n-butylamino group, isobutylamino group, tert-butylamino group, n-pentylamino group, isopentylamino group, and hexylamino group.

[0059] As used herein, examples of the "dialkylamino group" include amino groups di-substituted with the same or different linear or branched C1-C6 alkyl groups, such as a dimethylamino group, diethylamino group, di(n-propyl)amino group, diisopropylamino group, di(n-butyl)amino group, diisobutylamino group, di(tert-butyl)amino group, di(n-pentyl)amino group, diisopentylamino group, dihexylamino group, methylethylamino group, and methylisopropylamino group.

[0060] As used herein, the term "cycloalkylamino group" includes, for example, an amino group having one or two of the above-listed cycloalkyl groups, etc. Specific examples include N-cyclopropylamino, N,N-dicyclopropylamino, N-cyclobutylamino, N-cyclopentylamino, N-cyclohexylamino, N-cycloheptylamino, etc.

[0061] As used herein, examples of the "cycloalkyl-alkylamino group" include C3-C7 cycloalkyl-substituted C1-C4 alkylamino groups such as cyclopropylmethylamino group, cyclobutylmethylamino group, cyclopentylmethylamino group, cyclohexylmethylamino group and cycloheptylmethylamino group.

[0062] In this specification, the term "acyl group" refers to an alkylcarbonyl group or an arylcarbonyl group.

[0063] As used herein, examples of an "alkylcarbonyl group" include straight-chain or branched-chain (C1-C6 alkyl)carbonyl groups such as a methylcarbonyl group, ethylcarbonyl group, n-propylcarbonyl group, isopropylcarbonyl group, n-butylcarbonyl group, isobutylcarbonyl group, tert-butylcarbonyl group, n-pentylcarbonyl group, isopentylcarbonyl group, and hexylcarbonyl group.

[0064] As used herein, the term "arylcarbonyl group" includes (C6-C13 aryl)carbonyl groups such as a phenylcarbonyl group, naphthylcarbonyl group, fluorenylcarbonyl group, anthrylcarbonyl group, biphenylylcarbonyl group, tetrahydronaphthylcarbonyl group, chromanylcarbonyl group, 2,3-dihydro-1,4-dioxanaphthalenylcarbonyl group, indanylcarbonyl group, and phenanthrylcarbonyl group.

[0065] As used herein, the term "acylamino group" refers to an alkylcarbonylamino group or an arylcarbonylamino group.

[0066] As used herein, examples of the "alkylcarbonylamino group" include straight-chain or branched-chain (C1-C6 alkyl)carbonylamino groups such as a methylcarbonylamino group, ethylcarbonylamino group, n-propylcarbonylamino group, isopropylcarbonylamino group, n-butylcarbonylamino group, isobutylcarbonylamino group, tert-butylcarbonylamino group, n-pentylcarbonylamino group, isopentylcarbonylamino group, and hexylcarbonylamino group.

[0067] As used herein, examples of the "arylcarbonylamino group" include (C6-C13 aryl)carbonylamino groups such as a phenylcarbonylamino group, a naphthylcarbonylamino group, a fluorenylcarbonylamino group, an anthrylcarbonylamino group, a biphenylylcarbonylamino group, a tetrahydronaphthylcarbonylamino group, a chromanylcarbonylamino group, a 2,3-dihydro-1,4-dioxanaphthalenylcarbonylamino group, an indanylcarbonylamino group, and a phenanthrylcarbonylamino group.

[0068] In this specification, the term "acyloxy group" refers to an alkylcarbonyloxy group or an arylcarbonyloxy group.

[0069] As used herein, examples of the "alkylcarbonyloxy group" include straight-chain or branched-chain (C1-C6 alkyl)carbonyloxy groups such as a methylcarbonyloxy group, ethylcarbonyloxy group, n-propylcarbonyloxy group, isopropylcarbonyloxy group, n-butylcarbonyloxy group, isobutylcarbonyloxy group, tert-butylcarbonyloxy group, n-pentylcarbonyloxy group, isopentylcarbonyloxy group, and hexylcarbonyloxy group.

[0070] As used herein, examples of the "arylcarbonyloxy group" include (C6-C13 aryl)carbonyloxy groups such as a phenylcarbonyloxy group, a naphthylcarbonyloxy group, a fluorenylcarbonyloxy group, an anthrylcarbonyloxy group, a biphenylylcarbonyloxy group, a tetrahydronaphthylcarbonyloxy group, a chromanylcarbonyloxy group, a 2,3-dihydro-1,4-dioxanaphthalenylcarbonyloxy group, an indanylcarbonyloxy group, and a phenanthrylcarbonyloxy group.

[0071] In the present specification, the "alkoxycarbonyl group" may be either a straight-chain or branched-chain alkoxycarbonyl group, and examples thereof include (C1-C6 alkoxy)carbonyl groups such as a methoxycarbonyl group, ethoxycarbonyl group, propoxycarbonyl group, isopropoxycarbonyl group, butoxycarbonyl group, isobutoxycarbonyl group, tert-butoxycarbonyl group, pentyloxycarbonyl group, isopentyloxycarbonyl group, and hexyloxycarbonyl group.

[0072] As used herein, examples of the "aralkyloxycarbonyl group" include (C7-C13 aralkyl)oxycarbonyl groups such as a benzyloxycarbonyl group, a phenethyloxycarbonyl group, a naphthylmethyloxycarbonyl group, and a fluorenylmethyloxycarbonyl group.

[0073] In the present specification, the term "saturated heterocyclic group" refers to a monocyclic or polycyclic saturated heterocyclic group having at least one heteroatom (preferably 1 to 3) selected from a nitrogen atom, an oxygen atom, and a sulfur atom, and specific examples thereof include a morpholinyl group, a pyrrolidinyl group, a piperidinyl group, a piperazinyl group, an azepanyl group, a diazepanyl group, a tetrahydrofuranyl group, a tetrahydropyranyl group, a tetrahydrothiophenyl group, a thiazolidinyl group, and an oxazolidinyl group.

[0074] In the present specification, the term "unsaturated heterocyclic group" refers to a monocyclic or polycyclic, fully unsaturated or partially unsaturated heterocyclic group having at least one heteroatom (preferably 1 to 3) selected from a nitrogen atom, an oxygen atom, and a sulfur atom, and specifically includes an imidazolyl group, a thienyl group, a furyl group, a pyrrolyl group, an oxazolyl group, an isoxazolyl group, a thiazolyl group, an isothiazolyl group, a thiadiazolyl group, a pyrazolyl group, a triazolyl group, a tetrazolyl group, a pyridyl group, a pyrazyl group, a pyrimidinyl group, a pyridazinyl group, a pyrazolopyridyl group, a pyrazol ... Examples thereof include an azolopyrimidinyl group, an indolyl group, an isoindolyl group, an indazolyl group, a triazolopyridyl group, a benzimidazolyl group, a benzoxazolyl group, a benzisoxazolyl group, a benzothiazolyl group, a benzothienyl group, a benzofuranyl group, a 1,3-dihydroisobenzofuranyl group, a purinyl group, a benzotriazolyl group, an imidazopyridinyl group, a quinolinyl group, an isoquinolinyl group, a quinazolinyl group, a quinoxalinyl group, a phthalazinyl group, a methylenedioxyphenyl group, an ethylenedioxyphenyl group, and a dihydrobenzofuranyl group.

[0075] In the present specification, examples of the "unsaturated hydrocarbon ring group" include a hydrocarbon ring having 5 to 14 carbon atoms and consisting of a single ring or multiple rings, which has at least one unsaturated bond (e.g., 1 to 8 unsaturated bonds), and is preferably an aromatic hydrocarbon group, or a monocyclic or bicyclic 5- to 14-membered unsaturated hydrocarbon group.

[0076] In the present specification, examples of the "aromatic hydrocarbon group" include C6-C14 aromatic hydrocarbon groups such as phenyl group, naphthyl group, anthracenyl group, phenanthryl group, fluorenyl group, and tetrahydronaphthyl group.

[0077] In the present specification, examples of the "monocyclic or bicyclic 5- to 14-membered unsaturated hydrocarbon group" include a cyclopentadienyl group, a phenyl group, a naphthyl group, a tetrahydronaphthyl group, an azulenyl group, and a heptalenyl group.

[0078] In the present specification, examples of the "monocyclic 5- to 10-membered unsaturated hydrocarbon group" include a cyclopentadienyl group, a phenyl group, and a cyclooctatetraenyl group.

[0079] In the present specification, the term "saturated heterocyclic oxy group" refers to a saturated heterocyclic oxy group having a heteroatom selected from a nitrogen atom, an oxygen atom, and a sulfur atom. Specific examples include a morpholinyloxy group, a 1-pyrrolidinyloxy group, a piperidinyloxy group, a piperazinyloxy group, a 4-methyl-1-piperazinyloxy group, a tetrahydrofuranyloxy group, a tetrahydropyranyloxy group, a tetrahydrothiophenyloxy group, a thiazolidinyloxy group, and an oxazolidinyloxy group. A saturated heterocyclic oxy group having 1 to 3 heteroatoms selected from a nitrogen atom, an oxygen atom, and a sulfur atom is preferred.

[0080] In the description of groups in this specification, "CA-CB" indicates that the group has A to B carbon atoms. For example, a "C1-C6 alkyl group" indicates an alkyl group having 1 to 6 carbon atoms, and a "C6-C14 aromatic hydrocarbon oxy group" indicates an oxy group to which an aromatic hydrocarbon group having 6 to 14 carbon atoms is bonded. Furthermore, an "A- to B-membered ring" indicates that the number of atoms constituting the ring (number of ring members) is A to B. For example, a "4- to 10-membered nitrogen-containing saturated heterocyclic group" means a nitrogen-containing saturated heterocyclic group having 4 to 10 ring members.

[0081] In the compound represented by general formula (I), ring A represents a saturated heterocyclic group having a nitrogen atom, which may be bridged or may form a spiro ring. As shown in the general formula (I), the nitrogen atom of ring A is bonded to a carbonyl group, a carbothionyl group, or a methylene group.

[0082] Examples of the "monocyclic nitrogen-containing saturated heterocyclic group" in the "monocyclic, bridged, or spirocyclic nitrogen-containing saturated heterocyclic group" represented by ring A include saturated heterocyclic groups having a monocyclic nitrogen atom, such as a pyrrolidinyl group, a piperidinyl group, a piperazinyl group, an azepanyl group, and a diazepanyl group, and are preferably monocyclic nitrogen-containing saturated heterocyclic groups having 1 to 3 nitrogen atoms, 0 to 1 sulfur atom, and 0 to 2 oxygen atoms as heteroatoms, and more preferably 1 to 2 nitrogen atoms as heteroatoms. more preferably a monocyclic 4- to 10-membered nitrogen-containing saturated heterocyclic group having 1 or 2 nitrogen atoms as heteroatoms; more preferably a pyrrolidinyl group, piperidinyl group, piperazinyl group, azepanyl group, or diazepanyl group; more preferably a pyrrolidinyl group, piperidinyl group, azepanyl group, or diazepanyl group; more preferably a pyrrolidinyl group or diazepanyl group; more preferably a pyrrolidinyl group.

[0083] The "bridged nitrogen-containing saturated heterocyclic group" in the "monocyclic, bridged or spirocyclic nitrogen-containing saturated heterocyclic group" represented by ring A includes:

[0084]

[0085] and the like, and preferably

[0086]

[0087] and more preferably

[0088]

[0089] and more preferably

[0090]

[0091] and more preferably

[0092]

[0093] and more preferably

[0094]

[0095] is.

[0096] Examples of the "spirocyclic nitrogen-containing saturated heterocyclic group" in the "monocyclic, bridged or spirocyclic nitrogen-containing saturated heterocyclic group" represented by ring A include a spirocyclic group having 0 to 2 oxygen atoms bonded to any two 4- to 7-membered nitrogen-containing saturated heterocyclic rings, preferably a 7- to 12-membered spirocyclic group having 2 nitrogen atoms bonded to any two 4- to 7-membered nitrogen-containing saturated heterocyclic rings and 0 to 1 oxygen atom, more preferably a diazaspiroheptanyl group, A diazaspirooctanyl group, a diazaspirononanyl group, a diazaspirodecanyl group, a diazaspironoundecanyl group, an oxadiazaspiroheptanyl group, an oxadiazaspirooctanyl group, an oxadiazaspirononanyl group, an oxadiazaspirodecanyl group, or an oxadiazaspironoundecanyl group, more preferably a diazaspirooctanyl group, a diazaspirononanyl group, a diazaspirodecanyl group, or an oxadiazaspirononanyl group, and even more preferably and 2,7-diazaspiro[3.4]octanyl, 3,7-diazaspiro[3.4]octanyl, 2,7-diazaspiro[3.5]nonanyl, 2,8-diazaspiro[3.5]nonanyl, 3,7-diazaspiro[3.5]nonanyl, 3,8-diazaspiro[4.4]nonanyl, 3,8-diazaspiro[3.5]decanyl, or 9-oxa-diazaspiro[3.5]nonanyl, more preferably 2,7-diazaspiro[3.4]octanyl.

[0039] The diazaspiro[3.4]octanyl group, 3,7-diazaspiro[3.4]octanyl group, 2,7-diazaspiro[3.5]nonanyl group, 2,8-diazaspiro[3.5]nonanyl group, or 9-oxa-diazaspiro[3.5]nonanyl group, more preferably a 2,7-diazaspiro[3.4]octanyl group, 3,7-diazaspiro[3.4]octanyl group, or 2,8-diazaspiro[3.5]nonanyl group, more preferably a 2,8-diazaspiro[3.5]nonanyl group.

[0097] The "monocyclic, bridged or spirocyclic nitrogen-containing saturated heterocyclic group" represented by ring A is preferably a monocyclic, bridged or spirocyclic 4- to 14-membered nitrogen-containing saturated heterocyclic group having 1 to 3 nitrogen atoms, 0 to 1 sulfur atom, and 0 to 2 oxygen atoms as heteroatoms, more preferably a monocyclic 4- to 10-membered nitrogen-containing saturated heterocyclic group having 1 to 2 nitrogen atoms as heteroatoms;

[0098]

[0099] or a spirocyclic group having 0 to 2 oxygen atoms to which any two of 4- to 7-membered nitrogen-containing saturated heterocyclic rings are bonded, more preferably a monocyclic 4- to 10-membered nitrogen-containing saturated heterocyclic group having 1 to 2 nitrogen atoms as heteroatoms;

[0100]

[0101] and a 7- to 12-membered spirocyclic group having two nitrogen atoms and 0 to 1 oxygen atom to which any two of 4- to 7-membered nitrogen-containing saturated heterocyclic rings are bonded, more preferably a pyrrolidinyl group, a piperidinyl group, a piperazinyl group, an azepanyl group, a diazepanyl group,

[0102]

[0103] , 2,7-diazaspiro[3.4]octanyl group, 3,7-diazaspiro[3.4]octanyl group, 2,7-diazaspiro[3.5]nonanyl group, 2,8-diazaspiro[3.5]nonanyl group, 3,7-diazaspiro[3.5]nonanyl group, 3,8-diazaspiro[4.4]nonanyl group, 3,8-diazaspiro[4.5]decanyl group, or 9-oxa-diazaspiro[3.5]nonanyl group, more preferably a pyrrolidinyl group, a piperidinyl group, an azepanyl group, a diazepanyl group,

[0104]

[0105] , 2,7-diazaspiro[3.4]octanyl group, 3,7-diazaspiro[3.4]octanyl group, 2,7-diazaspiro[3.5]nonanyl group, 2,8-diazaspiro[3.5]nonanyl group, or 9-oxa-diazaspiro[3.5]nonanyl group, more preferably a pyrrolidinyl group,

[0106]

[0107] or a 2,8-diazaspiro[3.5]nonanyl group, more preferably a pyrrolidinyl group,

[0108]

[0109] is.

[0110] In the compound represented by general formula (I), ring B represents a monocyclic or bicyclic unsaturated hydrocarbon group, or a monocyclic or bicyclic unsaturated heterocyclic group which may be substituted with an oxo group.

[0111] The "monocyclic or bicyclic unsaturated hydrocarbon group" represented by ring B is preferably a monocyclic or bicyclic 5- to 14-membered unsaturated hydrocarbon group, more preferably a phenyl group or a naphthyl group, and more preferably a phenyl group.

[0112] The "monocyclic or bicyclic unsaturated heterocyclic group" represented by ring B is a monocyclic or bicyclic fully unsaturated or partially unsaturated heterocyclic group having heteroatoms selected from nitrogen atoms, oxygen atoms, and sulfur atoms, preferably a 5- to 14-membered monocyclic or bicyclic fully unsaturated heterocyclic group or partially unsaturated heterocyclic group having 0 to 4 nitrogen atoms, 0 to 2 sulfur atoms, and 0 to 3 oxygen atoms as heteroatoms, and having at least one nitrogen atom, sulfur atom, or oxygen atom, more preferably an imidazolyl group, a thienyl group, a furyl group, a pyrrolidin ... a benzoyl group, an oxazolyl group, an isoxazolyl group, a thiazolyl group, an isothiazolyl group, a thiadiazolyl group, a pyrazolyl group, a triazolyl group, a tetrazolyl group, a pyridyl group, a pyrazolyl group, a pyrimidinyl group, a pyridazinyl group, a pyrazolopyridyl group, a pyrazolopyrimidinyl group, an indolyl group, an isoindolyl group, an indolinyl group, an indazolyl group, a triazolopyridyl group, a benzimidazolyl group, a benzoxazolyl group, a benzisoxazolyl group, a benzothiazolyl group, a benzotriazolyl group, a benzothienyl group, a benzofuranyl group, a purinyl group, an imidazopyridinyl group, a benzo[d][1,3]dioxolyl group, a quinolinyl group, an isoquinolinyl group, a quinazolinyl group, a quinoxalinyl group, a phthalazinyl group, a methylenedioxyphenyl group, an ethylenedioxyphenyl group, a dihydrobenzofuranyl group, a 1,3-dihydroisobenzofuranyl group, a dihydrobenzoxazolyl group (e.g., a 2,3-dihydrobenzo[d]oxazolyl group), a dihydrobenzoxazinyl group (e.g., a 3,4-dihydro-2H-benzo[b][1,4]oxazinyl group), a benzodioxolyl group (e.g., a benzo[d][1,3]dioxolyl group), a dihydrobenzodioxinyl group (e.g., a a 2,3-dihydrobenzo[b][1,4]dioxinyl group or the like), or a dihydrobenzothiazolyl group (for example, a 2,3-dihydrobenzo[d]thiazolyl group), and more preferably a pyridyl group, a pyrazolopyridyl group, a pyrazolopyrimidinyl group, an indolyl group, an indolinyl group, an indazolyl group, a benzimidazolyl group, a benzisoxazolyl group, a benzothiazolyl group, a benzotriazolyl group, an imidazopyridinyl group, a quinolinyl group, an isoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a phthalazinyl group, a dihydrobenzoxazolyl group, a 1,The monocyclic or bicyclic unsaturated heterocyclic group represented by ring B may be substituted with an oxo group. Examples of the monocyclic or bicyclic unsaturated heterocyclic group substituted with an oxo group include, for example, a 2-oxo-indolinyl group ...

[0113]

[0114] 2-oxo-2,3-dihydrobenzo[d]oxazolyl group

[0115]

[0116] 2-oxo-2,3-dihydrobenzo[d]thiazolyl group

[0117]

[0118] The monocyclic or bicyclic unsaturated heterocyclic group substituted with an oxo group is preferably a 2-oxo-indolinyl group, a 2-oxo-2,3-dihydrobenzo[d]oxazolyl group, or a 2-oxo-2,3-dihydrobenzo[d]thiazolyl group, more preferably a 2-oxo-2,3-dihydrobenzo[d]oxazolyl group or a 2-oxo-2,3-dihydrobenzo[d]thiazolyl group.

[0119] Ring B is preferably a monocyclic or bicyclic 5- to 14-membered unsaturated hydrocarbon group, or a monocyclic or bicyclic 5- to 14-membered unsaturated heterocyclic group which may be substituted with an oxo group and which has 0 to 4 nitrogen atoms, 0 to 2 sulfur atoms, and 0 to 3 oxygen atoms as heteroatoms, and which has at least one nitrogen atom, sulfur atom, or oxygen atom, more preferably a phenyl group, a naphthyl group, a pyridyl group, a pyrazolopyridyl group, a pyrazolopyrimidinyl group, an indolyl group, an indolinyl group, a 2-oxo-indolinyl group, an indazolyl group, a benzimidazolyl group, a benzisoxazolyl group, a benzothiazolyl group, a benzotriazolyl group, an imidazopyridinyl group, a quinolinyl group, an isoquinolinyl group, a quinazolinyl group, a quinoxalinyl group, a phthalazinyl group, or a 2-oxo-2,3-dihydrobenzo[d]oxazo and 2-oxo-2,3-dihydrobenzo[d]thiazolyl group, more preferably a phenyl group, a naphthyl group, a pyridyl group, a pyrazolopyridyl group, an indolyl group, an indolinyl group, an indazolyl group, a benzimidazolyl group, a benzisoxazolyl group, a benzotriazolyl group, a quinolinyl group, a 2-oxo-2,3-dihydrobenzo[d]oxazolyl group, a 1,3-dihydroisobenzofuranyl group, a dihydrobenzoxazinyl group, or a 2-oxo-2,3-dihydrobenzo[d]thiazolyl group, more preferably a phenyl group, an indolyl group, an indazolyl group, a benzisoxazolyl group, or a benzotriazolyl group, more preferably a benzotriazolyl group.

[0120] In the compound represented by general formula (I), R1 represents a nitro group or a cyano group, preferably a cyano group.

[0121] In the compound represented by general formula (I), R2 represents a halogen atom, preferably a fluorine atom. When there are multiple R2, these R2 may be the same or different.

[0122] In the compound represented by formula (I), l is an integer of 0 to 2, preferably an integer of 0 to 1.

[0123] In the compound represented by general formula (I), R3 represents an amino group, a C1-C6 alkyl group, a halogen atom, a cyano group, an oxo group, a hydroxyl group, a carbamoyl group, a sulfo group, a C1-C6 alkoxy group, or an amino(C1-C6 alkyl) group, which may have a substituent. When there are multiple R3s, they may be the same or different.

[0124] The "C1-C6 alkyl group" represented by R3 may be either linear or branched, and examples include a methyl group, an ethyl group, an n-propyl group, an isopropyl group, an n-butyl group, an isobutyl group, a tert-butyl group, an n-pentyl group, an isopentyl group, a hexyl group, and the like. A C1-C4 alkyl group is preferred, and a methyl group is more preferred.

[0125] Examples of the "mono(C1-C6 alkyl)amino group" represented by R3 include a methylamino group, ethylamino group, n-propylamino group, isopropylamino group, n-butylamino group, isobutylamino group, tert-butylamino group, n-pentylamino group, isopentylamino group, and hexylamino group, and are preferably a mono(C1-C4 alkyl)amino group, and more preferably a methylamino group, ethylamino group, or isopropylamino group.

[0126] Examples of the "di(C1-C6 alkyl)amino group" represented by R3 include a dimethylamino group, a diethylamino group, a di(n-propyl)amino group, a diisopropylamino group, a di(n-butyl)amino group, a diisobutylamino group, a di(tert-butyl)amino group, a di(n-pentyl)amino group, a diisopentylamino group, a dihexylamino group, a methylethylamino group, and a methylisopropylamino group, of which a dimethylamino group, a diethylamino group, a di(n-propyl)amino group, a diisopropylamino group, a di(n-butyl)amino group, a diisobutylamino group, a di(tert-butyl)amino group, a di(n-pentyl)amino group, a diisopentylamino group, a dihexylamino group, a methylethylamino group, or a methylisopropylamino group is preferred, a di(C1-C4 alkyl)amino group is more preferred, and a dimethylamino group is more preferred.

[0127] Examples of the "(C3-C7 cycloalkyl)amino group" represented by R3 include (C3-C7 cycloalkyl)amino groups such as cyclopropylamino group, cyclobutylamino group, cyclopentylamino group, cyclohexylamino group, and cycloheptylamino group, and are preferably cyclopropylamino group, cyclobutylamino group, cyclopentylamino group, cyclohexylamino group, or cycloheptylamino group, and more preferably cyclobutylamino group.

[0128] R3 is preferably an amino group which may have a substituent, a C1-C6 alkyl group, a halogen atom, a cyano group, an oxo group, a hydroxyl group, a carbamoyl group, a sulfo group, a C1-C6 alkoxy group, or an amino(C1-C6 alkyl) group, more preferably an amino group which may have one or two C1-C6 alkyl or C3-C7 cycloalkyl groups as substituents, a C1-C6 alkyl group, a halogen atom, a cyano group, an oxo group, a hydroxyl group, a carbamoyl group, a sulfo group, a C1-C6 alkoxy group, or an amino(C1-C6 alkyl) group, more preferably an amino group, a mono- or di(C1-C6 alkyl)amino group, a (C3-C7 cycloalkyl)amino group, or a C1-C6 alkyl group, more preferably an amino group, a methylamino group, an ethylamino group, an isopropylamino group, a dimethylamino group, a cyclobutylamino group, or a methyl group, more preferably an amino group or a methyl group, and more preferably an amino group.

[0129] In the compound represented by formula (I), m is an integer of 0 to 2, preferably an integer of 0 to 1.

[0130] In the compounds represented by general formula (I), R4 represents a halogen atom, a hydroxyl group, a nitro group, a cyano group, an amino group, a carboxy group, a (C2-C7 acyl)amino group, a (C2-C7 acyl)oxy group, an optionally substituted C1-C8 alkyl group, an optionally substituted C2-C6 alkenyl group, an optionally substituted C1-C6 alkoxy group, an optionally substituted C3-C7 cycloalkyl group, a mono- or di(C1-C6 alkyl)amino group, an optionally substituted carbamoyl group, an optionally substituted C2-C6 alkynyl group, an optionally substituted (C1-C6 alkyl)carbonyl group, an optionally substituted 4- to 14-membered nitrogen-containing saturated heterocyclic group, or an optionally substituted C6-C14 aromatic hydrocarbon group. When multiple R4s are present, those R4s may be the same or different.

[0131] In the present invention, when at least one R4 is a substituted C1-C8 alkyl group, a substituted C2-C6 alkenyl group, a substituted C1-C6 alkoxy group, a substituted C3-C7 cycloalkyl group, or a substituted carbamoyl group, examples of the substituent include a halogen atom, a carboxy group, a C1-C6 alkoxy group, a hydroxyl group, a C1-C6 alkyl group optionally having a hydroxyl group as a substituent, a monocyclic 5- to 10-membered unsaturated hydrocarbon group, a carbamoyl group optionally having a C1-C6 alkyl group or a monocyclic 5- to 10-membered unsaturated hydrocarbon group as a substituent, a (C2-C7 acyl)oxy group, an amino group optionally having a C1-C6 alkyl group or a C2-C7 acyl group as a substituent, a C3-C7 cycloalkyl group optionally having a hydroxyl group as a substituent, a (C1-C6 alkoxy)(C1-C6 alkyl) group, etc. When a plurality of such substituents are present, they may be the same or different.

[0132] The "C1-C8 alkyl group" in the "optionally substituted C1-C8 alkyl group" represented by R4 is preferably a methyl group, ethyl group, n-propyl group, isopropyl group, n-butyl group, isobutyl group, sec-butyl group, tert-butyl group, pentyl group, hexyl group, heptyl group, or octyl group, more preferably a C1-C6 alkyl group, more preferably a methyl group, ethyl group, n-propyl group, isopropyl group, n-butyl group, isobutyl group, sec-butyl group, tert-butyl group, pentyl group, or hexyl group, more preferably a methyl group, ethyl group, n-propyl group, isopropyl group, n-butyl group, isobutyl group, sec-butyl group, or tert-butyl group.

[0133] Examples of the "substituent" in the "optionally substituted C1-C8 alkyl group" represented by R4 include the substituents described above, but are preferably a halogen atom, an amino group, a hydroxyl group, a carboxy group, a carbamoyl group, an alkylcarbamoyl group, an acylamino group, an alkoxy group, a hydroxycycloalkyl group, or an acyloxy group, and more preferably a halogen atom, an amino group, a hydroxyl group, a carboxy group, a carbamoyl group, a (C1-C6 alkyl)carbamoyl group, a (C2-C7 acyl)amino group, a C1-C6 alkoxy group, a C3-C7 cycloalkyl group, a hydroxy(C3-C7 cycloalkyl) group, or ( and a (C2-C7 acyl)oxy group, more preferably a halogen atom, an amino group, a hydroxyl group, a carboxy group, a carbamoyl group, a (C1-C6 alkyl)carbamoyl group, a (C1-C6 alkyl)carbonylamino group, a C1-C6 alkoxy group, a C3-C7 cycloalkyl group, a hydroxy(C3-C7 cycloalkyl) group, or a (C1-C6 alkyl)carbonyloxy group, more preferably a fluorine atom, an amino group, a hydroxyl group, a carboxy group, a carbamoyl group, a methylcarbamoyl group, a dimethylcarbamoyl group, an acetylamino group, a methoxy group, a hydroxycyclopropyl group, or a methylcarbonyloxy group.

[0134] The "optionally substituted C1-C8 alkyl group" represented by R4 is preferably an unsubstituted C1-C8 alkyl group, or a C1-C8 alkyl group optionally having as a substituent a halogen atom, an amino group, a hydroxyl group, a carboxy group, a carbamoyl group, a (C1-C6 alkyl)carbamoyl group, a (C1-C6 alkyl)carbonylamino group, a C1-C6 alkoxy group, a C3-C7 cycloalkyl group, a hydroxy(C3-C7 cycloalkyl) group, or a (C1-C6 alkyl)carbonyloxy group, more preferably a methyl group, an ethyl group, an n-propyl group, an isopropyl group, a tert-butyl group, a difluoromethyl group, a trifluoromethyl group, a fluoroethyl group, an aminoethyl group, a hydroxymethyl group, a hydroxyethyl group, a hydroxypropyl group, a hydroxydimethylethyl group, a hydroxymethylpropyl group, a hydroxymethylbutyl group, a hydroxyethylbutyl group, a carboxymethyl group, a carbamoylmethyl group, a methylcarbamoylmethyl group, a dimethylcarbamoylmethyl group, an acetyl and methylcarbonyloxyethyl group, more preferably a methyl group, an ethyl group, an n-propyl group, a tert-butyl group, a difluoromethyl group, a hydroxyethyl group, a hydroxymethylpropyl group, a hydroxymethylbutyl group, a hydroxyethylbutyl group, a carbamoylmethyl group, a methylcarbamoylmethyl group, a dimethylcarbamoylmethyl group, a methoxyethyl group, a hydroxycyclopropylmethyl group, a hydroxycyclobutylmethyl group, or a methylcarbonyloxyethyl group, more preferably a methyl group, a difluoromethyl group, a hydroxymethylpropyl group, a hydroxymethylbutyl group, a hydroxycyclobutylmethyl group, a methoxyethyl group, or a hydroxycyclobutylmethyl group, more preferably a methyl group, a difluoromethyl group, a hydroxymethylpropyl group, a hydroxyethylbutyl group, or a hydroxycyclobutylmethyl group.

[0135] The "optionally substituted C2-C6 alkenyl group" represented by R4 is preferably an unsubstituted C2-C6 alkenyl group, more preferably a vinyl group, an allyl group, a 1-propenyl group, a 2-methyl-2-propenyl group, an isopropenyl group, a 1-, 2-, or 3-butenyl group, an isobutenyl group, a 2-, 3-, or 4-pentenyl group, a 2-methyl-2-butenyl group, a 3-methyl-2-butenyl group, a 5-hexenyl group, a 1-cyclopentenyl group, a 1-cyclohexenyl group, or a 3-methyl-3-butenyl group, and more preferably an isobutenyl group.

[0136] Examples of the "C2-C6 alkynyl group" in the "optionally substituted C2-C6 alkynyl group" represented by R4 include an ethynyl group, a 1- or 2-propynyl group, a 1-, 2- or 3-butynyl group, a 1-methyl-2-propynyl group, etc. The "optionally substituted C2-C6 alkynyl group" is preferably an unsubstituted C2-C6 alkynyl group.

[0137] The "C1-C6 alkoxy group" in the "optionally substituted C1-C6 alkoxy group" represented by R4 is preferably a methoxy group, an ethoxy group, an n-propoxy group, an isopropoxy group, an n-butoxy group, an isobutoxy group, a sec-butoxy group, a tert-butoxy group, a pentyloxy group, or a hexyloxy group, and more preferably a methoxy group, an ethoxy group, an n-propoxy group, an isopropoxy group, an n-butoxy group, an isobutoxy group, a sec-butoxy group, or a tert-butoxy group.

[0138] Examples of the "substituent" in the "optionally substituted C1-C6 alkoxy group" represented by R4 include the substituents mentioned above, and is preferably a hydroxyl group or a 5- to 14-membered unsaturated hydrocarbon group, more preferably a hydroxyl group or a monocyclic 5- to 10-membered unsaturated hydrocarbon group, and more preferably a hydroxyl group or a phenyl group.

[0139] The "optionally substituted C1-C6 alkoxy group" represented by R4 is preferably a C1-C6 alkoxy group optionally having a hydroxyl group or a 5- to 14-membered unsaturated hydrocarbon group as a substituent, more preferably a C1-C6 alkoxy group optionally having a hydroxyl group or a monocyclic 5- to 10-membered unsaturated hydrocarbon group as a substituent, more preferably a C1-C6 alkoxy group optionally having a hydroxyl group or a phenyl group as a substituent, and more preferably a methoxy group, a hydroxypropoxy group, or a benzyloxy group.

[0140] The "optionally substituted C3-C7 cycloalkyl group" represented by R4 is preferably a C3-C7 cycloalkyl group optionally having a hydroxyalkyl group, alkoxyalkyl group, hydroxycycloalkyl group, or unsaturated hydrocarbon carbamoyl group as a substituent, more preferably a C3-C7 cycloalkyl group optionally having a hydroxy(C1-C4 alkyl) group, a (C1-C4 alkoxy)(C1-C4 alkyl) group, a hydroxy(C3-C7 cycloalkyl) group, or a (C6-C14 aromatic hydrocarbon)carbamoyl group as a substituent, more preferably a C3-C7 cycloalkyl group optionally having a hydroxy(C1-C4 alkyl) group, a (C1-C4 alkoxy)(C1-C4 alkyl) group, a hydroxy(C3-C7 cycloalkyl) group, or a phenylcarbamoyl group as a substituent, more preferably a cyclopropyl group, a hydroxymethylcyclopropyl group, a methoxymethylcyclopropyl group, a hydroxycyclopropylcyclopropyl group, or a phenylcarbamoylcyclopropyl group, more preferably a cyclopropyl group or a hydroxymethylcyclopropyl group, and more preferably a cyclopropyl group.

[0141] The "mono- or di(C1-C6 alkyl)amino group" represented by R4 is preferably a methylamino group, an ethylamino group, an n-propylamino group, an isopropylamino group, an n-butylamino group, an isobutylamino group, a tert-butylamino group, an n-pentylamino group, an isopentylamino group, a hexylamino group, a dimethylamino group, a diethylamino group, a di(n-propyl)amino group, a diisopropylamino group, a di(n-butyl)amino group, a diisobutylamino group, a di(tert-butyl)amino group, a di(n-pentyl)amino group, a diisopentylamino group, The amino group is a dihexylamino group, a methylethylamino group, or a methylisopropylamino group, more preferably a methylamino group, an ethylamino group, an n-propylamino group, an isopropylamino group, an n-butylamino group, an isobutylamino group, a tert-butylamino group, a dimethylamino group, a diethylamino group, a di(n-propyl)amino group, a diisopropylamino group, a di(n-butyl)amino group, a diisobutylamino group, a di(tert-butyl)amino group, a methylethylamino group, or a methylisopropylamino group, more preferably a dimethylamino group.

[0142] The "optionally substituted carbamoyl group" represented by R4 is preferably a carbamoyl group optionally having an alkyl group as a substituent, more preferably a carbamoyl group optionally having a C1-C6 alkyl group as a substituent, and more preferably a carbamoyl group, a methylcarbamoyl group, or a dimethylcarbamoyl group.

[0143] Examples of the "alkylcarbonyl group" in the "optionally substituted (C1-C6 alkyl)carbonyl group" represented by R4 include straight-chain or branched-chain (C1-C6 alkyl)carbonyl groups such as a methylcarbonyl group, ethylcarbonyl group, n-propylcarbonyl group, isopropylcarbonyl group, n-butylcarbonyl group, isobutylcarbonyl group, tert-butylcarbonyl group, n-pentylcarbonyl group, isopentylcarbonyl group, and hexylcarbonyl group.

[0144] Examples of the "saturated heterocyclic group having a nitrogen atom" in the "optionally substituted 4- to 14-membered nitrogen-containing saturated heterocyclic group" represented by R4 include a morpholinyl group, an azetidinyl group, a pyrrolidinyl group, a piperidinyl group, and a piperazinyl group.

[0145] Examples of the "optionally substituted C6-C14 aromatic hydrocarbon group" represented by R4 include aromatic hydrocarbon groups which may have a methyl group as a C6-C14 substituent, such as a phenyl group, a toluyl group, a xylyl group, a naphthyl group, an anthracenyl group, a phenanthryl group, a fluorenyl group, and a tetrahydronaphthyl group.

[0146] R4 is preferably a halogen atom, a hydroxyl group, a nitro group, a cyano group, an amino group, a carboxy group, a (C2-C7 acyl)amino group, a (C2-C7 acyl)oxy group, an optionally substituted C1-C8 alkyl group, an optionally substituted C2-C6 alkenyl group, an optionally substituted C1-C6 alkoxy group, an optionally substituted C3-C7 cycloalkyl group, a mono- or di(C1-C6 alkyl)amino group, an optionally substituted carbamoyl group, an optionally substituted C2-C6 alkynyl ... and a C6-C14 aromatic hydrocarbon group which may have a substituent, more preferably a halogen atom, a nitro group, a cyano group, a carboxy group, a C1-C8 alkyl group which may have a substituent, a C2-C6 alkenyl group which may have a substituent, a C1-C6 alkoxy group which may have a substituent, a C3-C7 cycloalkyl group which may have a substituent, a mono- or di(C1-C6 alkyl)amino group, or a C6-C14 aromatic hydrocarbon group which may have a substituent. and a carbamoyl group, more preferably a halogen atom, a nitro group, a cyano group, a carboxy group, a C1-C6 alkyl group optionally having as a substituent a halogen atom, an amino group, a hydroxyl group, a carboxy group, a carbamoyl group, a (C1-C6 alkyl)carbamoyl group, a (C1-C6 alkyl)carbonylamino group, a C1-C6 alkoxy group, a C3-C7 cycloalkyl group, a hydroxy(C3-C7 cycloalkyl) group, or a (C1-C6 alkyl)carbonyloxy group, a C2-C6 alkenyl group, a hydroxyl group as a substituent, or a monocyclic and a C1-C6 alkoxy group which may have a 5- to 10-membered unsaturated hydrocarbon group, a C3-C7 cycloalkyl group which may have as a substituent a hydroxyl group, a hydroxy(C1-C4 alkyl) group, a (C1-C4 alkoxy)(C1-C4 alkyl) group, a hydroxy(C3-C7 cycloalkyl) group, or a (C6-C14 aromatic hydrocarbon)-substituted carbamoyl group, a mono- or di(C1-C6 alkyl)amino group, or a carbamoyl group which may have as a substituent a C1-C6 alkyl group, more preferably a fluorine atom, a chlorine atom,a bromine atom, an iodine atom, a nitro group, a cyano group, a carboxy group, a methyl group, an ethyl group, an n-propyl group, an isopropyl group, a tert-butyl group, a difluoromethyl group, a trifluoromethyl group, a fluoroethyl group, an aminoethyl group, a hydroxymethyl group, a hydroxyethyl group, a hydroxypropyl group, a hydroxydimethylethyl group, a hydroxymethylpropyl group, a hydroxymethylbutyl group, a hydroxyethylbutyl group, a carboxymethyl group, a carbamoylmethyl group, a methylcarbamoylmethyl group, a dimethylcarbamoylmethyl group, an acetylaminoethyl group, a methoxyethyl group, a hydroxycyclopropylmethyl group, a hydroxycyclopropylethyl group, a hydroxycyclobutylmethyl group, a methylcarbonyloxyethyl group, an isobutenyl group, a methoxy group, a hydroxypropoxy group, a cyclopropyl group, a hydroxymethylcyclopropyl group, a methoxymethylcyclopropyl group, a hydroxycyclopropylcyclopropyl group, a phenylcarbamoylcyclopropyl group, a benzyloxy group, a dimethylamino group, a carbamoyl group, a methylcarbamoyl group, or a dimethylcarbamoyl group, more preferred or a fluorine atom, a chlorine atom, a bromine atom, a nitro group, a cyano group, a carboxy group, a methyl group, an ethyl group, an n-propyl group, a tert-butyl group, a difluoromethyl group, a hydroxyethyl group, a hydroxymethylpropyl group, a hydroxymethylbutyl group, a hydroxyethylbutyl group, a carbamoylmethyl group, a methylcarbamoylmethyl group, a dimethylcarbamoylmethyl group, a methoxyethyl group, a hydroxycyclopropylmethyl group, a hydroxycyclobutylmethyl group, a methylcarbonyloxyethyl group, a methoxy group, a cyclopropyl group, a hydroxymethylcyclopropyl group, a dimethylamino group, a carbamoyl group, a methylcarbamoyl group, or a dimethylcarbamoyl group, more preferably a fluorine atom, a chlorine atom, a bromine atom, a cyano group, a methyl group, a difluoromethyl group, a hydroxymethylpropyl group, a hydroxymethylbutyl group, a hydroxyethylbutyl group, a methoxyethyl group, a hydroxycyclobutylmethyl group, or a cyclopropyl group, more preferably a fluorine atom, a chlorine atom, a bromine atom, a cyano group, a methyl group, a difluoromethyl group, a hydroxymethylpropyl group, a hydroxyethylbutyl group, a methoxyethyl group, a hydroxycyclobutylmethyl group, or a cyclopropyl groupor a hydroxycyclobutylmethyl group.

[0147] In the compound represented by formula (I), n is an integer of 0 to 5, preferably an integer of 0 to 3.

[0148] In the compound represented by general formula (I), R5 and R6 may be the same or different and represent a hydrogen atom or a C1-C6 alkyl group, or R5 and R6 may combine to form an oxo group or a thioxo group. When R5 and R6 are the same or different and represent a hydrogen atom or a C1-C6 alkyl group, at least one of R5 and R6 is a hydrogen atom.

[0149] The "C1-C6 alkyl group" represented by R5 and R6 may be either linear or branched, and examples thereof include a methyl group, an ethyl group, an n-propyl group, an isopropyl group, an n-butyl group, an isobutyl group, a tert-butyl group, an n-pentyl group, an isopentyl group, and a hexyl group. A C1-C4 alkyl group is preferred, and a methyl group is more preferred.

[0150] R5 and R6 are preferably the same or different and represent a hydrogen atom or a C1-C6 alkyl group, or R5 and R6 may combine to form an oxo group or a thioxo group, and when R5 and R6 are the same or different and represent a hydrogen atom or a C1-C6 alkyl group, at least one of R5 and R6 is a hydrogen atom, more preferably a hydrogen atom, or R5 and R6 may combine to form an oxo group.

[0151] The biphenyl compound represented by general formula (I) preferably includes, in formula (I), ring A is a monocyclic, bridged or spirocyclic 4-14 membered nitrogen-containing saturated heterocyclic group having 1 to 3 nitrogen atoms, 0 to 1 sulfur atom and 0 to 2 oxygen atoms as heteroatoms, ring B is a monocyclic or bicyclic 5-14 membered unsaturated heterocyclic group which may be substituted with a monocyclic or bicyclic 5-14 membered unsaturated hydrocarbon group or an oxo group and has 0 to 4 nitrogen atoms, 0 to 2 sulfur atoms and 0 to 3 oxygen atoms as heteroatoms, and at least one nitrogen atom, sulfur atom or oxygen atom, R1 is a nitro group or a cyano group, R2 is a halogen atom, R3 is an amino group, a mono- or di(C1-C6 alkyl)amino group, a (C3-C7 cycloalkyl)amino group, or a C1-C6 alkyl group; R4 is a halogen atom, a nitro group, a cyano group, a carboxy group, an optionally substituted C1-C8 alkyl group, an optionally substituted C2-C6 alkenyl group, an optionally substituted C1-C6 alkoxy group, an optionally substituted C3-C7 cycloalkyl group, a mono- or di(C1-C6 alkyl)amino group, or an optionally substituted carbamoyl group; When at least one R4 is a substituted C1-C8 alkyl group, a substituted C2-C6 alkenyl group, a substituted C1-C6 alkoxy group, a substituted C3-C7 cycloalkyl group, or a substituted carbamoyl group, the substituent is a halogen atom, a carboxy group, a C1-C6 alkoxy group, a hydroxyl group, a C1-C6 alkyl group optionally having a hydroxyl group as a substituent, a monocyclic 5- to 10-membered unsaturated hydrocarbon group, a carbamoyl group optionally having a C1-C6 alkyl group or a monocyclic 5- to 10-membered unsaturated hydrocarbon group as a substituent, a (C2-C7 acyl)oxy group, an amino group optionally having a C1-C6 alkyl group or a C2-C7 acyl group as a substituent, a C3-C7 cycloalkyl group optionally having a hydroxyl group as a substituent, or a (C1-C6 alkoxy)(C1-C6 alkyl) group.When a plurality of such substituents are present, they may be the same or different; R5 and R6 may be the same or different and represent a hydrogen atom or a C1-C6 alkyl group, or R5 and R6 may combine to form an oxo group or a thioxo group; when R5 and R6 are the same or different and represent a hydrogen atom or a C1-C6 alkyl group, at least one of R5 and R6 is a hydrogen atom; 1 is an integer of 0 to 2; m is an integer of 0 to 2; n is an integer of 0 to 5; when 1 is 2, two R2s may be the same or different; when m is 2, two R3s may be the same or different; when n is 2 to 5, two to five R4s may be the same or different.

[0152] More preferably, in formula (I), ring A is a pyrrolidinyl group, a piperidinyl group, a piperazinyl group, an azepanyl group, a diazepanyl group,

[0153]

[0154] , 2,7-diazaspiro[3.4]octanyl group, 3,7-diazaspiro[3.4]octanyl group, 2,7-diazaspiro[3.5]nonanyl group, 2,8-diazaspiro[3.5]nonanyl group, 3,7-diazaspiro[3.5]nonanyl group, 3,8-diazaspiro[4.4]nonanyl group, 3,8-diazaspiro[4.5]decanyl group, or 9-oxa-diazaspiro[3.5]nonanyl group; Ring B is a monocyclic or bicyclic 5- to 14-membered unsaturated hydrocarbon group, or a monocyclic or bicyclic 5- to 14-membered unsaturated heterocyclic group which may be substituted with an oxo group and which has 0 to 4 nitrogen atoms, 0 to 2 sulfur atoms, and 0 to 3 oxygen atoms as heteroatoms, and which has at least one nitrogen atom, sulfur atom, or oxygen atom, R1 is a nitro group or a cyano group, R2 is a halogen atom, R3 is an amino group, a methylamino group, an ethylamino group, an isopropylamino group, a dimethylamino group, a cyclobutylamino group, or a methyl group, R4 is a halogen atom, a nitro group, a cyano group, a carboxy group, an optionally substituted C1-C8 alkyl group, an optionally substituted C2-C6 alkenyl group, an optionally substituted C1-C6 alkoxy group, an optionally substituted C3-C7 cycloalkyl group, a mono- or di(C1-C6 alkyl)amino group, or an optionally substituted carbamoyl group; When at least one R4 is a substituted C1-C8 alkyl group, a substituted C2-C6 alkenyl group, a substituted C1-C6 alkoxy group, a substituted C3-C7 cycloalkyl group, or a substituted carbamoyl group, the substituent is a halogen atom, a carboxy group, a C1-C6 alkoxy group, a hydroxyl group, a C1-C6 alkyl group optionally having a hydroxyl group as a substituent, a monocyclic 5- to 10-membered unsaturated hydrocarbon group, a carbamoyl group optionally having a C1-C6 alkyl group or a monocyclic 5- to 10-membered unsaturated hydrocarbon group as a substituent, a C2-C7 acyl group, an amino group optionally having a C1-C6 alkyl group or a C2-C7 acyl group as a substituent, a C3-C7 cycloalkyl group optionally having a hydroxyl group as a substituent, or a (C1-C6 alkoxy)(C1-C6 alkyl) group.When a plurality of such substituents are present, they may be the same or different; R5 and R6 may be the same or different and represent a hydrogen atom or a C1-C6 alkyl group, or R5 and R6 may combine to form an oxo group or a thioxo group; when R5 and R6 are the same or different and represent a hydrogen atom or a C1-C6 alkyl group, at least one of R5 and R6 is a hydrogen atom; 1 is an integer of 0 to 2; m is an integer of 0 to 2; n is an integer of 0 to 5; when 1 is 2, two R2s may be the same or different; when m is 2, two R3s may be the same or different; when n is 2 to 5, two to five R4s may be the same or different.

[0155] More preferably, in formula (I), ring A is a pyrrolidinyl group, a piperidinyl group, a piperazinyl group, an azepanyl group, a diazepanyl group,

[0156]

[0157] , 2,7-diazaspiro[3.4]octanyl group, 3,7-diazaspiro[3.4]octanyl group, 2,7-diazaspiro[3.5]nonanyl group, 2,8-diazaspiro[3.5]nonanyl group, 3,7-diazaspiro[3.5]nonanyl group, 3,8-diazaspiro[4.4]nonanyl group, 3,8-diazaspiro[4.5]decanyl group, or 9-oxa-diazaspiro[3.5]nonanyl group; Ring B is a monocyclic or bicyclic 5- to 14-membered unsaturated hydrocarbon group, or a monocyclic or bicyclic 5- to 14-membered unsaturated heterocyclic group which may be substituted with an oxo group and which has 0 to 4 nitrogen atoms, 0 to 2 sulfur atoms, and 0 to 3 oxygen atoms as heteroatoms, and which has at least one nitrogen atom, sulfur atom, or oxygen atom, R1 is a nitro group or a cyano group, R2 is a halogen atom, R3 is an amino group, a methylamino group, an ethylamino group, an isopropylamino group, a dimethylamino group, a cyclobutylamino group, or a methyl group, R4 is a halogen atom, a nitro group, a cyano group, a carboxy group, a C1-C8 alkyl group which may have as a substituent a halogen atom, an amino group, a hydroxyl group, a carboxy group, a carbamoyl group, a (C1-C6 alkyl)carbamoyl group, a (C1-C6 alkyl)carbonylamino group, a C1-C6 alkoxy group, a (C1-C6 alkyl)carbonyl group, a C3-C7 cycloalkyl group, a hydroxy(C3-C7 cycloalkyl) group, or a (C1-C6 alkyl)carbonyloxy group, a C2-C6 alkenyl group, a hydroxy group as a substituent, a monocyclic C1-C6 alkoxy group which may have a 5- to 10-membered unsaturated hydrocarbon group; a C3-C7 cycloalkyl group which may have as a substituent a hydroxyl group, a hydroxy(C1-C4 alkyl) group, a (C1-C4 alkoxy)(C1-C4 alkyl) group, a hydroxy(C3-C7 cycloalkyl) group, or a (C6-C14 aromatic hydrocarbon)-substituted carbamoyl group; a mono- or di(C1-C6 alkyl)amino group; or a carbamoyl group which may have as a substituent a C1-C6 alkyl group;R5 and R6 are the same or different and represent a hydrogen atom or a C1-C6 alkyl group, or R5 and R6 may combine to form an oxo group or a thioxo group; when R5 and R6 are the same or different and represent a hydrogen atom or a C1-C6 alkyl group, at least one of R5 and R6 is a hydrogen atom; 1 is an integer of 0 to 2; m is an integer of 0 to 2; n is an integer of 0 to 5; when 1 is 2, two R2s may be the same or different; when m is 2, two R3s may be the same or different; when n is 2 to 5, two to five R4s may be the same or different; a compound or a salt thereof.

[0158] More preferably, in formula (I), ring A is a pyrrolidinyl group, a piperidinyl group, a piperazinyl group, an azepanyl group, a diazepanyl group,

[0159]

[0160] , 2,7-diazaspiro[3.4]octanyl group, 3,7-diazaspiro[3.4]octanyl group, 2,7-diazaspiro[3.5]nonanyl group, 2,8-diazaspiro[3.5]nonanyl group, 3,7-diazaspiro[3.5]nonanyl group, 3,8-diazaspiro[4.4]nonanyl group, 3,8-diazaspiro[4.5]decanyl group, or 9-oxa-diazaspiro[3.5]nonanyl group; Ring B is a phenyl group, a naphthyl group, a pyridyl group, a pyrazolopyridyl group, a pyrazolopyrimidinyl group, an indolyl group, an indolinyl group, a 2-oxo-indolinyl group, an indazolyl group, a benzimidazolyl group, a benzisoxazolyl group, a benzothiazolyl group, a benzotriazolyl group, an imidazopyridinyl group, a quinolinyl group, an isoquinolinyl group, a quinoxalinyl group, a quinazolinyl group, a phthalazinyl group, a 2-oxo-2,3-dihydrobenzo[d]oxazolyl group, a 1,3-dihydroisobenzofuranyl group, a dihydrobenzoxazinyl group, a benzodioxolyl group, a dihydrobenzodioxinyl group, or a 2-oxo-2,a 3-dihydrobenzo[d]thiazolyl group, R1 being a nitro group or a cyano group, R2 being a fluorine atom, R2 being located on the phenyl group at the ortho position relative to R1, and R3 being an amino group, a methylamino group, an ethylamino group, an isopropylamino group, a dimethylamino group, a cyclobutylamino group, or a methyl group (when a plurality of R3s are present, the R3s may be the same or different), R4 is a fluorine atom, chlorine atom, bromine atom, iodine atom, nitro group, cyano group, carboxy group, methyl group, ethyl group, n-propyl group, isopropyl group, tert-butyl group, difluoromethyl group, trifluoromethyl group, fluoroethyl group, aminoethyl group, hydroxymethyl group, hydroxyethyl group, hydroxypropyl group, hydroxydimethylethyl group, hydroxymethylpropyl group, hydroxymethylbutyl group, hydroxyethylbutyl group, carboxymethyl group, carbamoylmethyl group, methylcarbamoylmethyl group, dimethylcarbamoylmethyl group, acetylaminoethyl group, methoxyethyl group, hydroxycyclopropylmethyl group, hydroxycyclopropylethyl group, hydroxycyclobutylmethyl group, methylcarbonyloxyethyl group, isobutenyl group, methoxy group, hydroxypropoxy group, cyclopropyl group, hydroxymethylcyclopropyl group, methoxymethylcyclopropyl group, hydroxycyclopropylcyclopropyl group, phenylcarbamoylcyclopropyl group, benzyloxy group, dimethylamino group, carbamoyl group, methylcarbamoyl group, or dimethylcarbamoyl group; R5 and R6 may be the same or different and represent a hydrogen atom or a C1-C6 alkyl group, or R5 and R6 may combine to form an oxo group or a thioxo group; when R5 and R6 are the same or different and represent a hydrogen atom or a C1-C6 alkyl group, at least one of R5 and R6 is a hydrogen atom; 1 is an integer of 0 to 2; m is an integer of 0 to 2; n is an integer of 0 to 3; when m is 2, two R3s may be the same or different; and when n is 2 or 3, two to three R4s may be the same or different.

[0161] More preferably, in formula (I), ring A is a pyrrolidinyl group, a piperidinyl group, an azepanyl group, a diazepanyl group,

[0162]

[0163] , 2,7-diazaspiro[3.4]octanyl group, 3,7-diazaspiro[3.4]octanyl group, 2,7-diazaspiro[3.5]nonanyl group, 2,8-diazaspiro[3.5]nonanyl group, or 9-oxa-diazaspiro[3.5]nonanyl group, and ring B is a phenyl group, a naphthyl group, a pyridyl group, a pyrazolopyridyl group, an indolyl group, an indolinyl group, an indazolyl group, a benzimidazolyl group, a benzisoxazolyl group, a benzotriazolyl group, a quinolinyl group, a 2-oxo-2,3-dihydrobenzo[d]oxazolyl group, a 1,3-dihydroisobenzofuranyl group, a dihydrobenzoxazinyl group, or a 2-oxo-2,a 3-dihydrobenzo[d]thiazolyl group, R1 is a cyano group, R2 is a fluorine atom, R2 is located on the phenyl group at the ortho position relative to R1, and R3 is an amino group, a methylamino group, an ethylamino group, an isopropylamino group, a dimethylamino group, a cyclobutylamino group, or a methyl group (when a plurality of R3s are present, the R3s may be the same or different), R4 is a fluorine atom, chlorine atom, bromine atom, nitro group, cyano group, carboxy group, methyl group, ethyl group, n-propyl group, tert-butyl group, difluoromethyl group, hydroxyethyl group, hydroxymethylpropyl group, hydroxymethylbutyl group, hydroxyethylbutyl group, carbamoylmethyl group, methylcarbamoylmethyl group, dimethylcarbamoylmethyl group, methoxyethyl group, hydroxycyclopropylmethyl group, hydroxycyclobutylmethyl group, methylcarbonyloxyethyl group, methoxy group, cyclopropyl group, hydroxymethylcyclopropyl group, dimethylamino group, carbamoyl group, methylcarbamoyl group, or dimethylcarbamoyl group; R5 and R6 are the same or different and represent a hydrogen atom or a C1-C6 alkyl group, or R5 and R6 may together form an oxo group or a thioxo group; when R5 and R6 are the same or different and represent a hydrogen atom or a C1-C6 alkyl group, at least one of R5 and R6 is a hydrogen atom; The compound or salt thereof is: l is an integer of 0 to 2; m is an integer of 0 to 2; n is an integer of 0 to 3; when m is 2, two R3s may be the same or different; and when n is 2 or 3, two to three R4s may be the same or different.

[0164] More preferably, in formula (I), ring A is a pyrrolidinyl group,

[0165]

[0166] or a 2,8-diazaspiro[3.5]nonanyl group, ring B is a phenyl group, an indolyl group, an indazolyl group, a benzisoxazolyl group, or a benzotriazolyl group, R1 is a cyano group, R2 is a fluorine atom, R2 is located at the ortho position on the phenyl group relative to R1, R3 is an amino group or a methyl group (when a plurality of R3s are present, the R3s may be the same or different), R4 is a fluorine atom, a chlorine atom, a bromine atom, a cyano group, a methyl group, a difluoromethyl group, a hydroxymethylpropyl group, a hydroxymethylbutyl group, a hydroxyethylbutyl group, a methoxyethyl group, a hydroxycyclobutylmethyl group, or a cyclopropyl group, R5 and R6 are hydrogen atoms, or R5 and R6 may together form an oxo group, 1 is an integer of 0 to 2, m is an integer of 0 to 2, and n is an integer of 0 to 3, When m is 2, two R3s may be the same or different, and when n is 2 or 3, two to three R4s may be the same or different, or a salt thereof.

[0167] More preferably, in formula (I), ring A is a pyrrolidinyl group,

[0168]

[0169] a compound or a salt thereof, wherein: ring B is a phenyl group, indolyl group, indazolyl group, benzisoxazolyl group, or benzotriazolyl group; R1 is a cyano group; R2 is a fluorine atom; R2 is located on the phenyl group at the ortho position relative to R1; R3 is an amino group (when a plurality of R3s are present, the R3s may be the same or different); R4 is a fluorine atom, chlorine atom, bromine atom, cyano group, methyl group, difluoromethyl group, hydroxymethylpropyl group, hydroxyethylbutyl group, or hydroxycyclobutylmethyl group; R5 and R6 are hydrogen atoms, or R5 and R6 may together form an oxo group; 1 is an integer of 0 to 2; m is an integer of 0 to 2; and n is an integer of 0 to 3; when m is 2, two R3s may be the same or different; and when n is 2 or 3, two to three R4s may be the same or different.

[0170] More preferably, in formula (I), ring A is a pyrrolidinyl group,

[0171]

[0172] a compound or a salt thereof, wherein ring B is a phenyl group or a benzotriazolyl group, R1 is a cyano group, R2 is a fluorine atom, R2 is located on the phenyl group at the ortho position relative to R1, R3 is an amino group (when a plurality of R3s are present, the R3s may be the same or different), R4 is a fluorine atom, a bromine atom, a hydroxymethylpropyl group, or a hydroxyethylbutyl group, R5 and R6 are hydrogen atoms, or R5 and R6 may combine to form an oxo group, 1 is an integer of 0 to 2, m is an integer of 0 to 2, and n is an integer of 0 to 3, and when m is 2, two R3s may be the same or different, and when n is 2 or 3, two to three R4s may be the same or different.

[0173] In one aspect of the present invention, the biphenyl compound represented by general formula (I) is preferably one in which, in formula (I), ring A is a monocyclic or bridged 4- to 8-membered nitrogen-containing saturated heterocyclic group having 1 to 3 nitrogen atoms as heteroatoms, ring B is a monocyclic 5- to 8-membered unsaturated hydrocarbon group, or a bicyclic 8- to 14-membered unsaturated heterocyclic group having 1 to 4 nitrogen atoms as heteroatoms, R1 is a cyano group, R2 is a halogen atom, R3 is an amino group, and R4 is a halogen atom or a C1-C8 alkyl group optionally having a hydroxyl group as a substituent. When a plurality of the substituents are present, they may be the same or different; R5 and R6 represent a hydrogen atom, or R5 and R6 may combine to form an oxo group; 1 is an integer of 0 to 2; m is an integer of 0 to 2; n is an integer of 0 to 3; when 1 is 2, two R2s may be the same or different; when m is 2, two R3s may be the same or different; and when n is 2 or 3, two to three R4s may be the same or different.

[0174] More preferably, in formula (I), ring A is a pyrrolidinyl group,

[0175]

[0176] wherein ring B is a phenyl group or a benzotriazolyl group, R1 is a cyano group, R2 is a halogen atom, R3 is an amino group, R4 is a halogen atom or a C1-C8 alkyl group optionally having a hydroxyl group as a substituent, when a plurality of the substituents are present, they may be the same or different, R5 and R6 represent a hydrogen atom, or R5 and R6 may together form an oxo group, l is an integer of 0 to 2, m is an integer of 0 to 2, n is an integer of 0 to 3, when l is 2, two R2s may be the same or different, when m is 2, two R3s may be the same or different, when n is 2 to 3, two to three R4s may be the same or different, or a salt thereof.

[0177] More preferably, in formula (I), ring A is a pyrrolidinyl group,

[0178]

[0179] wherein ring B is a phenyl group or a benzotriazolyl group, R1 is a cyano group, R2 is a fluorine atom, R3 is an amino group, and R4 is a fluorine atom, a bromine atom, or a hydroxy(C1-C8 alkyl) group. When a plurality of such substituents are present, they may be the same or different, R5 and R6 may represent a hydrogen atom, or R5 and R6 may combine to form an oxo group, l is an integer of 0 to 2, m is an integer of 0 to 1, and n is an integer of 0 to 3. When l is 2, two R2s may be the same or different, and when n is 2 or 3, two to three R4s may be the same or different.

[0180] More preferably, in formula (I), ring A is a pyrrolidinyl group,

[0181]

[0182] wherein ring B is a phenyl group or a benzotriazolyl group, R1 is a cyano group, R2 is a fluorine atom, R3 is an amino group, and R4 is a fluorine atom, a bromine atom, a hydroxymethylpropyl group, or a hydroxyethylbutyl group. When a plurality of such substituents are present, they may be the same or different, R5 and R6 may represent a hydrogen atom, or R5 and R6 may combine to form an oxo group, 1 is an integer of 0 to 2, m is an integer of 0 to 1, and n is an integer of 0 to 3. When 1 is 2, two R2s may be the same or different, and when n is 2 or 3, two to three R4s may be the same or different. The compound or a salt thereof is

[0183] Specific examples of biphenyl compounds in the present invention include Example Compounds 1 to 295 produced in the Examples described below, but are not limited to these.

[0184] Examples of suitable biphenyl compounds include: 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile; 4-[5-[(3-endo)-3-amino-8-azabicyclo[3.2.1]octane-8-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile; 5'-((1S,2S,4R)-rel-2-amino-7-azabicyclo[2.2.1]heptane-7-carbonyl)-2",3-difluoro-4"-(2-hydroxy-2-methylpropyl)-[1,1':2',1''-terphenyl]-4-carbonitrile-isomer-B; 5'-((1S,2S,4R)-rel-2-amino-7-azabicyclo[2.2.1]heptane-7-carbonyl)-2'-(6,7-difluoro-1-(2-hydroxy-2-methylpropyl)-1H-benzo[d][1,2,3]triazol-5-yl)-3-fluoro-[1,1'-biphenyl]-4-carbonitrile-isomer-B; 5'-((1S,2S,4R)-rel-2-amino-7-azabicyclo[2.2.1]heptane-7-carbonyl)-2'-(1-(2-ethyl-2-hydroxybutyl)-6,7-difluoro-1H-benzo[d][1,2,3]triazol-5-yl)-3-fluoro-[1,1'-biphenyl]-4-carbonitrile-isomer-X; 5'-((1S,2S,4R)-rel-2-amino-7-azabicyclo[2.2.1]heptane-7-carbonyl)-2'-(7-bromo-6-fluoro-1-(2-hydroxy-2-methylpropyl)-1H-benzo[d][1,2,3]triazol-5-yl)-3-fluoro-[1,1'-biphenyl]-4-carbonitrile-isomer-X; 5'-(((1S,2S,4R)-rel-2-amino-7-azabicyclo[2.2.1]heptane-7-yl)methyl)-2'-(6,7-difluoro-1-(2-hydroxy-2-methylpropyl)-1H-benzo[d][1,2,3]triazol-5-yl)-3-fluoro-[1,1'-biphenyl]-4-carbonitrile-isomer-X.

[0185] Next, a method for producing the compound according to the present invention will be described.

[0186] The biphenyl compound represented by the general formula (I) can be produced, for example, by the following production method or the method shown in the Examples. However, the production method of the biphenyl compound represented by the general formula (I) is not limited to these reaction examples. [In steps 1 to 9, in the formula, L1, L2 and L3 each independently represent a leaving group or NH 2 or OH, W is a hydroxyl group, a C1-C6 alkoxy group, or

[0187]

[0188] and Q1 is L1 or

[0189]

[0190] and Q2 is L2 or

[0191]

[0192] wherein X represents an oxygen atom or a sulfur atom, E1 represents hydrogen or an optionally substituted C1-C6 alkyl group, and when E1 is an optionally substituted C1-C6 alkyl group, it may form a ring together with BOO, and ring A, ring B, R1, R2, R3, R4, R5, R6, l, m, and n are as defined above. Furthermore, R5a represents a C1-C6 alkyl group.]

[0193]

[0194] (Step 1) Suzuki Reaction This step is a method for producing a compound represented by general formula (IV) by Suzuki reaction using a compound represented by general formula (II).

[0195] This step can be carried out in accordance with a generally known method (for example, Chemical Reviews, Vol. 95, p. 2457, 1995). Protection of substituents, removal and conversion of protecting groups, and conversion of leaving groups L1, L2, and L3 can be carried out appropriately.

[0196] Examples of the leaving group represented by L1, L2 and L3 include halogen atoms such as chlorine atom, bromine atom and iodine atom, and organic sulfonyloxy groups such as trifluoromethylsulfonyloxy group and p-tolylsulfonyloxy group.

[0197] The amount of aromatic boronic acid or aromatic boronic acid ester (III) used is 0.5 to 10 moles, preferably 0.8 to 3 moles, per mole of the compound represented by formula (II).

[0198] Examples of the transition metal catalyst include palladium catalysts such as palladium acetate, tetrakis(triphenylphosphine)palladium, 1,1′-bis(diphenylphosphino)ferrocene-palladium(II) dichloride, bis(dibenzylideneacetone)dipalladium(0), and tris(dibenzylideneacetone)dipalladium(0); and nickel catalysts such as nickel chloride.

[0199] If necessary, a ligand may be added. Examples of the ligand include triphenylphosphine, tricyclohexylphosphine, (diphenylphosphino)ferrocene, 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl, and Silica-SMAP. The amount of the transition metal catalyst used varies depending on the type of catalyst, but is usually 0.0001 to 1 mol, and preferably 0.01 to 0.5 mol, per mol of the compound represented by general formula (II). The amount of the ligand used is usually 0.0001 to 4 mol, and preferably 0.01 to 2 mol, per mol of the compound represented by general formula (II).

[0200] Examples of the base include organic amines such as triethylamine, alkali metal salts such as sodium carbonate, potassium carbonate, cesium carbonate, sodium phosphate, tripotassium phosphate, sodium hydroxide, potassium hydroxide, alkali metal alkoxides such as sodium methoxide, sodium ethoxide, sodium tert-butoxide, potassium tert-butoxide, etc. The amount of the base used is usually 0.1 to 10 mol, preferably 1 to 5 mol, per 1 mol of the compound represented by general formula (II).

[0201] Any solvent may be used as long as it does not adversely affect the reaction, and examples thereof include toluene, acetonitrile, 1,2-dimethoxyethane, tetrahydrofuran, 1,4-dioxane, ethanol, N,N-dimethylformamide, water, and mixtures thereof. The reaction time is 0.1 to 7 days, preferably 0.5 to 24 hours. The reaction temperature is 0°C to the boiling temperature of the solvent, preferably 20°C to 160°C.

[0202] The compound represented by general formula (IV) thus obtained can be isolated and purified by a known separation and purification means, for example, concentration, concentration under reduced pressure, crystallization, solvent extraction, reprecipitation, chromatography, etc., or can be subjected to the next step without isolation and purification.

[0203] Alternatively, a compound represented by general formula (II) may be reacted with a compound represented by general formula (V) or (VI) in the same manner as in (Step 2) described below to obtain L2.

[0204]

[0205] Alternatively, the reaction for converting the

[0206] (Step 2) Suzuki Reaction This step is a method for producing a compound represented by general formula (I') by Suzuki reaction using a compound represented by general formula (IV).

[0207] This step can be carried out in the same manner as in (Step 1).

[0208]

[0209] In the case where the reaction for converting into the compound (VI) is carried out first and L1) is a boronic acid or a boronic acid ester derivative, compound (VI) is used in the reaction.

[0210] L3 in (VI) is the same as L1 and L2 in (Step 1), and the amount of (VI) used is usually 1 to 10 mol, preferably 1 to 5 mol, per 1 mol of the compound represented by general formula (IV).

[0211]

[0212] (Step 3) Boronic acid esterification reaction This step is a method for producing a compound represented by general formula (IX) in which L2 is converted into a boronic acid ester by a boronic acid esterification reaction using a compound represented by general formula (IV) and a diborane compound (VIII) in the presence of a transition metal catalyst and a base, optionally with the addition of a ligand.

[0213] The amount of diborane compound (VIII) used is 1 to 10 moles, preferably 1 to 5 moles, per mole of the compound represented by formula (IV).

[0214] The transition metal catalyst can be used in the same manner as in Step 1.

[0215] In addition to the base used in Step 1, potassium acetate, sodium acetate, etc. can be used.

[0216] The ligand can be the same as in step 1, and is preferably Silica-SMAP.

[0217] The solvent can be the same as in step 1.

[0218] The reaction temperature is usually 0 to 200° C., preferably 50 to 160° C. The reaction time is usually 5 minutes to 3 days, preferably 5 minutes to 10 hours.

[0219] Before this step 3, the compound represented by the general formula (II)

[0220]

[0221] may be introduced first, and then L1 may be subjected to a boronate esterification reaction in the same manner as in step 3.

[0222]

[0223] (Step 4) Amidation Reaction This step is a method for producing a compound represented by general formula (XI) by an amidation reaction using a carboxylic acid compound represented by general formula (VII), an amine compound represented by general formula (X), and a condensing agent.

[0224] The amount of the amine compound (X) used is 0.5 to 10 moles, preferably 0.8 to 5 moles, per mole of the compound represented by formula (VII).

[0225] Examples of the condensing agent include benzotriazol-1-yloxy-trisdimethylaminophosphonium salt, 4-(4,6-dimethoxy-1,3,5-triazin-2-yl)-4-methylmorpholinium chloride, a combination of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide and 1-hydroxybenzotriazole, O-(7-azabenzotriazo-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate, etc. The amount added is 1 to 100 moles, preferably 1 to 5 moles, relative to 1 mole of the compound represented by general formula (VII).

[0226] Furthermore, a base can be added to the above reaction as needed. Examples of the base include organic bases such as triethylamine, diisopropylethylamine, and pyridine, and inorganic bases such as potassium carbonate. The amount added is 1 to 100 mol, and preferably 1 to 10 mol, per 1 mol of the compound represented by general formula (VII).

[0227] The solvent is not particularly limited as long as it does not interfere with the reaction, and examples thereof include toluene, chloroform, tetrahydrofuran, N,N-dimethylformamide, dimethylacetamide, N-methylpyrrolidin-2-one, and the like, or mixed solvents thereof.

[0228] The reaction temperature is usually −78 to 200° C., preferably 0 to 50° C. The reaction time is usually 5 minutes to 3 days, preferably 5 minutes to 10 hours.

[0229] The compound represented by general formula (XI) thus obtained can be isolated and purified by a known separation and purification means, for example, concentration, concentration under reduced pressure, crystallization, solvent extraction, reprecipitation, chromatography, etc., or can be subjected to the next step without isolation and purification.

[0230]

[0231] (Step 5) Thiation Reaction This step is a method for producing a thioamide compound represented by general formula (XII) by reacting a compound represented by general formula (XI) with a thiolation reagent.

[0232] The thiolation reagent may be, for example, Lawesson's reagent, etc. The amount added is 1 to 10 moles, preferably 1 to 5 moles, per mole of the compound represented by general formula (XI).

[0233] The solvent can be the same as in step 1.

[0234] The reaction temperature is usually 0 to 200° C., preferably 0 to 100° C. The reaction time is usually 5 minutes to 3 days, preferably 5 minutes to 10 hours.

[0235] The compound represented by general formula (XII) thus obtained can be isolated and purified by a known separation and purification means, for example, concentration, concentration under reduced pressure, crystallization, solvent extraction, reprecipitation, chromatography, etc., or can be subjected to the next step without isolation and purification.

[0236]

[0237] (Step 6) Reduction Reaction to Primary Alcohol This step is a method for producing a primary alcohol compound (XIII) by reacting a carboxylic acid compound represented by general formula (VII) with a reducing agent. Examples of reducing agents include borane and lithium aluminum hydride. Other examples include sodium borohydride and lithium borohydride, which are used after forming an activated ester in the system. Examples of active esterifying agents include WSC·HCl, which is used together with HATU and HOBt. The amount of the reducing agent added is 1 to 10 mol, preferably 1 to 5 mol, per mol of the compound represented by general formula (VII). The amount of the active esterifying agent added is 1 to 10 mol, preferably 1 to 5 mol, per mol of the compound represented by general formula (VII). The solvent can be the same as in Step 1. The reaction temperature is usually 0 to 200°C, preferably 0 to 100°C. The reaction time is usually 5 minutes to 3 days, preferably 5 minutes to 10 hours.

[0238] The compound represented by general formula (XIII) thus obtained can be isolated and purified by a known separation and purification means, for example, concentration, concentration under reduced pressure, crystallization, solvent extraction, reprecipitation, chromatography, etc., or can be subjected to the next step without isolation and purification.

[0239]

[0240] (Step 7) Alkylation Reaction This step is a method for producing a secondary alcohol compound (XV) by reacting an aldehyde compound represented by general formula (XIV) with an alkyl metal reagent. Examples of alkyl metal reagents include alkyllithium and alkylmagnesium reagents. The amount of alkyl metal reagent added is 1 to 10 moles, preferably 1 to 5 moles, per mole of the compound represented by general formula (XIV). The solvent can be the same as in Step 5. The reaction temperature is usually −78 to 200°C, preferably −78 to 0°C. The reaction time is usually 5 minutes to 3 days, preferably 5 minutes to 10 hours.

[0241] The compound represented by general formula (XV) thus obtained can be isolated and purified by a known separation and purification means, for example, concentration, concentration under reduced pressure, crystallization, solvent extraction, reprecipitation, chromatography, etc., or can be subjected to the next step without isolation and purification.

[0242]

[0243] (Step 8) Oxidation reaction to aldehyde or ketone This step is a method for producing an aldehyde or ketone compound represented by general formula (XVII) using an alcohol compound represented by general formula (XVI) and an oxidizing agent.

[0244] Examples of the oxidizing agent include manganese dioxide, tetrapropylammonium perruthenate, sulfur trioxide pyridine complex, DESS-MARTIN periodinane, and pyridinium chlorochromate. The amount of the oxidizing agent added is 1 to 10 moles, preferably 1 to 5 moles, per mole of the compound represented by general formula (XVI). The same solvent as in step 5 can be used. The reaction temperature is usually −78 to 200°C, preferably 0 to 100°C. The reaction time is usually 5 minutes to 3 days, preferably 5 minutes to 10 hours. The compound represented by general formula (XVII) thus obtained can be isolated and purified by known separation and purification means, such as concentration, vacuum concentration, crystallization, solvent extraction, reprecipitation, and chromatography, or can be subjected to the next step without isolation and purification.

[0245]

[0246] (Step 9) Reductive amination reaction This step is a method for producing a compound represented by general formula (XVIII) by using an amine compound represented by general formula (X) and a reducing agent with an aldehyde or ketone compound represented by general formula (XVII).

[0247] Examples of the reducing agent include sodium triacetoxyborohydride, sodium cyanoborohydride, sodium borohydride, etc. The amount of the reducing agent to be added is 1 to 10 mol, preferably 1 to 5 mol, relative to 1 mol of the compound represented by general formula (XVII).

[0248] The solvent is not particularly limited as long as it does not interfere with the reaction, and examples thereof include toluene, chloroform, tetrahydrofuran, dichloromethane, methanol, ethanol, and the like, or mixed solvents thereof.

[0249] The compound represented by general formula (XVIII) thus obtained can be isolated and purified by a known separation and purification means, for example, concentration, concentration under reduced pressure, crystallization, solvent extraction, reprecipitation, chromatography, etc., or can be subjected to the next step without isolation and purification.

[0250] Conversion of the substituents W, X, and leaving groups L1, L2, and L3 can be carried out appropriately.

[0251] In any of Steps 1 to 9, protection of substituents, removal of protecting groups, and conversion can be carried out as appropriate. For example, functional groups having an active proton such as an amino group, an imino group, a hydroxyl group, a carboxyl group, a carbonyl group, an amide group, and indole can be protected in an appropriate step in each production method by using a protecting reagent or by introducing a protecting group into the functional group according to a conventional method, and then the protecting group can be removed.

[0252] The "protecting group for an amino or imino group" is not particularly limited as long as it has the function, and examples thereof include aralkyl groups such as benzyl, p-methoxybenzyl, 3,4-dimethoxybenzyl, o-nitrobenzyl, p-nitrobenzyl, benzhydryl, trityl, and cumyl; lower alkanoyl groups such as formyl, acetyl, propionyl, butyryl, pivaloyl, trifluoroacetyl, and trichloroacetyl; benzoyl; arylalkanoyl groups such as phenylacetyl and phenoxyacetyl; lower alkoxycarbonyl groups such as methoxycarbonyl, ethoxycarbonyl, propyloxycarbonyl, and tert-butoxycarbonyl; and p-nitrobenzyloxycarbonyl. lower alkylsulfonyl groups such as methylsulfonyl group, ethylsulfonyl group, tert-butylsulfonyl group; lower alkylsulfinyl groups such as tert-butylsulfinyl group; arylsulfonyl groups such as benzenesulfonyl group, toluenesulfonyl group; and imide groups such as phthalimide group, with a trifluoroacetyl group, an acetyl group, a tert-butoxycarbonyl group, a benzyloxycarbonyl group, a trimethylsilylethoxymethyl group, and a cumyl group being particularly preferred.

[0253] The "hydroxyl-protecting group" is not particularly limited as long as it has that function, and examples thereof include lower alkyl groups such as methyl, ethyl, propyl, isopropyl, and tert-butyl; lower alkylsilyl groups such as trimethylsilyl and tert-butyldimethylsilyl; lower alkoxymethyl groups such as methoxymethyl and 2-methoxyethoxymethyl; tetrahydropyranyl; trimethylsilylethoxymethyl; aralkyl groups such as benzyl, p-methoxybenzyl, 2,3-dimethoxybenzyl, o-nitrobenzyl, p-nitrobenzyl, and trityl; and acyl groups such as formyl, acetyl, and trifluoroacetyl, with methyl, methoxymethyl, tetrahydropyranyl, trimethylsilylethoxymethyl, tert-butyldimethylsilyl, and acetyl being particularly preferred.

[0254] The "carboxyl-protecting group" is not particularly limited as long as it has that function, and examples thereof include lower alkyl groups such as methyl, ethyl, propyl, isopropyl, and tert-butyl; halo-lower alkyl groups such as 2,2,2-trichloroethyl; lower alkenyl groups such as allyl; trimethylsilylethoxymethyl; and aralkyl groups such as benzyl, p-methoxybenzyl, p-nitrobenzyl, benzhydryl, and trityl, with methyl, ethyl, tert-butyl, allyl, benzyl, p-methoxybenzyl, and trimethylsilylethoxymethyl being particularly preferred.

[0255] The "carbonyl group-protecting group" is not particularly limited as long as it has the function, and examples thereof include ketals and acetals such as ethylene ketal, trimethylene ketal, dimethyl ketal, ethylene acetal, trimethylene acetal, and dimethyl acetal.

[0256] The "protecting group for a functional group having an active proton, such as an amide group or indole" is not particularly limited as long as it has that function, and examples thereof include lower alkyl groups such as a methyl group, an ethyl group, a propyl group, an isopropyl group, and a tert-butyl group; lower alkylsilyl groups such as a trimethylsilyl group and a tert-butyldimethylsilyl group; lower alkoxymethyl groups such as a methoxymethyl group and a 2-methoxyethoxymethyl group;

[0257] The method for removing the protecting group varies depending on the type of the protecting group, the stability of the target compound, and the like, but can be carried out, for example, according to a method described in the literature (see Protective Groups in Organic Synthesis, 3rd Edition, T. W. Greene, John Wiley & Sons, 1999) or a method equivalent thereto, for example, solvolysis using an acid or a base, i.e., a method involving the action of, for example, 0.01 molar to a large excess of an acid, preferably trifluoroacetic acid, formic acid, hydrochloric acid, or the like, or an equimolar to a large excess of a base, preferably potassium hydroxide, calcium hydroxide, or the like; chemical reduction using a metal hydride complex, or the like; or catalytic reduction using a palladium-carbon catalyst, a Raney nickel catalyst, or the like.

[0258] The biphenyl compound represented by formula (I) can be easily isolated and purified by conventional separation means, such as solvent extraction, recrystallization, preparative reversed-phase high performance liquid chromatography, column chromatography, and preparative thin-layer chromatography.

[0259] When the biphenyl compound represented by general formula (I) has isomers such as optical isomers, stereoisomers, rotamers, and tautomers, all isomers and mixtures thereof are encompassed within the compound unless otherwise specified. For example, when the biphenyl compound represented by general formula (I) has optical isomers, optical isomers resolved from the racemate are also encompassed within the compound unless otherwise specified. These isomers can be obtained as single compounds by known synthesis and separation techniques (e.g., concentration, solvent extraction, column chromatography, recrystallization, etc.).

[0260] As described above, unless otherwise specified, the biphenyl compound represented by general formula (I) includes each enantiomer and a mixture thereof. In addition, the biphenyl compound represented by general formula (I) may be a mixture of R- and S-enantiomers, in which the R-enantiomer is 90% or more, 95% or more, or 99% or more, or the S-enantiomer is 90% or more, 95% or more, or 99% or more, etc.

[0261] Examples of optical resolution methods include a diastereomeric method in which a biphenyl compound represented by general formula (I) is reacted with an optical resolving agent to form a salt, and one enantiomer is resolved by utilizing the difference in solubility of the resulting salt; a preferential crystallization method in which one enantiomer is added as a crystal seed to a supersaturated solution of a racemate; and column chromatography such as HPLC using a chiral column. Optical resolution agents that can be used in the diastereomeric method can be appropriately selected from acidic resolving agents such as tartaric acid, malic acid, lactic acid, mandelic acid, 10-camphorsulfonic acid, and derivatives thereof; and basic resolving agents such as alkaloid compounds such as brucine, strychnine, and quinine, amino acid derivatives, cinchonidine, and α-methylbenzylamine. In addition to the method of obtaining a biphenyl compound represented by general formula (I) as a mixture of enantiomers and then optically resolving it as described above, only one of the enantiomers of the biphenyl compound represented by general formula (I) can be obtained by using only one of the enantiomers optically resolved by the method described above as a raw material for synthesizing the biphenyl compound represented by general formula (I). Examples of a method for obtaining one of the enantiomers from the biphenyl compound represented by general formula (I) or a raw material compound thereof include a method in which reaction conditions such as a catalyst are adjusted in a reaction step in which an asymmetric carbon is generated so that one of the enantiomers is preferentially obtained.

[0262] The biphenyl compound represented by general formula (I) or a salt thereof may be in the form of a crystal, and whether the crystalline form is a single one or a polymorphic mixture, the compound or a salt thereof is included in the compound or a salt thereof. The crystal can be produced by crystallization using a crystallization method known per se. The biphenyl compound represented by general formula (I) or a salt thereof may be a solvate (e.g., a hydrate, etc.) or a non-solvate, and both are included in the biphenyl compound represented by general formula (I) or a salt thereof. Isotopes (e.g., 3 H. 14 C. 35 S. 125 Compounds labeled with a biphenyl compound such as phenylalanine (I) are also included in the biphenyl compound represented by formula (I) or a salt thereof.

[0263] The salt of the biphenyl compound represented by formula (I) or a production intermediate thereof refers to a salt conventionally used in the field of organic chemistry. The salt is preferably a pharmaceutically acceptable salt. For example, when the compound has a carboxyl group, it may be a base addition salt at the carboxyl group, or when the compound has an amino group or a basic heterocyclic group, it may be an acid addition salt at the amino group or a basic heterocyclic group.

[0264] Examples of the base addition salt include alkali metal salts such as sodium salts and potassium salts; alkaline earth metal salts such as calcium salts and magnesium salts; ammonium salts; and organic amine salts such as trimethylamine salts, triethylamine salts, dicyclohexylamine salts, ethanolamine salts, diethanolamine salts, triethanolamine salts, procaine salts, and N,N'-dibenzylethylenediamine salts.

[0265] Examples of the acid addition salts include inorganic acid salts such as hydrochlorides, sulfates, nitrates, phosphates, and perchlorates; organic acid salts such as acetates, formates, maleates, fumarates, tartrates, citrates, ascorbates, and trifluoroacetates; and sulfonates such as methanesulfonates, isethionates, benzenesulfonates, and p-toluenesulfonates.

[0266] The biphenyl compound represented by the general formula (I) or a salt thereof is useful as a medicament for preventing or treating, preferably treating, diseases in which LSD1 is involved due to its excellent LSD1 inhibitory activity.

[0267] The antitumor effect is enhanced by using a biphenyl compound represented by general formula (I) or a salt thereof in combination with another antitumor agent. The combination of the biphenyl compound represented by general formula (I) or a salt thereof with another antitumor agent may be in the form of a single formulation (i.e., a combination drug) or in the form of two or more separate formulations administered in combination.

[0268] In the present invention, the antitumor effect can be evaluated, for example, as a decrease in tumor volume, a stasis of tumor growth, or an extension of survival time.

[0269] In one embodiment, there is provided an antitumor agent comprising a biphenyl compound represented by general formula (I) or a salt thereof in combination with another antitumor agent. In another embodiment, there is provided an agent for enhancing the antitumor effect of another antitumor agent, which comprises a biphenyl compound represented by general formula (I) or a salt thereof as an active ingredient.

[0270] Other antitumor agents include, but are not limited to, antimetabolites, antitumor antibiotics, molecular targeted drugs, platinum-based drugs, and plant alkaloid-based drugs.

[0271] Examples of the antimetabolite include 5-fluorouracil (5-FU), 5-fluoro-2'-deoxyuridine (FdUrd), tegafur, tegafur / uracil combinations (e.g., UFT), tegafur / gimeracil / oteracil combinations (e.g., TS-1), pemetrexed, trifluridine, trifluridine / tipiracil hydrochloride combinations (e.g., Lonsurf), gemcitabine, capecitabine, nelarabine, clofarabine, cytarabine, DNA methylation inhibitors (azacitidine, decitabine, guadecitabine, etc.), and the like, preferably cytarabine, or DNA methylation inhibitors such as azacitidine, decitabine, guadecitabine, and the like, more preferably cytarabine, azacitidine, decitabine, or guadecitabine.

[0272] Examples of antitumor antibiotics include anthracycline antitumor antibiotics such as daunorubicin, doxorubicin, amrubicin, idarubicin, and epirubicin, mitomycin C, and bleomycin, with anthracycline antitumor antibiotics being preferred, and daunorubicin being more preferred.

[0273] Examples of molecularly targeted drugs include all-trans retinoic acid or a derivative thereof, a human MDM2 (mouse double minute 2) (HDM2; human double minute 2) inhibitor, or an HDAC inhibitor.

[0274] The all-trans retinoic acid or a derivative thereof is preferably tretinoin (ATRA) or tamibarotene, more preferably tretinoin (ATRA).

[0275] The human MDM2 (HDM2) inhibitor is preferably RG7388 (RO5503781), AMG-232, DS-3032b, RG7112 (RO5045337), SAR405838, or MK-8242, more preferably RG7388.

[0276] HDAC inhibitors include vorinostat, panobinostat, romidepsin, belinostat, and the like.

[0277] The molecular targeted drug is preferably all-trans retinoic acid or a derivative thereof, a human MDM2 (HDM2) inhibitor, or an HDAC inhibitor, more preferably tretinoin (ATRA) or RG7388.

[0278] Examples of platinum-based drugs include oxaliplatin, carboplatin, cisplatin, nedaplatin, etc., and carboplatin or cisplatin is preferred.

[0279] Examples of plant alkaloid drugs include microtubule inhibitors such as paclitaxel, docetaxel, vinblastine, vincristine, vindesine, vinorelbine, and eribulin, and topoisomerase inhibitors such as irinotecan (SN-38), nogitecan, and etoposide, of which taxane microtubule inhibitors such as paclitaxel and docetaxel, or topoisomerase inhibitors such as irinotecan (SN-38), nogitecan, and etoposide are preferred, and paclitaxel, irinotecan (SN-38), or etoposide are more preferred.

[0280] The other antitumor agent is preferably an antimetabolite, an antitumor antibiotic, a molecular targeted drug, a platinum-based drug, or a plant alkaloid-based drug, more preferably an antimetabolite, an antitumor antibiotic, all-trans retinoic acid or a derivative thereof, a human MDM2 (HDM2) inhibitor, an HDAC inhibitor, a platinum-based drug, or a plant alkaloid-based drug, more preferably an antimetabolite, an antitumor antibiotic, all-trans retinoic acid or a derivative thereof, a human MDM2 (HDM2) inhibitor, a platinum-based drug, or a plant alkaloid-based drug, more preferably an antimetabolite, an antitumor antibiotic, all-trans retinoic acid or a derivative thereof, a human MDM2 (HDM2) inhibitor, a platinum-based drug, or a plant alkaloid-based drug. or a derivative thereof, a human MDM2 (HDM2) inhibitor, a platinum-based drug, a topoisomerase inhibitor, or a taxane-based microtubule inhibitor, more preferably cytarabine, a DNA methylation inhibitor, an anthracycline antitumor antibiotic, all-trans retinoic acid or a derivative thereof, a platinum-based drug, a topoisomerase inhibitor, or a taxane-based microtubule inhibitor, more preferably cytarabine, azacitidine, decitabine, guadecitabine, daunorubicin, tretinoin (ATRA), RG7388, carboplatin, cisplatin, paclitaxel, irinotecan (SN-38), or etoposide.

[0281] The tumors targeted by the present invention are not particularly limited as long as they exhibit an antitumor effect enhancement effect, but are preferably tumors against which the biphenyl compound represented by general formula (I) or a salt thereof exhibits an antitumor effect, and more preferably malignant tumors in which LSD1 is involved.

[0282] Here, "LSD1-associated malignant tumors" include malignant tumors whose incidence can be reduced, symptoms can be alleviated, and / or they can be cured by deleting, suppressing, and / or inhibiting the function of LSD1. Target malignant tumors are not particularly limited, and examples include head and neck cancer, esophageal cancer, gastric cancer, colon cancer, rectal cancer, liver cancer, gallbladder / bile duct cancer, biliary tract cancer, pancreatic cancer, lung cancer, breast cancer, ovarian cancer, cervical cancer, uterine cancer, kidney cancer, bladder cancer, prostate cancer, testicular tumors, bone and soft tissue sarcoma, leukemia, myelodysplastic syndrome, chronic myeloproliferative disease, malignant lymphoma, multiple myeloma, skin cancer, brain tumor, mesothelioma, etc. Preferred examples include lung cancer (non-small cell lung cancer, small cell lung cancer, etc.), leukemia, and myelodysplastic syndrome.

[0283] When using a biphenyl compound or a salt thereof and other antitumor agents as a medicine, a pharmaceutical carrier may be added as needed, and one or more of various administration forms may be adopted depending on the purpose of prevention or treatment. Such forms may include, for example, oral preparations, injections, suppositories, ointments, patches, etc. In the case of a biphenyl compound or a salt thereof, oral preparations are preferred. These administration forms can be prepared by formulation methods known and commonly used by those skilled in the art.

[0284] The administration schedule of the biphenyl compound represented by formula (I) or a salt thereof and the other antitumor agent is appropriately selected within a range that enhances the antitumor effect, and each active ingredient can be administered simultaneously or separately at intervals. When administered separately, it does not matter which one is administered first.

[0285] The biphenyl compound represented by formula (I) or a salt thereof and other antitumor agents may be formulated by dividing the active ingredients into multiple dosage forms or by combining them into a single dosage form (i.e., formulated as a combination drug) based on the dosage form and administration schedule of each active ingredient. Furthermore, each formulation may be manufactured and sold together in a single package suitable for combined use, or each formulation may be manufactured and sold separately in separate packages.

[0286] As pharmaceutical carriers, various organic or inorganic carrier substances commonly used as formulation materials are used, and are incorporated as excipients, binders, disintegrants, lubricants, coating agents in solid formulations, and as solvents, solubilizers, suspending agents, isotonicity agents, pH adjusters / buffers, soothing agents, etc. in liquid formulations. Furthermore, formulation additives such as preservatives, antioxidants, colorants, flavorings / odors, stabilizers, etc. can also be used as needed.

[0287] When preparing oral solid preparations, tablets, coated tablets, granules, powders, capsules, etc. can be produced by conventional methods using excipients, binders, disintegrants, lubricants, colorants, flavorings, odorants, etc.

[0288] Examples of excipients include lactose, sucrose, D-mannitol, glucose, starch, calcium carbonate, kaolin, microcrystalline cellulose, and anhydrous silicic acid. Examples of binders include water, ethanol, 1-propanol, 2-propanol, simple syrup, glucose solution, α-starch solution, gelatin solution, D-mannitol, carboxymethylcellulose, hydroxypropylcellulose, hydroxypropyl starch, methylcellulose, ethylcellulose, shellac, calcium phosphate, and polyvinylpyrrolidone. Examples of disintegrants include dry starch, sodium alginate, powdered agar, sodium bicarbonate, calcium carbonate, sodium lauryl sulfate, monoglyceride stearate, and lactose. Examples of lubricants include purified talc, sodium stearate, magnesium stearate, borax, and polyethylene glycol. Examples of colorants include titanium oxide and iron oxide. Examples of flavorings and corrigents include sucrose, orange peel, citric acid, and tartaric acid.

[0289] When preparing oral liquid preparations, oral liquid preparations, syrups, elixirs, etc. can be produced by conventional methods using flavoring agents, buffers, stabilizers, odorants, etc.

[0290] Flavoring agents may be those listed above, buffers may include sodium citrate, and stabilizers may include tragacanth, gum arabic, and gelatin. If necessary, enteric coating or coating may be applied to oral preparations by known methods to prolong their effectiveness. Examples of such coating agents include hydroxypropylmethylcellulose, ethylcellulose, hydroxymethylcellulose, hydroxypropylcellulose, polyoxyethylene glycol, and Tween 80 (registered trademark).

[0291] When preparing injections, subcutaneous, intramuscular and intravenous injections can be produced by conventional methods using pH adjusting agents, buffering agents, stabilizers, isotonicity agents, local anesthetics and the like.

[0292] Examples of pH adjusters and buffers include sodium citrate, sodium acetate, and sodium phosphate. Examples of stabilizers include sodium pyrosulfite, EDTA, thioglycolic acid, and thiolactic acid. Examples of local anesthetics include procaine hydrochloride and lidocaine hydrochloride. Examples of isotonic agents include sodium chloride, glucose, D-mannitol, and glycerin.

[0293] The formulations of other antitumor agents also include their DDS (Drug Delivery System) formulations. For example, "paclitaxel" includes albumin-suspended paclitaxel (e.g., Abraxane) and paclitaxel micelles (e.g., NK105), and "cisplatin" includes cisplatin micelles (e.g., NC-6004).

[0294] The amount of the biphenyl compound to be incorporated into each of the above-mentioned dosage unit forms varies depending on the symptoms of the patient to whom it is to be administered or on the dosage form, but it is generally desirable that the amount per dosage unit form be 0.05 to 1000 mg for oral preparations, 0.01 to 500 mg for injections, and 1 to 1000 mg for suppositories.

[0295] The daily dose of the biphenyl compound having the above-mentioned dosage form varies depending on the symptoms, body weight, age, sex, etc. of the patient and cannot be determined in general, but the daily dose of the biphenyl compound for an adult (body weight 50 kg) is usually 0.05 to 5000 mg, preferably 0.1 to 1000 mg, and is preferably administered once a day or in divided doses about 2 to 3 times a day.

[0296] The present invention will be described in more detail below with reference to examples, but the present invention is not limited thereto. Although the present invention has been fully explained with reference to examples, it is understood that various changes and modifications may be made by those skilled in the art. Therefore, as long as such changes and modifications do not deviate from the scope of the present invention, they are included in the present invention.

[0297] Unless otherwise specified, commercially available reagents were used in the examples. For silica gel column chromatography, a Biotage SNAP-ULTRA® Silica prepacked column was used, and for basic silica gel column chromatography, a Biotage KP-NH® prepacked column was used. NMR spectra were measured using an AL400 (400 MHz; JEOL), a Mercury 400 (400 MHz; Agilent Technologies), or a 500 MHz Bruker AVANCE III HD NMR Spectrometer (500 MHz; BURKER). Tetramethylsilane was used as the internal standard when the deuterated solvent contained tetramethylsilane, and the NMR solvent was used as the internal standard otherwise. All δ values ​​are expressed in ppm. The microwave reaction was carried out using an Initiator manufactured by Biotage.

[0298] LCMS spectra were measured using a Waters ACQUITY SQD (quadrupole type) under the following conditions: Column: Waters ACQUITY UPLC (registered trademark) BEH C18, 2.1 × 50 mm, 1.7 μm MS detection: ESI positive UV detection: 254 and 280 nm Column flow rate: 0.5 mL / min Mobile phase: water / acetonitrile (0.1% formic acid) Injection amount: 1 μL Gradient (table 1) Time (min) Water Acetonitrile 0 95 5 0.1 95 5 2.1 5 95 3.0 STOP

[0299] Reverse-phase preparative HPLC purification was carried out using a preparative system manufactured by Gilson under the following conditions: Column: Waters Xselect CSH Prep C18 5 μm OBD (19 × 50 mm) + (19 × 100 mm) UV detection: 254 nm Column flow rate: 18 mL / min Mobile phase: water / acetonitrile (0.1% formic acid) Injection volume: 0.1-0.5 mL

[0300] The meanings of the abbreviations are as follows:

[0301] s: Singlet d: Doublet t: Triplet q: Quartet dd: Double doublet dt: Double triplet td: Triple doublet tt: Triple triplet ddd: Double double doublet ddt: Double double triplet dtd: Double triple doublet tdd: Triple double doublet m: Multiplet br: Broad brs: Broad singlet THF: Tetrahydrofuran DMF: N,N-dimethylformamide DME: 1,2-dimethoxyethane DMSO: Dimethyl sulfoxide HATU: O-(7-azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate TEA: Triethylamine WSC HCl: 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride t-BuOH: Tertiary butanol DMAP: N,N-dimethylaminopyridine Pd(PPh 3 ) 4 : tetrakis(triphenylphosphine)palladium(0) Pd(dba) 2 : Bis(dibenzylideneacetone)palladium(0) PCy 3 : Tricyclohexylphosphine TFA: Trifluoroacetic acid Pd(OAc) 2 : Palladium acetate KOAc: Potassium acetate PdCl 2 (dppf): [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride PdCl 2 (dppf)CH 2 Cl 2 : [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) dichloride dichloromethane complex DMEAD: di-2-methoxyethyl azodicarboxylate PPh 3 : Triphenylphosphine DMA: Dimethylacetamide MeMgBr: Methyl magnesium bromide EtMgBr: Ethyl magnesium bromide MTBE: Methyl tertiary butyl ether DCM: Dichloromethane Boc 2O: Di-tertiary butyl dicarbonate NBS: N-bromosuccinimide X-phos: 2-dicyclohexylphosphino-2',4',6'-triisopropylbiphenyl MeOH: Methanol EtOH: Ethanol IPE: Diisopropyl ether TBAF: Tetrabutylammonium fluoride Pd 2 (dba) 3 : Tris(dibenzylideneacetone)dipalladium(0) PdCl 2 (PPh 3 )  2 : Palladium chloride bistriphenylphosphine S-Phos: 2-dicyclohexylphosphino-2,6-dimethoxybiphenyl HOBt: 1-hydroxybenzotriazole Pd / C: palladium on carbon NMP: N-methyl-2-pyrrolidinone.

[0302] Example 1 Synthesis of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-(p-tolyl)phenyl]benzonitrile (Step 1) 19 g of 3-bromo-4-chlorobenzoic acid was dissolved in 160 mL of DMF. 20 g of DMAP and 31 g of WSC HCl were added at 25°C, followed by 38 mL of t-BuOH, and the mixture was stirred overnight at room temperature. Ethyl acetate was added, and the mixture was washed sequentially with water and saturated brine. The organic layer was dried over anhydrous sodium sulfate, and the solvent was then distilled off. The residue was purified by silica gel column chromatography (mobile phase: hexane / ethyl acetate) to obtain tert-butyl 3-bromo-4-chlorobenzoate.

[0303] (Step 2) 1.3 g of tert-butyl 3-bromo-4-chlorobenzoate obtained in Step 1 above was dissolved in 8.7 mL of 1,4-dioxane. 3 ) 4 151 mg of 2M Na 2 CO 35.4 mL of an aqueous solution was added, and the reaction solution was stirred in a microwave reactor at 120° C. for 30 minutes. The reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (mobile phase: hexane / ethyl acetate) to obtain tert-butyl 4-chloro-3-(4-cyanophenyl)benzoate.

[0304] (Step 3) 1.1 g of tert-butyl 4-chloro-3-(4-cyanophenyl)benzoate obtained in Step 2 above was dissolved in 17 mL of 1,4-dioxane. 2 157 mg, potassium phosphate 1.5 g, 1 M PCy 3 0.57 mL of a THF solution was added. The reaction solution was stirred at 160°C for 30 minutes in a microwave reaction apparatus. Chloroform was added, insoluble matter was filtered off, and the solvent was evaporated. The residue was purified by silica gel column chromatography (mobile phase: hexane / ethyl acetate), and the solvent was evaporated. The residue was dissolved in 2 mL of TFA. The solvent was evaporated. Ethyl acetate was added, and the mixture was washed successively with water and saturated brine. The organic layer was dried over anhydrous sodium sulfate, and the solvent was evaporated to obtain 3-(4-cyanophenyl)-4-(p-tolyl)benzoic acid.

[0305] (Step 4) 10 mg of 3-(4-cyanophenyl)-4-(p-tolyl)benzoic acid obtained in Step 3 above, 6 mg of tert-butyl N-[(3S)-pyrrolidin-3-yl]carbamate, and 24 mg of HATU were dissolved in 0.5 mL of THF. 0.013 mL of TEA was added at room temperature, and the mixture was stirred overnight at 50°C. The reaction solution was concentrated under reduced pressure, and the solvent was distilled off. The residue was purified by silica gel column chromatography (mobile phase: hexane / ethyl acetate) to give tert-butyl N-[(3S)-1-[3-(4-cyanophenyl)-4-(p-tolyl)benzoyl]pyrrolidin-3-yl]carbamate.

[0306] (Step 5) 15 mg of tert-butyl N-[(3S)-1-[3-(4-cyanophenyl)-4-(p-tolyl)benzoyl]pyrrolidin-3-yl]carbamate obtained in Step 4 above was dissolved in 0.3 mL of TFA, and the progress of the reaction was confirmed by LCMS, followed by concentration under reduced pressure. The residue was purified by reverse-phase HPLC (mobile phase: water / acetonitrile) to obtain the title compound.

[0307] Example 2 Synthesis of 4-[5-[(3S)-3-aminopyrrolidine-1-carbothioyl]-2-(p-tolyl)phenyl]benzonitrile 6 mg of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-(p-tolyl)phenyl]benzonitrile obtained in Example 1 (Step 5) was dissolved in 0.8 mL of THF. 3.8 mg of Lawesson's Reagent was added at room temperature, and the mixture was stirred at room temperature for 30 minutes. Chloroform was added, and the mixture was separated with aqueous sodium bicarbonate. The organic layer was dried over anhydrous sodium sulfate, and the solvent was then evaporated. The residue was purified by reverse-phase HPLC (mobile phase: water / acetonitrile) to obtain the title compound.

[0308] Example 3 Synthesis of 4-[5-(4-aminopiperidine-1-carbonyl)-2-(p-tolyl)phenyl]benzonitrile (Step 1) 20 mg of 3-(4-cyanophenyl)-4-(p-tolyl)benzoic acid obtained in Example 1 (Step 3) was dissolved in 1 mL of THF. 13 mg of tert-butyl N-(4-piperidyl)carbamate, 49 mg of HATU, and 0.027 mL of TEA were added at room temperature, and the mixture was stirred overnight at 50°C. The reaction solution was concentrated under reduced pressure, and the solvent was distilled off. The residue was purified by silica gel column chromatography (mobile phase: hexane / ethyl acetate) to obtain tert-butyl N-[1-[3-(4-cyanophenyl)-4-(p-tolyl)benzoyl]-4-piperidyl]carbamate. (Step 2) 30 mg of tert-butyl N-[1-[3-(4-cyanophenyl)-4-(p-tolyl)benzoyl]-4-piperidyl]carbamate obtained in Step 1 above was dissolved in 0.3 mL of TFA, and the progress of the reaction was confirmed by LCMS, followed by concentration under reduced pressure. The residue was purified by reverse-phase HPLC (mobile phase: water / acetonitrile) to obtain the title compound.

[0309] Example 4 Synthesis of 4-[5-(2,8-diazaspiro[3.5]nonane-2-carbonyl)-2-(p-tolyl)phenyl]benzonitrile The title compound was obtained according to the procedure of Example 1 (steps 1 to 5) except for using tert-butyl 2,8-diazaspiro[3.5]nonane-8-carboxylate hydrochloride in place of tert-butyl N-[(3S)-pyrrolidin-3-yl]carbamate.

[0310] Example 5 Synthesis of 4-[5-(2,7-diazaspiro[3.4]octane-7-carbonyl)-2-(p-tolyl)phenyl]benzonitrile The title compound was obtained according to the procedure of Example 1 (steps 1 to 5) except for using tert-butyl 2,7-diazaspiro[3.4]octane-2-carboxylate instead of tert-butyl N-[(3S)-pyrrolidin-3-yl]carbamate.

[0311] Example 6 Synthesis of 4-[5-(3,8-diazaspiro[4.4]nonane-8-carbonyl)-2-(p-tolyl)phenyl]benzonitrile The title compound was obtained according to the procedure of Example 1 (steps 1 to 5) except that tert-butyl 3,8-diazaspiro[4.4]nonane-8-carboxylate was used instead of tert-butyl N-[(3S)-pyrrolidin-3-yl]carbamate.

[0312] Example 7 Synthesis of 4-[5-[(3-exo)-3-amino-8-azabicyclo[3.2.1]octane-8-carbonyl]-2-(p-tolyl)phenyl]benzonitrile (Step 1) 500 mg of 3-bromo-4-chlorobenzoic acid was dissolved in 5.3 mL of DMA. 1 g of HATU, 0.59 mL of TEA, and then 480 mg of tert-butyl N-[(3-exo)-8-azabicyclo[3.2.1]octan-3-yl]carbamate were added at room temperature, and the mixture was stirred at room temperature for 1 hour. Ethyl acetate was added, and the mixture was washed successively with water and saturated brine. The organic layer was dried over anhydrous sodium sulfate, and the solvent was then evaporated. The residue was purified by silica gel column chromatography (mobile phase: hexane / ethyl acetate) to obtain tert-butyl N-[(3-exo)-8-(3-bromo-4-chloro-benzoyl)-8-azabicyclo[3.2.1]octan-3-yl]carbamate.

[0313] (Step 2) 200 mg of tert-butyl N-[(3-exo)-8-(3-bromo-4-chloro-benzoyl)-8-azabicyclo[3.2.1]octan-3-yl]carbamate obtained in Step 1 above was dissolved in 2.3 mL of 1,4-dioxane. 3 ) 4 16 mg of 2M Na 2 CO 3 1.1 mL of an aqueous solution was added, and the reaction solution was stirred in a microwave reactor at 120° C. for 30 minutes. The solvent was evaporated, and the residue was purified by silica gel column chromatography (mobile phase: hexane / ethyl acetate) to obtain tert-butyl N-[(3-exo)-8-[4-chloro-3-(4-cyanophenyl)benzoyl]-8-azabicyclo[3.2.1]octan-3-yl]carbamate.

[0314] (Step 3) 15 mg of tert-butyl N-[(3-exo)-8-[4-chloro-3-(4-cyanophenyl)benzoyl]-8-azabicyclo[3.2.1]octan-3-yl]carbamate obtained in Step 2 above was dissolved in 0.322 mL of 1,4-dioxane. 5.3 mg of p-tolylboronic acid and Pd(dba) were added at room temperature.2 0.93 mg, 1 M PCy 3 0.003 mL of the THF solution and 21 mg of tripotassium phosphate were added, and the reaction solution was stirred for 30 minutes at 160° C. in a microwave reactor. The solvent was evaporated, and the residue was purified by silica gel column chromatography (mobile phase: hexane / ethyl acetate) to obtain tert-butyl N-[(3-exo)-8-[3-(4-cyanophenyl)-4-(p-tolyl)benzoyl]-8-azabicyclo[3.2.1]octan-3-yl]carbamate.

[0315] (Step 4) 15 mg of tert-butyl N-[(3-exo)-8-[3-(4-cyanophenyl)-4-(p-tolyl)benzoyl]-8-azabicyclo[3.2.1]octan-3-yl]carbamate obtained in Step 3 above was dissolved in 0.3 mL of TFA, and the progress of the reaction was confirmed by LCMS, followed by concentration under reduced pressure. The residue was purified by reverse-phase HPLC (mobile phase: water / acetonitrile) to obtain the title compound.

[0316] Example 8 Synthesis of 4-[5-[(3S)-3-amino-3-methyl-pyrrolidine-1-carbonyl]-2-(p-tolyl)phenyl]benzonitrile The title compound was obtained according to the procedure of Example 1 (steps 1 to 5), except that tert-butyl N-[(3S)-3-methylpyrrolidin-3-yl]carbamate was used instead of tert-butyl N-[(3S)-pyrrolidin-3-yl]carbamate.

[0317] Example 9 Synthesis of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-(2-chloro-4-methyl-phenyl)phenyl]benzonitrile (Step 1) 10 g of 3-bromo-4-chloro-benzoic acid was dissolved in 85 mL of DMA. 24 g of HATU, 12 mL of TEA, and then 8.7 g of tert-butyl N-[(3S)-pyrrolidin-3-yl]carbamate were added at room temperature, and the mixture was stirred at room temperature for 1 hour. Ethyl acetate was added, and the mixture was washed sequentially with water and saturated brine. The organic layer was dried over anhydrous sodium sulfate, and the solvent was then evaporated. The residue was purified by silica gel column chromatography (mobile phase: hexane / ethyl acetate) to obtain tert-butyl N-[(3S)-1-(3-bromo-4-chloro-benzoyl)pyrrolidin-3-yl]carbamate.

[0318] (Step 2) 2.2 g of tert-butyl N-[(3S)-1-(3-bromo-4-chloro-benzoyl)pyrrolidin-3-yl]carbamate obtained in Step 1 above was dissolved in 13.6 mL of 1,4-dioxane. 1.5 g of 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzonitrile and Pd(PPh 3 ) 4 189 mg of 2M Na 2 CO 3 6.8 mL of aqueous solution was added, and the reaction solution was stirred at 120°C for 30 minutes in a microwave reactor. Ethyl acetate was added, and the mixture was washed successively with water and saturated brine. The organic layer was dried over anhydrous sodium sulfate, and the solvent was then distilled off. The residue was purified by silica gel column chromatography (mobile phase: hexane / ethyl acetate) to give tert-butyl N-[(3S)-1-[4-chloro-3-(4-cyanophenyl)benzoyl]pyrrolidin-3-yl]carbamate.

[0319] (Step 3) 500 mg of tert-butyl N-[(3S)-1-[4-chloro-3-(4-cyanophenyl)benzoyl]pyrrolidin-3-yl]carbamate obtained in Step 2 above was dissolved in 9.8 mL of 1,4-dioxane. 226 mg of the above, 346 mg of KOAc, 596 mg of bis(pinacolato)diborane, and 150 mg of Silica-SMAP (Wako Pure Chemical Industries, Ltd.) were added and stirred at 160°C overnight. The mixture was filtered through Celite, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (mobile phase: hexane / ethyl acetate) to obtain tert-butyl N-[(3S)-1-[3-(4-cyanophenyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoyl]pyrrolidin-3-yl]carbamate.

[0320] (Step 4) 15 mg of tert-butyl N-[(3S)-1-[3-(4-cyanophenyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoyl]pyrrolidin-3-yl]carbamate obtained in Step 3 above, 12 mg of 1-bromo-2-chloro-4-methyl-benzene, Pd(PPh 3 ) 4 1.7 mg of the sucrose was suspended in 1.5 mL of 1,4-dioxane. 2 CO 3 0.7 mL of an aqueous solution was added, and the mixture was stirred for 30 minutes at 120° C. The reaction solution was filtered, and the solvent was evaporated to obtain tert-butyl N-[(3S)-1-[4-(2-chloro-4-methyl-phenyl)-3-(4-cyanophenyl)benzoyl]pyrrolidin-3-yl]carbamate.

[0321] (Step 5) 15 mg of tert-butyl N-[(3S)-1-[4-(2-chloro-4-methyl-phenyl)-3-(4-cyanophenyl)benzoyl]pyrrolidin-3-yl]carbamate obtained in Step 4 above was dissolved in 0.3 mL of TFA, and the progress of the reaction was confirmed by LCMS, followed by concentration under reduced pressure. The residue was purified by reverse-phase HPLC (mobile phase: water / acetonitrile) to obtain the title compound.

[0322] Example 10 Synthesis of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-(3-chloro-4-methyl-phenyl)phenyl]benzonitrile The title compound was obtained according to Example 9 (steps 1 to 5), except that 4-bromo-2-chloro-1-methyl-benzene was used instead of 1-bromo-2-chloro-4-methyl-benzene.

[0323] Example 11 Synthesis of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[3-fluoro-4-(trifluoromethyl)phenyl]phenyl]benzonitrile The title compound was obtained according to the procedure of Example 9 (steps 1 to 5), except that 4-bromo-2-fluoro-1-(trifluoromethyl)benzene was used instead of 1-bromo-2-chloro-4-methyl-benzene.

[0324] Example 12 Synthesis of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-(4-methyl-2-nitrophenyl)phenyl]benzonitrile (Step 1) 15 mg of tert-butyl N-[(3S)-1-[4-chloro-3-(4-cyanophenyl)benzoyl]pyrrolidin-3-yl]carbamate obtained in Example 9 (Step 2), 18 mg of 4-methyl-2-nitrophenylboronic acid, pinacol ester, and Pd(dba) 2 1.6 mg, 1 M PCy 3 0.003 mL of the THF solution and 15 mg of tripotassium phosphate were added, and the reaction solution was stirred for 30 minutes at 160° C. in a microwave reactor. The solvent was evaporated, and the residue was purified by silica gel column chromatography (mobile phase: hexane / ethyl acetate) to obtain tert-butyl N-[(3S)-1-[3-(4-cyanophenyl)-4-(4-methyl-2-nitrophenyl)benzoyl]pyrrolidin-3-yl]carbamate.

[0325] (Step 2) 10 mg of tert-butyl N-[(3S)-1-[3-(4-cyanophenyl)-4-(4-methyl-2-nitrophenyl)benzoyl]pyrrolidin-3-yl]carbamate obtained in Step 1 above was dissolved in 0.3 mL of TFA, and the progress of the reaction was confirmed by LCMS, followed by concentration under reduced pressure. The residue was purified by reversed-phase HPLC (mobile phase: water / acetonitrile) to obtain the title compound.

[0326] Example 13 Synthesis of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[4-(difluoromethyl)phenyl]phenyl]benzonitrile The title compound was obtained according to the procedure of Example 9 (steps 1 to 5), except that 1-bromo-4-(difluoromethyl)benzene was used instead of 1-bromo-2-chloro-4-methyl-benzene.

[0327] Example 14 Synthesis of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[4-(trifluoromethyl)phenyl]phenyl]benzonitrile The title compound was obtained according to the procedure of Example 12 (steps 1 and 2) except that [4-(trifluoromethyl)phenyl]boronic acid was used instead of 4-methyl-2-nitrophenylboronic acid pinacol ester.

[0328] Example 15 Synthesis of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-(2-fluoro-4-methyl-phenyl)phenyl]benzonitrile (Step 1) 1.7 g of tert-butyl N-[(3S)-1-[4-chloro-3-(4-cyanophenyl)benzoyl]pyrrolidin-3-yl]carbamate obtained in Example 9 (Step 2) was dissolved in 20 mL of 1,4-dioxane. 980 mg of (2-fluoro-4-methyl-phenyl)boronic acid and Pd(dba) were added at room temperature. 2 110 mg, 1 M PCy 30.4 mL of the THF solution and 2.5 g of tripotassium phosphate were added, and the reaction mixture was stirred in a microwave reactor at 160° C. for 45 minutes. The mixture was purified with NH silica gel, washed with methanol / ethyl acetate, and the solvent was evaporated to give tert-butyl N-[(3S)-1-[3-(4-cyanophenyl)-4-(2-fluoro-4-methyl-phenyl)benzoyl]pyrrolidin-3-yl]carbamate.

[0329] (Step 2) 1.7 g of tert-butyl N-[(3S)-1-[3-(4-cyanophenyl)-4-(2-fluoro-4-methyl-phenyl)benzoyl]pyrrolidin-3-yl]carbamate obtained in Step 1 was dissolved in 44 mL of TFA and stirred for 10 minutes. The solvent was evaporated, and the mixture was purified by reverse phase HPLC (mobile phase: water / acetonitrile) to obtain the title compound.

[0330] Example 16 Synthesis of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-(p-tolyl)phenyl]-2-fluoro-benzonitrile (Step 1) 14 g of tert-butyl N-[(3S)-1-(3-bromo-4-chloro-benzoyl)pyrrolidin-3-yl]carbamate obtained in Example 9 (Step 1) was dissolved in 87 mL of 1,4-dioxane. 6.3 g of (4-cyano-3-fluoro-phenyl)boronic acid and Pd(PPh 3 ) 4 1.2 g of 2M Na 2 CO 3 44 mL of aqueous solution was added, and the mixture was stirred at 90°C overnight. Ethyl acetate was added, and the mixture was washed successively with water and saturated brine. The organic layer was dried over anhydrous sodium sulfate, and the solvent was then distilled off. The residue was purified by silica gel column chromatography (mobile phase: hexane / ethyl acetate) to obtain tert-butyl N-[(3S)-1-[4-chloro-3-(4-cyano-3-fluorophenyl)benzoyl]pyrrolidin-3-yl]carbamate.

[0331] (Step 2) 48 mg of tert-butyl N-[(3S)-1-[4-chloro-3-(4-cyano-3-fluorophenyl)benzoyl]pyrrolidin-3-yl]carbamate obtained in Step 1 above was dissolved in 0.5 mL of 1,4-dioxane. 29 mg of p-tolylboronic acid and Pd(dba) were added at room temperature. 2 3.1 mg, 1 M PCy 3 0.005 mL of a THF solution and 68 mg of tripotassium phosphate were added, and the reaction mixture was stirred in a microwave reactor at 160° C. for 45 minutes. The mixture was purified with NH silica gel, washed with methanol / ethyl acetate, and the solvent was evaporated to give tert-butyl N-[(3S)-1-[3-(4-cyano-3-fluoro-phenyl)-4-(p-tolyl)benzoyl]pyrrolidin-3-yl]carbamate.

[0332] (Step 3) 1.2 mL of TFA was added to 48 mg of tert-butyl N-[(3S)-1-[3-(4-cyano-3-fluoro-phenyl)-4-(p-tolyl)benzoyl]pyrrolidin-3-yl]carbamate obtained in Step 2 above, and the mixture was stirred for 10 minutes. The solvent was evaporated, and the mixture was purified by reverse-phase HPLC (mobile phase: water / acetonitrile) to obtain the title compound.

[0333] Example 17 Synthesis of 4-[5-[(3-endo)-3-amino-8-azabicyclo[3.2.1]octane-8-carbonyl]-2-(p-tolyl)phenyl]-2-fluoro-benzonitrile (Step 1) 700 mg of 3-bromo-4-chloro-benzoic acid was dissolved in 15 mL of THF. 1.2 g of HATU, 0.83 mL of TEA, and then 700 mg of tert-butyl N-[(3-endo)-8-azabicyclo[3.2.1]octan-3-yl]carbamate were added at room temperature, and the mixture was stirred at 50°C for 1 hour. The solvent was evaporated, and the residue was purified by silica gel column chromatography (mobile phase: hexane / ethyl acetate) to obtain tert-butyl N-[(3-endo)-8-(3-bromo-4-chloro-benzoyl)-8-azabicyclo[3.2.1]octan-3-yl]carbamate.

[0334] (Step 2) 1.2 g of tert-butyl-N-[(3-endo)-8-(3-bromo-4-chloro-benzoyl)-8-azabicyclo[3.2.1]octan-3-yl]carbamate obtained in Step 1 was dissolved in 6.7 mL of 1,4-dioxane. 461 mg of (4-cyano-3-fluoro-phenyl)boronic acid and PdCl were added at room temperature. 2 (dppf) 58mg, 2M Na 2 CO 3 3.3 mL of an aqueous solution was added, and the mixture was stirred at 95°C overnight. Ethyl acetate was added, and the mixture was washed successively with water and saturated brine. The organic layer was dried over anhydrous sodium sulfate, and the solvent was then distilled off. The residue was purified by silica gel column chromatography (mobile phase: hexane / ethyl acetate) to obtain tert-butyl N-[(3-endo)-8-[4-chloro-3-(4-cyano-3-fluoro-phenyl)benzoyl]-8-azabicyclo[3.2.1]octan-3-yl]carbamate.

[0335] (Step 3) 17 mg of tert-butyl N-[(3-endo)-8-[4-chloro-3-(4-cyano-3-fluorophenyl)benzoyl]-8-azabicyclo[3.2.1]octan-3-yl]carbamate obtained in Step 2 above was dissolved in 0.5 mL of 1,4-dioxane. 9.6 mg of p-tolylboronic acid and Pd(dba) were added at room temperature. 2 1.6 mg, potassium phosphate 15 mg, 1 M PCy 3 0.004 mL of a THF solution was added, and the mixture was stirred in a microwave reactor at 160° C. for 30 minutes. The reaction solution was filtered through NH silica gel, and the solvent in the filtrate was evaporated to give tert-butyl N-[(3-endo)-8-[3-(4-cyano-3-fluoro-phenyl)-4-(p-tolyl)benzoyl]-8-azabicyclo[3.2.1]octan-3-yl]carbamate.

[0336] (Step 4) 15 mg of tert-butyl N-[(3-endo)-8-[3-(4-cyano-3-fluoro-phenyl)-4-(p-tolyl)benzoyl]-8-azabicyclo[3.2.1]octan-3-yl]carbamate obtained in Step 3 above was dissolved in 0.3 mL of TFA, and the progress of the reaction was confirmed by LCMS, followed by concentration under reduced pressure. The residue was purified by reverse phase HPLC (mobile phase: water / acetonitrile) to obtain the title compound.

[0337] Example 18 Synthesis of 4-[5-[(3-exo)-3-amino-8-azabicyclo[3.2.1]octane-8-carbonyl]-2-(1-methylindol-5-yl)phenyl]-2-fluoro-benzonitrile (Step 1) 300 mg of tert-butyl N-[(3-exo)-8-(3-bromo-4-chloro-benzoyl)-8-azabicyclo[3.2.1]octan-3-yl]carbamate obtained in Example 7 (Step 1) was dissolved in 1.7 mL of 1,4-dioxane. 123 mg of (4-cyano-3-fluoro-phenyl)boronic acid and PdCl were added at room temperature. 2 (dppf) 17mg, 2M Na 2 CO 3 0.85 mL of aqueous solution was added, and the reaction solution was stirred at 120°C for 30 minutes in a microwave reactor. Ethyl acetate was added, and the mixture was washed successively with water and saturated brine. The organic layer was dried over anhydrous sodium sulfate, and the solvent was then distilled off. The residue was purified by silica gel column chromatography (mobile phase: hexane / ethyl acetate) to obtain tert-butyl N-[(3-exo)-8-[4-chloro-3-(4-cyano-3-fluoro-phenyl)benzoyl]-8-azabicyclo[3.2.1]octan-3-yl]carbamate.

[0338] (Step 2) 10 mg of tert-butyl N-[(3-exo)-8-[4-chloro-3-(4-cyano-3-fluorophenyl)benzoyl]-8-azabicyclo[3.2.1]octan-3-yl]carbamate obtained in Step 1 was dissolved in 0.5 mL of 1,4-dioxane. 7.2 mg of (1-methylindol-5-yl)boronic acid and Pd(dba) were added at room temperature. 20.9 mg, potassium phosphate tribasic 8.8 mg, 1 M PCy 3 0.002 mL of THF solution was added, and the reaction solution was stirred at 160°C for 30 minutes in a microwave reactor. The reaction solution was filtered through NH silica gel, and the solvent of the filtrate was distilled off. The residue was purified by silica gel column chromatography (mobile phase: hexane / ethyl acetate) to obtain tert-butyl N-[(3-exo)-8-[3-(4-cyano-3-fluoro-phenyl)-4-(1-methylindol-5-yl)benzoyl]-8-azabicyclo[3.2.1]octan-3-yl]carbamate.

[0339] (Step 3) 15 mg of tert-butyl N-[(3-exo)-8-[3-(4-cyano-3-fluoro-phenyl)-4-(1-methylindol-5-yl)benzoyl]-8-azabicyclo[3.2.1]octan-3-yl]carbamate obtained in Step 2 above was dissolved in 0.3 mL of TFA, and the progress of the reaction was confirmed by LCMS, followed by concentration under reduced pressure. The residue was purified by reverse phase HPLC (mobile phase: water / acetonitrile) to obtain the title compound.

[0340] Example 19 Synthesis of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-(p-tolyl)phenyl]-2,6-difluorobenzonitrile (Step 1) 2 g of 4-bromo-3-chlorobenzoic acid was dissolved in 17 mL of DMA. 4.8 g of HATU, 2.4 mL of TEA, and then 1.7 g of tert-butyl N-[(3S)-pyrrolidin-3-yl]carbamate were added at room temperature, and the mixture was stirred at room temperature for 1 hour. Ethyl acetate was added, and the mixture was washed sequentially with water and saturated brine. The organic layer was dried over anhydrous sodium sulfate, and the solvent was then distilled off. The residue was purified by silica gel column chromatography (mobile phase: hexane / ethyl acetate) to obtain tert-butyl N-[(3S)-1-(4-bromo-3-chlorobenzoyl)pyrrolidin-3-yl]carbamate.

[0341] (Step 2) The tert-butyl N-[(3S)-1-(4-bromo-3-chloro-benzoyl)pyrrolidin-3-yl]carbamate obtained in Step 1 above was dissolved in 10.6 mL of 1,4-dioxane. 3 ) 4 147 mg of 2M Na 2 CO 3 5.3 mL of aqueous solution and 693 mg of p-tolylboronic acid were added, and the reaction solution was stirred at 120°C for 30 minutes in a microwave reactor. Ethyl acetate was added, and the mixture was washed successively with water and saturated brine. The organic layer was dried over anhydrous sodium sulfate, and the solvent was then distilled off. The residue was purified by silica gel column chromatography (mobile phase: hexane / ethyl acetate) to obtain tert-butyl N-[(3S)-1-[3-chloro-4-(p-tolyl)benzoyl]pyrrolidin-3-yl]carbamate.

[0342] (Step 3) 666 mg of tert-butyl N-[(3S)-1-[3-chloro-4-(p-tolyl)benzoyl]pyrrolidin-3-yl]carbamate obtained in Step 2 above was dissolved in 16 mL of 1,4-dioxane. 2 36 mg, KOAc 473 mg, bis(pinacolato)diborane 815 mg, 1 M PCy 3 0.24 mL of a THF solution was added, and the mixture was degassed and purged with nitrogen, followed by stirring overnight at 80°C. The reaction solution was filtered through Celite, and the solvent in the filtrate was evaporated. The residue was purified by silica gel column chromatography (mobile phase: hexane / ethyl acetate) to obtain tert-butyl N-[(3S)-1-[4-(p-tolyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoyl]pyrrolidin-3-yl]carbamate.

[0343] (Step 4) 15 mg of tert-butyl N-[(3S)-1-[4-(p-tolyl)-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoyl]pyrrolidin-3-yl]carbamate obtained in Step 3 above, 12.9 mg of 4-bromo-2,6-difluorobenzonitrile, Pd(PPh 3 )4 1.7 mg of the sucrose was suspended in 1.5 mL of 1,4-dioxane. 2 CO 3 0.7 mL of an aqueous solution was added, and the reaction mixture was stirred in a microwave reactor at 120° C. for 30 minutes. The reaction mixture was filtered, and the solvent was then evaporated to give tert-butyl N-[(3S)-1-[3-(4-cyano-3,5-difluoro-phenyl)-4-(p-tolyl)benzoyl]pyrrolidin-3-yl]carbamate.

[0344] (Step 5) 15 mg of tert-butyl N-[(3S)-1-[3-(4-cyano-3,5-difluoro-phenyl)-4-(p-tolyl)benzoyl]pyrrolidin-3-yl]carbamate obtained in Step 4 above was dissolved in 0.3 mL of TFA, and the progress of the reaction was confirmed by LCMS, followed by concentration under reduced pressure. The residue was purified by reverse phase HPLC (mobile phase: water / acetonitrile) to obtain the title compound.

[0345] Example 20 Synthesis of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-methoxyethyl)phenyl]phenyl]-2-fluorobenzonitrile (Step 1) 4.5 g of 1-bromo-2-fluoro-4-(2-methoxyethyl)benzene was suspended in 48 mL of 1,4-dioxane and stirred. 7.4 g of bis(pinacolato)diborane, 3.8 g of KOAc, and PdCl were added. 2 0.71 g of (dppf) was added and the mixture was stirred overnight at 90°C. Ethyl acetate was added, and the mixture was filtered through Celite. The filtrate was washed successively with water and saturated brine. The organic layer was dried over anhydrous sodium sulfate, and the solvent was then distilled off. The residue was purified by silica gel column chromatography (mobile phase: hexane / ethyl acetate) to obtain 2-[2-fluoro-4-(2-methoxyethyl)phenyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane.

[0346] (Step 2) 150 mg of tert-butyl N-[(3S)-1-[4-chloro-3-(4-cyano-3-fluorophenyl)benzoyl]pyrrolidin-3-yl]carbamate obtained in Example 16 (Step 1), 189 mg of 2-[2-fluoro-4-(2-methoxyethyl)phenyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane obtained in the above Step 1, Pd(dba) 2 15 mg, potassium phosphate tribasic 144 mg, 1 M PCy 3 0.034 mL of the THF solution was dissolved in 3.8 mL of 1,4-dioxane. The reaction solution was stirred at 160°C for 45 minutes in a microwave reactor. The reaction solution was filtered through NH silica gel, and the solvent in the filtrate was distilled off. The residue was purified by silica gel column chromatography (mobile phase: hexane / ethyl acetate) to give tert-butyl N-[(3S)-1-[3-(4-cyanophenyl)-4-[2-fluoro-4-(2-methoxyethyl)phenyl]benzoyl]pyrrolidin-3-yl]carbamate.

[0347] (Step 3) 150 mg of tert-butyl N-[(3S)-1-[3-(4-cyanophenyl)-4-[2-fluoro-4-(2-methoxyethyl)phenyl]benzoyl]pyrrolidin-3-yl]carbamate obtained in Step 2 above was dissolved in 10 mL of TFA, and the progress of the reaction was confirmed by LCMS, followed by concentration under reduced pressure. The residue was purified by reverse phase HPLC (mobile phase: water / acetonitrile) to obtain the title compound.

[0348] Example 21 Synthesis of 4-[5-[(3-endo)-3-amino-8-azabicyclo[3.2.1]octane-8-carbonyl]-2-(2-fluoro-4-methyl-phenyl)phenyl]-2-fluoro-benzonitrile The title compound was obtained according to the procedure of Example 17 (steps 1 to 4), except that (2-fluoro-4-methyl-phenyl)boronic acid was used in place of p-tolylboronic acid.

[0349] Example 22 Synthesis of 4-[5-[(3-endo)-3-amino-8-azabicyclo[3.2.1]octane-8-carbonyl]-2-[2-fluoro-4-(2-methoxyethyl)phenyl]phenyl]-2-fluoro-benzonitrile (Step 1) 1.00 g of tert-butyl 3-bromo-4-chlorobenzoate obtained in Example 1 (Step 1) was dissolved in 8.6 mL of 1,4-dioxane. 509 mg of (4-cyano-3-fluoro-phenyl)boronic acid and Pd(PPh 3 ) 4 119 mg of 2M Na 2 CO 3 4.3 mL of an aqueous solution was added, and the reaction solution was stirred in a microwave reactor at 120°C for 30 minutes. The reaction solution was filtered, and the solvent was evaporated. The residue was purified by silica gel column chromatography (mobile phase: hexane / ethyl acetate) to obtain tert-butyl 4-chloro-3-(4-cyano-3-fluorophenyl)benzoate.

[0350] (Step 2) 1.00 g of tert-butyl 4-chloro-3-(4-cyano-3-fluorophenyl)benzoate obtained in Step 1 above was dissolved in 15 mL of 1,4-dioxane. 1.69 g of 2-[2-fluoro-4-(2-methoxyethyl)phenyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane obtained in Example 20 (Step 1), Pd(dba) 2 138 mg, potassium phosphate 1.28 g, 1 M PCy 3 0.30 mL of a THF solution was added. The reaction solution was stirred at 160°C for 30 minutes in a microwave reaction apparatus. Chloroform was added, insoluble matter was filtered off, and the solvent was distilled off. The residue was purified by silica gel column chromatography (mobile phase: hexane / ethyl acetate), and the solvent was distilled off. The residue was dissolved in 2 mL of TFA, and the solvent was distilled off. Ethyl acetate was added, and the mixture was washed successively with water and saturated brine. The organic layer was dried over anhydrous sodium sulfate, and the solvent was distilled off to obtain 3-(4-cyano-3-fluoro-phenyl)-4-[2-fluoro-4-(2-methoxyethyl)phenyl]benzoic acid.

[0351] (Step 3) 10 mg of 3-(4-cyano-3-fluoro-phenyl)-4-[2-fluoro-4-(2-methoxyethyl)phenyl]benzoic acid obtained in Step 2 above, 5.8 mg of tert-butyl N-[(3-endo)-8-azabicyclo[3.2.1]octan-3-yl]carbamate, and 19 mg of HATU were dissolved in 0.5 mL of THF. 0.007 mL of TEA was added at room temperature, and the mixture was stirred overnight at 50°C. The reaction solution was concentrated under reduced pressure, and the solvent was distilled off. The residue was purified by silica gel column chromatography (mobile phase: hexane / ethyl acetate) to give tert-butyl N-[(3-endo)-8-[3-(4-cyano-3-fluoro-phenyl)-4-[2-fluoro-4-(2-methoxyethyl)phenyl]benzoyl]-8-azabicyclo[3.2.1]octan-3-yl]carbamate.

[0352] (Step 4) 10.9 mg of tert-butyl N-[(3-endo)-8-[3-(4-cyano-3-fluoro-phenyl)-4-[2-fluoro-4-(2-methoxyethyl)phenyl]benzoyl]-8-azabicyclo[3.2.1]octan-3-yl]carbamate obtained in Step 3 above was dissolved in 0.3 mL of TFA, and the progress of the reaction was confirmed by LCMS, followed by concentration under reduced pressure. The residue was purified by reverse phase HPLC (mobile phase: water / acetonitrile) to obtain the title compound.

[0353] Example 23 Synthesis of 4-[5-[(3-exo)-3-amino-8-azabicyclo[3.2.1]octane-8-carbonyl]-2-(6-fluoro-1-methyl-indol-5-yl)phenyl]-2-fluoro-benzonitrile (Step 1) 270 mg of tert-butyl N-[(3-exo)-8-[4-chloro-3-(4-cyano-3-fluoro-phenyl)benzoyl]-8-azabicyclo[3.2.1]octan-3-yl]carbamate obtained in Example 18 (Step 1) was dissolved in 2.8 mL of 1,4-dioxane. Pd(OAc) 22.5 mg of the above, 164 mg of KOAc, 283 mg of bis(pinacolato)diborane, and 4.6 mg of Silica-SMAP were added and stirred at 150°C overnight. The mixture was filtered through Celite, and the filtrate was concentrated under reduced pressure. The residue was purified by silica gel column chromatography (mobile phase: hexane / ethyl acetate) to give tert-butyl N-[(3-exo)-8-[3-(4-cyano-3-fluoro-phenyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoyl]-8-azabicyclo[3.2.1]octan-3-yl]carbamate.

[0354] (Step 2) 10 mg of tert-butyl N-[(3-exo)-8-[3-(4-cyano-3-fluorophenyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoyl]-8-azabicyclo[3.2.1]octan-3-yl]carbamate obtained in Step 1 above, 4.8 mg of 5-bromo-6-fluoro-1-methyl-indole, PdCl 2 0.71 mg of (dppf) was suspended in 0.5 mL of 1,4-dioxane. 11 mg of tripotassium phosphate was added at room temperature, and the mixture was stirred at 125°C for 45 minutes. The reaction solution was filtered, and the solvent was then distilled off to obtain tert-butyl N-[(3-exo)-8-[3-(4-cyano-3-fluoro-phenyl)-4-(6-fluoro-1-methyl-indol-5-yl)benzoyl]-8-azabicyclo[3.2.1]octan-3-yl]carbamate.

[0355] (Step 3) 8 mg of tert-butyl N-[(3-exo)-8-[3-(4-cyano-3-fluoro-phenyl)-4-(6-fluoro-1-methyl-indol-5-yl)benzoyl]-8-azabicyclo[3.2.1]octan-3-yl]carbamate obtained in Step 2 above was dissolved in 0.3 mL of TFA, and the progress of the reaction was confirmed by LCMS, followed by concentration under reduced pressure. The residue was purified by reverse phase HPLC (mobile phase: water / acetonitrile) to obtain the title compound.

[0356] Example 24 Synthesis of 4-[5-[(3-exo)-3-amino-8-azabicyclo[3.2.1]octane-8-carbonyl]-2-(6-fluoro-1-methyl-indazol-5-yl)phenyl]-2-fluoro-benzonitrile (Step 1) 10 mg of tert-butyl N-[(3-exo)-8-[3-(4-cyano-3-fluoro-phenyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoyl]-8-azabicyclo[3.2.1]octan-3-yl]carbamate obtained in Example 23 (Step 1) was dissolved in 0.5 mL of 1,4-dioxane. 4.8 mg of 5-bromo-6-fluoro-1-methyl-indazole and PdCl were added at room temperature. 2 0.71 mg of (dppf) and 11 mg of tripotassium phosphate were added, and the mixture was stirred for 45 minutes in a microwave reaction apparatus at 125° C. After filtering the reaction solution, the solvent was distilled off to obtain tert-butyl N-[(3-exo)-8-[3-(4-cyano-3-fluoro-phenyl)-4-(6-fluoro-1-methyl-indazol-5-yl)benzoyl]-8-azabicyclo[3.2.1]octan-3-yl]carbamate.

[0357] (Step 2) 15 mg of tert-butyl N-[(3-exo)-8-[3-(4-cyano-3-fluoro-phenyl)-4-(6-fluoro-1-methyl-indazol-5-yl)benzoyl]-8-azabicyclo[3.2.1]octan-3-yl]carbamate obtained in Step 1 above was dissolved in 0.3 mL of TFA, and the progress of the reaction was confirmed by LCMS, followed by concentration under reduced pressure. The residue was purified by reverse phase HPLC (mobile phase: water / acetonitrile) to obtain the title compound.

[0358] Example 25 Synthesis of 4-[5-[(3S)-3-amino-3-methyl-pyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-methoxyethyl)phenyl]phenyl]-2-fluoro-benzonitrile (Step 1) 10 mg of 3-(4-cyano-3-fluoro-phenyl)-4-[2-fluoro-4-(2-methoxyethyl)phenyl]benzoic acid obtained in Example 22 (Step 2) and 5.1 mg of tert-butyl N-[(3S)-3-methylpyrrolidin-3-yl]carbamate were dissolved in 0.5 mL of THF. 0.011 mL of TEA and 19 mg of HATU were added at room temperature, and the mixture was stirred overnight at 50°C. The reaction solution was concentrated under reduced pressure, and the solvent was distilled off. tert-Butyl N-[(3S)-1-[3-(4-cyano-3-fluoro-phenyl)-4-[2-fluoro-4-(2-methoxyethyl)phenyl]benzoyl]-3-methyl-pyrrolidin-3-yl]carbamate was obtained.

[0359] (Step 2) 15 mg of tert-butyl N-[(3S)-1-[3-(4-cyano-3-fluoro-phenyl)-4-[2-fluoro-4-(2-methoxyethyl)phenyl]benzoyl]-3-methyl-pyrrolidin-3-yl]carbamate obtained in Step 1 above was dissolved in 0.3 mL of TFA, and the progress of the reaction was confirmed by LCMS, followed by concentration under reduced pressure. The residue was purified by reverse phase HPLC (mobile phase: water / acetonitrile) to obtain the title compound.

[0360] Example 26 Synthesis of 4-[5-[(3-exo)-3-amino-8-azabicyclo[3.2.1]octane-8-carbonyl]-2-[2-fluoro-4-(2-methoxyethyl)phenyl]phenyl]-2-fluoro-benzonitrile (Step 1) 10 mg of 3-(4-cyano-3-fluoro-phenyl)-4-[2-fluoro-4-(2-methoxyethyl)phenyl]benzoic acid obtained in Example 22 (Step 2) and 5.8 mg of tert-butyl N-[(3-exo)-8-azabicyclo[3.2.1]octan-3-yl]carbamate were dissolved in 0.5 mL of THF. 0.011 mL of TEA and 19 mg of HATU were added at room temperature, and the mixture was stirred at 50°C overnight. The reaction solution was concentrated under reduced pressure, and the solvent was distilled off. tert-Butyl N-[(3-exo)-8-[3-(4-cyano-3-fluoro-phenyl)-4-[2-fluoro-4-(2-methoxyethyl)phenyl]benzoyl]-8-azabicyclo[3.2.1]octan-3-yl]carbamate was obtained.

[0361] (Step 2) 15 mg of tert-butyl N-[(3-exo)-8-[3-(4-cyano-3-fluoro-phenyl)-4-[2-fluoro-4-(2-methoxyethyl)phenyl]benzoyl]-8-azabicyclo[3.2.1]octan-3-yl]carbamate obtained in Step 1 above was dissolved in 0.3 mL of TFA, and the progress of the reaction was confirmed by LCMS, followed by concentration under reduced pressure. The residue was purified by reverse phase HPLC (mobile phase: water / acetonitrile) to obtain the title compound.

[0362] Example 27 Synthesis of 4-[5-(3,8-diazabicyclo[3.2.1]octane-8-carbonyl)-2-[2-fluoro-4-(2-methoxyethyl)phenyl]phenyl]-2-fluoro-benzonitrile The title compound was obtained according to the procedure of Example 22 (steps 1 to 4) except for using tert-butyl 3,8-diazabicyclo[3.2.1]octane-3-carboxylic acid in place of tert-butyl N-[(3-endo)-8-azabicyclo[3.2.1]octan-3-yl]carbamate.

[0363] Example 28 Synthesis of 4-[5-[(3-exo)-3-amino-8-azabicyclo[3.2.1]octane-8-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile (Step 1) 500 mg of methyl 2-(4-bromo-3-fluoro-phenyl)acetate was dissolved in 2.2 mL of THF. 5.40 mL of a 3 M MeMgBr ether solution was added dropwise at -30°C, and the mixture was stirred overnight at room temperature. The reaction solution was poured into an aqueous ammonium chloride solution, ethyl acetate was added, and the mixture was washed successively with water and saturated brine. The organic layer was dried over anhydrous sodium sulfate, and the solvent was then evaporated. The residue was purified by silica gel column chromatography (mobile phase: ethyl acetate / hexane=10%→50%) to obtain 1-(4-bromo-3-fluoro-phenyl)-2-methyl-propan-2-ol.

[0364] (Step 2) 68 mg of tert-butyl N-[(3-exo)-8-[3-(4-cyano-3-fluorophenyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoyl]-8-azabicyclo[3.2.1]octan-3-yl]carbamate obtained in Example 23 (Step 1), 107 mg of 1-(4-bromo-3-fluorophenyl)-2-methyl-propan-2-ol obtained in the above Step 1, Pd(PPh 3 ) 4 6.42 mg of the sucrose was suspended in 0.93 mL of 1,4-dioxane. 2 CO 3 0.46 mL of an aqueous solution was added, and the mixture was stirred for 45 minutes at 125° C. The reaction solution was filtered, and the solvent was then evaporated to obtain tert-butyl N-[(3-exo)-8-[3-(4-cyano-3-fluoro-phenyl)-4-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]benzoyl]-8-azabicyclo[3.2.1]octan-3-yl]carbamate.

[0365] (Step 3) 90 mg of tert-butyl N-[(3-exo)-8-[3-(4-cyano-3-fluoro-phenyl)-4-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]benzoyl]-8-azabicyclo[3.2.1]octan-3-yl]carbamate obtained in Step 2 above was dissolved in 0.3 mL of TFA, and the progress of the reaction was confirmed by LCMS, followed by concentration under reduced pressure. The residue was purified by reverse phase HPLC (mobile phase: water / acetonitrile) to obtain the title compound.

[0366] Example 29 Synthesis of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[4-(hydroxymethyl)phenyl]phenyl]benzonitrile (Step 1) 500 mg of [4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methanol and 26 mg of DMAP were dissolved in 7.1 mL of THF, and 0.74 mL of TEA was added. 0.23 mL of acetyl chloride was added at room temperature, and the mixture was stirred for 1 hour. Ethyl acetate was added, and the mixture was washed successively with water and saturated brine. The organic layer was dried over anhydrous sodium sulfate, and the solvent was then evaporated. The residue was purified by silica gel column chromatography (mobile phase: hexane / ethyl acetate) to give [4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methyl acetate.

[0367] (Step 2) 100 mg of tert-butyl N-[(3S)-1-[4-chloro-3-(4-cyanophenyl)benzoyl]pyrrolidin-3-yl]carbamate obtained in Example 9 (Step 2) and 130 mg of [4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methyl acetate obtained in Step 1 above were dissolved in 1.2 mL of 1,4-dioxane. 2 6.8 mg, potassium phosphate tribasic 100 mg, 1 M PCy 30.02 mL of a THF solution was added. The mixture was stirred at 160°C for 1 hour in a microwave reactor. The reaction solution was filtered through NH silica gel, and the solvent in the filtrate was evaporated. The residue was purified by silica gel column chromatography (mobile phase: ethyl acetate / hexane = 30% → 100%) to give [4-[4-[(3S)-3-(tert-butoxycarbonylamino)pyrrolidine-1-carbonyl]-2-(4-cyanophenyl)phenyl]phenyl]methyl acetate.

[0368] (Step 3) 100 mg of [4-[4-[(3S)-3-(tert-butoxycarbonylamino)pyrrolidine-1-carbonyl]-2-(4-cyanophenyl)phenyl]phenyl]methyl acetate obtained in Step 2 above was dissolved in 2 mL of MeOH. 2 CO 3 65 mg of the above was added, and the mixture was stirred at room temperature for 30 minutes. Chloroform was added, and the mixture was washed successively with saturated aqueous ammonium chloride and saturated brine, dried over anhydrous sodium sulfate, and then the solvent was distilled off. The residue was purified by silica gel column chromatography (mobile phase: ethyl acetate / hexane=40%→100%) to give tert-butyl N-[(3S)-1-[3-(4-cyanophenyl)-4-[4-(hydroxymethyl)phenyl]benzoyl]pyrrolidin-3-yl]carbamate.

[0369] (Step 4) 15 mg of tert-butyl N-[(3S)-1-[3-(4-cyanophenyl)-4-[4-(hydroxymethyl)phenyl]benzoyl]pyrrolidin-3-yl]carbamate obtained in Step 3 above was dissolved in 0.3 mL of TFA, and the progress of the reaction was confirmed by LCMS, followed by concentration under reduced pressure. The residue was purified by reverse-phase HPLC (mobile phase: water / acetonitrile) to obtain the title compound.

[0370] Example 30 Synthesis of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[4-(2-methoxyethyl)phenyl]phenyl]benzonitrile (Step 1) 450 mg of 1-bromo-4-(2-methoxyethyl)benzene was dissolved in 5.2 mL of 1,4-dioxane. 797 mg of bis(pinacolato)diborane, 411 mg of KOAc, and PdCl were added. 2 77 mg of (dppf) was added, and the mixture was stirred overnight at 90°C. Ethyl acetate was added, and the mixture was filtered through Celite. The filtrate was washed successively with water and saturated brine. The organic layer was dried over anhydrous sodium sulfate, and the solvent was then distilled off. The residue was purified by silica gel column chromatography (mobile phase: ethyl acetate / hexane = 2% → 20%) to obtain 2-[4-(2-methoxyethyl)phenyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane.

[0371] (Step 2) 300 mg of tert-butyl N-[(3S)-1-[4-chloro-3-(4-cyanophenyl)benzoyl]pyrrolidin-3-yl]carbamate obtained in Example 9 (Step 2) and 369 mg of 2-[4-(2-methoxyethyl)phenyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane obtained in Step 1 above were dissolved in 2 mL of 1,4-dioxane. 2 32 mg, potassium phosphate tribasic 300 mg, 1 M PCy 3 0.07 mL of a THF solution was added, and the mixture was stirred in a microwave reactor at 160°C for 45 minutes. The reaction mixture was filtered through Celite, and the solvent in the filtrate was evaporated. The residue was purified by reverse-phase HPLC (mobile phase: water / acetonitrile) to give tert-butyl N-[(3S)-1-[3-(4-cyanophenyl)-4-[4-(2-methoxyethyl)phenyl]benzoyl]pyrrolidin-3-yl]carbamate.

[0372] (Step 3) 15 mg of tert-butyl N-[(3S)-1-[3-(4-cyanophenyl)-4-[4-(2-methoxyethyl)phenyl]benzoyl]pyrrolidin-3-yl]carbamate obtained in Step 2 above was dissolved in 0.3 mL of TFA, and the progress of the reaction was confirmed by LCMS, followed by concentration under reduced pressure. The residue was purified by reverse-phase HPLC (mobile phase: water / acetonitrile) to obtain the title compound.

[0373] Example 31 Synthesis of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[4-(2-hydroxyethyl)phenyl]phenyl]benzonitrile The title compound was obtained according to the procedure of Example 29 (steps 1 to 4), except that 2-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]ethanol was used in place of [4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methanol.

[0374] Example 32 Synthesis of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[4-(3-hydroxypropyl)phenyl]phenyl]benzonitrile The title compound was obtained according to the procedure of Example 29 (steps 1 to 4), except that 3-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]propan-1-ol was used in place of [4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methanol.

[0375] Example 33 Synthesis of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[4-[1-(hydroxymethyl)cyclopropyl]phenyl]phenyl]benzonitrile The title compound was obtained according to the procedure of Example 9 (steps 1 to 5) except that (1-(4-bromophenyl)cyclopropyl)methanol was used in place of 1-bromo-2-chloro-4-methyl-benzene.

[0376] Example 34 Synthesis of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]benzonitrile The title compound was obtained according to the procedure of Example 9 (steps 1 to 5), except that 1-(4-bromophenyl)-2-methylpropan-2-ol was used in place of 1-bromo-2-chloro-4-methyl-benzene.

[0377] Example 35 Synthesis of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[4-(2-hydroxypropoxy)phenyl]phenyl]benzonitrile (Step 1) In accordance with the procedure of Example 12 (Step 1), tert-butyl N-[(3S)-1-[4-(4-benzyloxyphenyl)-3-(4-cyanophenyl)benzoyl]pyrrolidin-3-yl]carbamate was obtained using (4-benzyloxyphenyl)boronic acid instead of 4-methyl-2-nitrophenylboronic acid pinacol ester.

[0378] (Step 2) 800 mg of tert-butyl N-[(3S)-1-[4-(4-benzyloxyphenyl)-3-(4-cyanophenyl)benzoyl]pyrrolidin-3-yl]carbamate obtained in Step 1 above and 160 mg of palladium hydroxide on carbon were suspended in 20 mL of EtOH. The atmosphere was replaced with hydrogen and the mixture was stirred at room temperature for 6 hours. The reaction solution was filtered through Celite, and the solvent was distilled off. The residue was purified by silica gel column chromatography (mobile phase: hexane / ethyl acetate) to give tert-butyl N-[(3S)-1-[3-(4-cyanophenyl)-4-(4-hydroxyphenyl)benzoyl]pyrrolidin-3-yl]carbamate.

[0379] (Step 3) 15 mg of tert-butyl N-[(3S)-1-[3-(4-cyanophenyl)-4-(4-hydroxyphenyl)benzoyl]pyrrolidin-3-yl]carbamate obtained in Step 2 above was dissolved in 0.5 mL of DMF. 2 CO 36.4 mg of the above and 5.4 mg of 2-methyloxirane were added, and the mixture was stirred at 120°C for 2 hours. Ethyl acetate was added, and the mixture was washed successively with water and saturated brine, dried over anhydrous sodium sulfate, and then the solvent was distilled off. The residue was purified by silica gel column chromatography (mobile phase: hexane / ethyl acetate) to give tert-butyl N-[(3S)-1-[3-(4-cyanophenyl)-4-[4-(2-hydroxypropoxy)phenyl]benzoyl]pyrrolidin-3-yl]carbamate.

[0380] (Step 4) 15 mg of tert-butyl N-[(3S)-1-[3-(4-cyanophenyl)-4-[4-(2-hydroxypropoxy)phenyl]benzoyl]pyrrolidin-3-yl]carbamate obtained in Step 3 above was dissolved in 0.3 mL of TFA, and the progress of the reaction was confirmed by LCMS, followed by concentration under reduced pressure. The residue was purified by reverse-phase HPLC (mobile phase: water / acetonitrile) to obtain the title compound.

[0381] Example 36 Synthesis of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-(2-fluoro-4-methyl-phenyl)phenyl]-2-fluoro-benzonitrile The title compound was obtained according to the procedure of Example 16 (steps 1 to 3), except that (2-fluoro-4-methyl-phenyl)boronic acid was used in place of p-tolylboronic acid.

[0382] Example 37 Synthesis of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile (Step 1) 4 g of tert-butyl N-[(3S)-1-[4-chloro-3-(4-cyano-3-fluoro-phenyl)benzoyl]pyrrolidin-3-yl]carbamate obtained in Example 16 (Step 1) was dissolved in 45 mL of 1,4-dioxane. Pd(OAc) 20.40 g of the above, 2.7 g of KOAc, 4.6 g of bis(pinacolato)diborane, and 0.72 g of Silica-SMAP were added and stirred at 150°C for 18 hours. The reaction solution was filtered and the solvent was distilled off. The residue was purified by silica gel column chromatography (mobile phase: hexane / ethyl acetate) to obtain tert-butyl N-[(3S)-1-[3-(4-cyano-3-fluoro-phenyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoyl]pyrrolidin-3-yl]carbamate.

[0383] (Step 2) 30 mg of tert-butyl N-[(3S)-1-[3-(4-cyano-3-fluoro-phenyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoyl]pyrrolidin-3-yl]carbamate obtained in Step 1 above and 28 mg of 1-(4-bromo-3-fluoro-phenyl)-2-methyl-propan-2-ol obtained in Example 28 (Step 1) were dissolved in 0.8 mL of 1,4-dioxane. 3 ) 4 3.2 mg of 2M Na 2 CO 3 0.4 mL of an aqueous solution was added, and the mixture was stirred at 120°C for 30 minutes in a microwave reaction apparatus. The reaction solution was filtered, and the solvent was distilled off. Ethyl acetate was added, and the mixture was washed successively with water and saturated brine, dried over anhydrous sodium sulfate, and the solvent was distilled off. The residue was purified by silica gel column chromatography (mobile phase: chloroform / methanol) to obtain tert-butyl N-[(3S)-1-[3-(4-cyano-3-fluoro-phenyl)-4-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]benzoyl]pyrrolidin-3-yl]carbamate.

[0384] (Step 3) 20 mg of tert-butyl N-[(3S)-1-[3-(4-cyano-3-fluoro-phenyl)-4-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]benzoyl]pyrrolidin-3-yl]carbamate obtained in Step 2 above was dissolved in 1 mL of MeOH. 1 mL of 12 M aqueous HCl solution was added at room temperature, and the mixture was stirred at room temperature for 30 minutes. 1 mL of water and 6 mL of 2 M aqueous sodium hydroxide solution were added to the reaction solution to neutralize it. Chloroform was added, and the mixture was washed successively with water and saturated brine, dried over anhydrous sodium sulfate, and the solvent was evaporated to obtain the title compound.

[0385] Example 38 Synthesis of 2-fluoro-4-[2-[2-fluoro-4-(2-methoxyethyl)phenyl]-5-(9-oxa-2,6-diazaspiro[3.5]nonane-2-carbonyl)phenyl]benzonitrile The title compound was obtained according to the procedure of Example 22 (steps 1 to 4), except that tert-butyl 9-oxa-2,6-diazaspiro[3.5]nonane-6-carboxylic acid was used in place of tert-butyl N-[(3-endo)-8-azabicyclo[3.2.1]octan-3-yl]carbamate.

[0386] Example 39 Synthesis of 4-[5-(2,3,3a,4,6,6a-hexahydro-1H-pyrrolo[3,4-c]pyrrole-5-carbonyl)-2-[2-fluoro-4-(2-methoxyethyl)phenyl]phenyl]-2-fluoro-benzonitrile The title compound was obtained according to the procedure of Example 22 (steps 1 to 4), except that tert-butyl 2,3,3a,4,6,6a-hexahydro-1H-pyrrolo[3,4-c]pyrrole-5-carboxylic acid was used in place of tert-butyl N-[(3-endo)-8-azabicyclo[3.2.1]octan-3-yl]carbamate.

[0387] Example 40 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile The title compound was obtained according to the procedure described in Example 37 (steps 1 to 3), except that 1-(4-bromophenyl)-2-methylpropan-2-ol was used instead of 1-(4-bromo-3-fluoro-phenyl)-2-methyl-propan-2-ol.

[0388] Example 41 Synthesis of 4-[5-[(3-endo)-3-amino-8-azabicyclo[3.2.1]octane-8-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile (Step 1) 300 mg of tert-butyl 4-chloro-3-(4-cyano-3-fluoro-phenyl)benzoate obtained in Example 22 (Step 1) was dissolved in 5 mL of 1,4-dioxane. Pd(OAc) 2 40 mg of the above, 300 mg of KOAc, 500 mg of bis(pinacolato)diborane, and 50 mg of Silica-SMAP were added and stirred at 100°C for 26 hours. The reaction solution was filtered and the solvent was distilled off. The residue was purified by silica gel column chromatography (mobile phase: hexane / ethyl acetate) to obtain tert-butyl 3-(4-cyano-3-fluoro-phenyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate.

[0389] (Step 2) 100 mg of tert-butyl 3-(4-cyano-3-fluoro-phenyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate obtained in Step 1 above was dissolved in 1.2 mL of DCM. 1.00 mL of TFA was added at room temperature, and the mixture was stirred at room temperature for 30 minutes. The reaction solution was concentrated under reduced pressure, and the solvent was distilled off. Chloroform was added, the mixture was washed with water, dried over anhydrous sodium sulfate, and the solvent was distilled off to obtain 3-(4-cyano-3-fluoro-phenyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid.

[0390] (Step 3) 500 mg of 3-(4-cyano-3-fluoro-phenyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid obtained in Step 2 above and 308 mg of tert-butyl N-[(3-endo)-8-azabicyclo[3.2.1]octan-3-yl]carbamate were dissolved in 4.5 mL of THF. 0.57 mL of TEA and 1 g of HATU were added at room temperature, and the mixture was stirred at 50°C for 1 hour. The reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (mobile phase: hexane / ethyl acetate) to obtain tert-butyl N-[(3-endo)-8-[3-(4-cyano-3-fluoro-phenyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoyl]-8-azabicyclo[3.2.1]octan-3-yl]carbamate.

[0391] (Step 4) 30 mg of tert-butyl N-[(3-endo)-8-[3-(4-cyano-3-fluoro-phenyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoyl]-8-azabicyclo[3.2.1]octan-3-yl]carbamate obtained in Step 3 above and 19 mg of 1-(4-bromo-3-fluoro-phenyl)-2-methyl-propan-2-ol obtained in Example 28 (Step 1) were dissolved in 0.5 mL of 1,4-dioxane. 3 ) 4 18 mg, 2 M Na 2 CO 3 0.3 mL of an aqueous solution was added, and the mixture was stirred in a microwave reactor at 120° C. for 30 minutes. The supernatant of the reaction mixture was removed and filtered through NH silica gel, and the solvent was evaporated to obtain tert-butyl-N-[(3-endo)-8-[3-(4-cyano-3-fluoro-phenyl)-4-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]benzoyl]-8-azabicyclo[3.2.1]octan-3-yl]carbamate.

[0392] (Step 5) 15 mg of tert-butyl-N-[(3-endo)-8-[3-(4-cyano-3-fluoro-phenyl)-4-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]benzoyl]-8-azabicyclo[3.2.1]octan-3-yl]carbamate obtained in Step 4 above was dissolved in 0.5 mL of MeOH. 0.5 mL of 12 M aqueous HCl was added at room temperature, and the mixture was stirred at room temperature for 30 minutes. Water and 3 mL of 2 M aqueous sodium hydroxide were added, and the mixture was separated and extracted with chloroform. The organic layer was dried over anhydrous sodium sulfate, and the solvent was then evaporated. The residue was purified by reverse-phase HPLC (mobile phase: water / acetonitrile) to obtain the title compound.

[0393] Example 42 Synthesis of 4-[5-[(3S)-3-(methylamino)pyrrolidine-1-carbonyl]-2-(p-tolyl)phenyl]benzonitrile The title compound was obtained according to the procedure of Example 1 (steps 1 to 5) except that (S), tert-butylmethyl(pyrrolidin-3-yl)carbamate was used in place of tert-butyl N-[(3S)-pyrrolidin-3-yl]carbamate.

[0394] Example 43 Synthesis of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-(4-benzyloxyphenyl)phenyl]benzonitrile The title compound was obtained according to the procedure of Example 9 (steps 1 to 5), except that 1-(benzyloxy)-4-bromobenzene was used instead of 1-bromo-2-chloro-4-methyl-benzene.

[0395] Example 44 Synthesis of 1-[4-[4-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-(4-cyanophenyl)phenyl]phenyl]-N-phenyl-cyclopropanecarboxamide The title compound was obtained according to the procedure of Example 9 (steps 1 to 5), except that 1-(4-bromophenyl)-N-phenylcyclopropanecarboxamide was used in place of 1-bromo-2-chloro-4-methyl-benzene.

[0396] Example 45 Synthesis of 2-[4-[4-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-(4-cyanophenyl)phenyl]phenyl]ethyl acetate (Step 1) In accordance with Example 29 (Step 1), 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenethyl acetate was obtained using 2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)ethanol instead of [4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]methanol.

[0397] (Step 2) The title compound was obtained in accordance with Example 12 (Steps 1 and 2), except that 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenethyl acetate obtained in Step 1 above was used in place of 4-methyl-2-nitrophenylboronic acid, pinacol ester.

[0398] Example 46 Synthesis of 4-[2-[4-(2-hydroxyethyl)phenyl]-5-[(3S)-3-(methylamino)pyrrolidine-1-carbonyl]phenyl]benzonitrile (Step 1) In accordance with the procedure of Example 1 (Steps 1 to 5), 2-[4-[2-(4-cyanophenyl)-4-[(3S)-3-(methylamino)pyrrolidine-1-carbonyl]phenyl]phenyl]ethyl acetate was obtained using 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenethyl acetate obtained in Example 45 (Step 1) instead of p-tolylboronic acid and (S),tert-butylmethyl(pyrrolidin-3-yl)carbamate instead of tert-butyl N-[(3S)-pyrrolidin-3-yl]carbamate.

[0399] (Step 2) In accordance with Example 29 (Step 3), the title compound was obtained using 2-[4-[2-(4-cyanophenyl)-4-[(3S)-3-(methylamino)pyrrolidine-1-carbonyl]phenyl]phenyl]ethyl acetate obtained in Step 1 above in place of [4-[4-[(3S)-3-(tert-butoxycarbonylamino)pyrrolidine-1-carbonyl]-2-(4-cyanophenyl)phenyl]phenyl]methyl acetate.

[0400] Example 47 Synthesis of 4-[2-[4-(2-methoxyethyl)phenyl]-5-[(3S)-3-(methylamino)pyrrolidine-1-carbonyl]phenyl]benzonitrile (Step 1) The title compound was obtained according to the procedure of Example 1 (Steps 1 to 5) except that (4-(2-methoxyethyl)phenyl)boronic acid was used in place of p-tolylboronic acid and (S),tert-butylmethyl(pyrrolidin-3-yl)carbamate was used in place of tert-butyl N-[(3S)-pyrrolidin-3-yl]carbamate.

[0401] Example 48 Synthesis of 4-[5-[(3S)-3-(dimethylamino)pyrrolidine-1-carbonyl]-2-[4-[1-(hydroxymethyl)cyclopropyl]phenyl]phenyl]benzonitrile The title compound was obtained according to the procedure of Example 1 (steps 1 to 4) except that [4-[1-(hydroxymethyl)cyclopropyl]phenyl]boronic acid was used in place of p-tolylboronic acid and (S)—N,N-dimethylpyrrolidin-3-amine was used in place of tert-butyl N-[(3S)-pyrrolidin-3-yl]carbamate.

[0402] Example 49 Synthesis of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-(3-fluoro-4-methyl-phenyl)phenyl]benzonitrile The title compound was obtained according to the procedure of Example 12 (steps 1 and 2) except that (3-fluoro-4-methyl-phenyl)boronic acid was used instead of 4-methyl-2-nitrophenylboronic acid, pinacol ester.

[0403] Example 50 Synthesis of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-(4-chlorophenyl)phenyl]benzonitrile The title compound was obtained according to the procedure of Example 9 (steps 1 to 5), except that 1-bromo-4-chloro-benzene was used instead of 1-bromo-2-chloro-4-methyl-benzene.

[0404] Example 51 Synthesis of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-(4-bromophenyl)phenyl]benzonitrile The title compound was obtained according to the procedure of Example 9 (steps 1 to 5), except that 1,4-dibromobenzene was used instead of 1-bromo-2-chloro-4-methyl-benzene.

[0405] Example 52 Synthesis of 5'-((1S,4S)-2,5-diazabicyclo[2.2.1]heptane-2-carbonyl)-4''-methyl-[1,1':2',1''-terphenyl]-4-carbonitrile The title compound was obtained according to the procedure of Example 1 (steps 1 to 5) except for using tert-butyl (1S,4S)-2,5-diazabicyclo[2.2.1]heptane-2-carboxylate instead of tert-butyl N-[(3S)-pyrrolidin-3-yl]carbamate.

[0406] Example 53 Synthesis of 4-[2-[4-(2-aminoethyl)phenyl]-5-[(3S)-3-aminopyrrolidine-1-carbonyl]phenyl]benzonitrile (Step 1) 50 mg of tert-butyl N-[(3S)-1-[3-(4-cyanophenyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoyl]pyrrolidin-3-yl]carbamate obtained in Example 9 (Step 3) was dissolved in 0.48 mL of 1,4-dioxane. 29 mg of 2-(4-bromophenyl)ethanamine and Pd(PPh) were added at room temperature. 3 ) 4 3.4 mg of 2M Na 2 CO 30.24 mL of an aqueous solution was added, and the mixture was stirred in a microwave reactor at 120° C. for 30 minutes. The residue was purified by silica gel column chromatography (mobile phase: hexane / ethyl acetate) to obtain tert-butyl N-[(3S)-1-[4-[4-(2-aminoethyl)phenyl]-3-(4-cyanophenyl)benzoyl]pyrrolidin-3-yl]carbamate.

[0407] (Step 2) 15 mg of tert-butyl N-[(3S)-1-[4-[4-(2-aminoethyl)phenyl]-3-(4-cyanophenyl)benzoyl]pyrrolidin-3-yl]carbamate obtained in Step 1 above was dissolved in 0.3 mL of TFA, and the progress of the reaction was confirmed by LCMS, followed by concentration under reduced pressure. The residue was purified by reverse-phase HPLC (mobile phase: water / acetonitrile) to obtain the title compound.

[0408] Example 54 Synthesis of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-(4-iodophenyl)phenyl]benzonitrile The title compound was obtained according to the procedure of Example 9 (steps 1 to 5), except that 1,4-diiodobenzene was used instead of 1-bromo-2-chloro-4-methyl-benzene.

[0409] Example 55 Synthesis of N-[2-[4-[4-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-(4-cyanophenyl)phenyl]phenyl]ethyl]acetamide 15 mg of tert-butyl N-[(3S)-1-[4-[4-(2-aminoethyl)phenyl]-3-(4-cyanophenyl)benzoyl]pyrrolidin-3-yl]carbamate obtained in Example 53 (Step 1) was dissolved in THF. 0.02 mL of TEA and then 4.6 mg of acetyl chloride were added at room temperature, and the mixture was stirred at room temperature for 1 hour. TFA was added to the residue, and the progress of the reaction was confirmed by LCMS, followed by concentration under reduced pressure. The residue was purified by reverse-phase HPLC (mobile phase: water / acetonitrile) to obtain the title compound.

[0410] Example 56 Synthesis of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-(4-propylphenyl)phenyl]benzonitrile The title compound was obtained according to the procedure of Example 12 (steps 1 and 2) except that (4-propylphenyl)boronic acid was used instead of 4-methyl-2-nitrophenylboronic acid pinacol ester.

[0411] Example 57 Synthesis of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-(2-naphthyl)phenyl]benzonitrile The title compound was obtained according to the procedure of Example 12 (steps 1 and 2) except that 2-naphthylboronic acid was used instead of 4-methyl-2-nitrophenylboronic acid pinacol ester.

[0412] Example 58 Synthesis of 4-[2-[4-[1-(hydroxymethyl)cyclopropyl]phenyl]-5-[(3S)-3-(methylamino)pyrrolidine-1-carbonyl]phenyl]benzonitrile The title compound was obtained according to the procedure of Example 1 (steps 1 to 5) except that [4-[1-(hydroxymethyl)cyclopropyl]phenyl]boronic acid was used in place of p-tolylboronic acid and (S),tert-butylmethyl(pyrrolidin-3-yl)carbamate was used in place of tert-butyl N-[(3S)-pyrrolidin-3-yl]carbamate.

[0413] Example 59 Synthesis of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[4-[(1-hydroxycyclopropyl)methyl]phenyl]phenyl]benzonitrile The title compound was obtained according to the procedure of Example 9 (steps 1 to 5) except that 1-[(4-bromophenyl)methyl]cyclopropanol was used in place of 1-bromo-2-chloro-4-methyl-benzene.

[0414] Example 60 Synthesis of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[4-(2-methylprop-1-enyl)phenyl]phenyl]benzonitrile The title compound was obtained according to the procedure of Example 9 (steps 1 to 5), except that 1-bromo-4-(2-methylprop-1-enyl)benzene was used instead of 1-bromo-2-chloro-4-methyl-benzene.

[0415] Example 61 Synthesis of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[4-(3-hydroxy-3-methyl-butyl)phenyl]phenyl]benzonitrile The title compound was obtained according to the procedure of Example 9 (steps 1 to 5), except that 4-(4-bromophenyl)-2-methyl-butan-2-ol was used in place of 1-bromo-2-chloro-4-methyl-benzene.

[0416] Example 62 Synthesis of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[4-[2-(1-hydroxycyclopropyl)ethyl]phenyl]phenyl]benzonitrile The title compound was obtained according to the procedure of Example 9 (steps 1 to 5) except that 1-[2-(4-bromophenyl)ethyl]cyclopropanol was used in place of 1-bromo-2-chloro-4-methyl-benzene.

[0417] Example 63 Synthesis of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[4-(2-hydroxyethyl)phenyl]phenyl]-2-fluoro-benzonitrile The title compound was obtained according to the procedure of Example 37 (steps 1 to 3), except that 2-(4-bromophenyl)ethanol was used instead of 1-(4-bromo-3-fluoro-phenyl)-2-methyl-propan-2-ol.

[0418] Example 64 Synthesis of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]benzonitrile The title compound was obtained according to the procedure of Example 9 (steps 1 to 5), except that 1-(4-bromo-3-fluoro-phenyl)-2-methyl-propan-2-ol obtained in Example 28 (step 1) was used instead of 1-bromo-2-chloro-4-methyl-benzene.

[0419] Example 65 Synthesis of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[4-(3-hydroxy-3-methyl-butyl)phenyl]phenyl]-2-fluoro-benzonitrile The title compound was obtained according to the procedure of Example 16 (steps 1 to 3), except that 2-methyl-4-[4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]butan-2-ol was used in place of p-tolylboronic acid.

[0420] Example 66 Synthesis of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[4-[1-(methoxymethyl)cyclopropyl]phenyl]phenyl]benzonitrile The title compound was obtained according to the procedure of Example 9 (steps 1 to 5), except that 1-bromo-4-[1-(methoxymethyl)cyclopropyl]benzene was used instead of 1-bromo-2-chloro-4-methyl-benzene.

[0421] Example 67 Synthesis of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-[(1-hydroxycyclopropyl)methyl]phenyl]phenyl]benzonitrile (Step 1) 500 mg of methyl-2-(4-bromo-3-fluorophenyl)acetate and 0.84 mL of tetraisopropyl orthotitanate were dissolved in 5 mL of THF. 1.9 mL of a 3M EtMgBr diethyl ether solution was added dropwise at 0°C, and the mixture was stirred overnight at room temperature. Ethyl acetate was added, and the mixture was washed successively with water and saturated brine. After drying over anhydrous sodium sulfate, the solvent was distilled off. The residue was purified by silica gel column chromatography (mobile phase: hexane / ethyl acetate) to obtain 1-[(4-bromo-3-fluorophenyl)methyl]cyclopropanol.

[0422] (Step 2) The title compound was obtained according to Example 9 (Steps 1 to 5), except that 1-[(4-bromo-3-fluorophenyl)methyl]cyclopropanol obtained in Step 1 above was used instead of 1-bromo-2-chloro-4-methyl-benzene.

[0423] Example 68 Synthesis of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[4-[1-(1-hydroxycyclopropyl)cyclopropyl]phenyl]phenyl]benzonitrile (Step 1) In accordance with Example 67 (Step 1), 1-[1-(4-bromophenyl)cyclopropyl]cyclopropanol was obtained except that methyl 1-(4-bromophenyl)cyclopropanecarboxylate was used instead of methyl-2-(4-bromo-3-fluoro-phenyl)acetate.

[0424] (Step 2) The title compound was obtained according to Example 9 (Steps 1 to 5), except that 1-[1-(4-bromophenyl)cyclopropyl]cyclopropanol obtained in Step 1 above was used instead of 1-bromo-2-chloro-4-methyl-benzene.

[0425] Example 69 Synthesis of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[4-(2-methoxyethyl)phenyl]phenyl]-2-fluoro-benzonitrile The title compound was obtained according to the procedure of Example 16 (Steps 1 to 3), except that 2-[4-(2-methoxyethyl)phenyl]-4,4,5,5-tetramethyl-1,3,2-dioxaborolane obtained in Example 30 (Step 1) was used instead of p-tolylboronic acid.

[0426] Example 70 Synthesis of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxyethyl)phenyl]phenyl]benzonitrile The title compound was obtained according to the procedure of Example 9 (steps 1 to 5), except that 2-(4-bromo-3-fluoro-phenyl)ethanol was used in place of 1-bromo-2-chloro-4-methyl-benzene.

[0427] Example 71 Synthesis of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-methoxyethyl)phenyl]phenyl]benzonitrile The title compound was obtained according to the procedure of Example 9 (steps 1 to 5), except that 1-bromo-2-fluoro-4-(2-methoxyethyl)benzene was used instead of 1-bromo-2-chloro-4-methyl-benzene.

[0428] Example 72 Synthesis of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[4-(2-hydroxy-1,1-dimethyl-ethyl)phenyl]phenyl]benzonitrile The title compound was obtained according to the procedure of Example 9 (steps 1 to 5), except that 2-(4-bromophenyl)-2-methyl-propan-1-ol was used in place of 1-bromo-2-chloro-4-methyl-benzene.

[0429] Example 73 Synthesis of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[4-(2-fluoroethyl)phenyl]phenyl]benzonitrile The title compound was obtained according to the procedure of Example 9 (steps 1 to 5), except that 1-bromo-4-(2-fluoroethyl)benzene was used instead of 1-bromo-2-chloro-4-methyl-benzene.

[0430] Example 74 Synthesis of 4-[5-(2,7-diazaspiro[3.4]octane-7-carbonyl)-2-[2-fluoro-4-(2-methoxyethyl)phenyl]phenyl]-2-fluoro-benzonitrile The title compound was obtained according to the procedure of Example 22 (steps 1 to 4), except that tert-butyl 2,7-diazaspiro[3.4]octane-2-carboxylic acid was used in place of tert-butyl N-[(3-endo)-8-azabicyclo[3.2.1]octan-3-yl]carbamate.

[0431] Example 75 Synthesis of 4-[5-(2,8-diazaspiro[3.5]nonane-2-carbonyl)-2-[2-fluoro-4-(2-methoxyethyl)phenyl]phenyl]-2-fluoro-benzonitrile The title compound was obtained according to the procedure of Example 22 (steps 1 to 4), except that tert-butyl 2,8-diazaspiro[3.5]nonane-8-carboxylic acid was used in place of tert-butyl N-[(3-endo)-8-azabicyclo[3.2.1]octan-3-yl]carbamate.

[0432] Example 76 Synthesis of 4-[5-(2,7-diazaspiro[3.4]octane-7-carbonyl)-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile The title compound was obtained according to the procedure of Example 41 (steps 1 to 5), except that tert-butyl 2,7-diazaspiro[3.4]octane-2-carboxylic acid was used in place of tert-butyl N-[(3-endo)-8-azabicyclo[3.2.1]octan-3-yl]carbamate.

[0433] Example 77 Synthesis of 4-[5-(2,8-diazaspiro[3.5]nonane-2-carbonyl)-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile The title compound was obtained according to the procedure of Example 41 (steps 1 to 5), except that tert-butyl 2,8-diazaspiro[3.5]nonane-8-carboxylic acid was used in place of tert-butyl N-[(3-endo)-8-azabicyclo[3.2.1]octan-3-yl]carbamate.

[0434] Example 78 Synthesis of 4-[5-(3,8-diazaspiro[4.5]decane-8-carbonyl)-2-[2-fluoro-4-(2-methoxyethyl)phenyl]phenyl]-2-fluoro-benzonitrile hydrochloride The title compound was obtained according to the procedure of Example 22 (steps 1 to 4), except that tert-butyl 3,8-diazaspiro[4.5]decane-3-carboxylic acid was used in place of tert-butyl N-[(3-endo)-8-azabicyclo[3.2.1]octan-3-yl]carbamate.

[0435] Example 79 Synthesis of 4-[5-(2,8-diazaspiro[3.5]nonane-8-carbonyl)-2-[2-fluoro-4-(2-methoxyethyl)phenyl]phenyl]-2-fluoro-benzonitrile The title compound was obtained according to the procedure of Example 22 (steps 1 to 4), except that tert-butyl 2,8-diazaspiro[3.5]nonane-2-carboxylic acid was used in place of tert-butyl N-[(3-endo)-8-azabicyclo[3.2.1]octan-3-yl]carbamate.

[0436] Example 80 Synthesis of 4-[5-(1,4-diazepane-1-carbonyl)-2-[2-fluoro-4-(2-methoxyethyl)phenyl]phenyl]-2-fluoro-benzonitrile hydrochloride The title compound was obtained according to the procedure of Example 22 (steps 1 to 4), except that tert-butyl-1,4-diazepane-1-carboxylic acid was used in place of tert-butyl N-[(3-endo)-8-azabicyclo[3.2.1]octan-3-yl]carbamate.

[0437] Example 81 Synthesis of 4-[5-(3,7-diazaspiro[3.4]octane-7-carbonyl)-2-[2-fluoro-4-(2-methoxyethyl)phenyl]phenyl]-2-fluoro-benzonitrile The title compound was obtained according to the procedure of Example 22 (steps 1 to 4), except that tert-butyl-3,7-diazaspiro[3.4]octane-3-carboxylic acid was used in place of tert-butyl N-[(3-endo)-8-azabicyclo[3.2.1]octan-3-yl]carbamate.

[0438] Example 82 Synthesis of 4-[5-[(1S,4S)-2,5-diazabicyclo[2.2.1]heptane-2-carbonyl]-2-[2-fluoro-4-(2-methoxyethyl)phenyl]phenyl]-2-fluoro-benzonitrile The title compound was obtained according to the procedure of Example 22 (steps 1 to 4), except that tert-butyl (1S,4S)-2,5-diazabicyclo[2.2.1]heptane-2-carboxylic acid was used in place of tert-butyl N-[(3-endo)-8-azabicyclo[3.2.1]octan-3-yl]carbamate.

[0439] Example 83 Synthesis of 4-[5-(3,7-diazaspiro[3.5]nonane-7-carbonyl)-2-[2-fluoro-4-(2-methoxyethyl)phenyl]phenyl]-2-fluoro-benzonitrile The title compound was obtained according to the procedure of Example 22 (steps 1 to 4), except that tert-butyl 3,7-diazaspiro[3.5]nonane-3-carboxylic acid was used in place of tert-butyl N-[(3-endo)-8-azabicyclo[3.2.1]octan-3-yl]carbamate.

[0440] Example 84 Synthesis of 4-[5-(2,7-diazaspiro[3.5]nonane-2-carbonyl)-2-[2-fluoro-4-(2-methoxyethyl)phenyl]phenyl]-2-fluoro-benzonitrile The title compound was obtained according to the procedure of Example 22 (steps 1 to 4), except that tert-butyl 2,7-diazaspiro[3.5]nonane-7-carboxylate hydrochloride was used in place of tert-butyl N-[(3-endo)-8-azabicyclo[3.2.1]octan-3-yl]carbamate.

[0441] Example 85 Synthesis of 4-[5-[(1R,4R)-2,5-diazabicyclo[2.2.1]heptane-2-carbonyl]-2-[2-fluoro-4-(2-methoxyethyl)phenyl]phenyl]-2-fluoro-benzonitrile The title compound was obtained according to the procedure of Example 22 (steps 1 to 4), except that tert-butyl-(1R,4R)-2,5-diazabicyclo[2.2.1]heptane-2-carboxylic acid was used in place of tert-butyl N-[(3-endo)-8-azabicyclo[3.2.1]octan-3-yl]carbamate.

[0442] Example 86 Synthesis of 2-fluoro-4-[2-[2-fluoro-4-(2-methoxyethyl)phenyl]-5-[(1S,4S)-5-methyl-2,5-diazabicyclo[2.2.1]heptane-2-carbonyl]phenyl]benzonitrile The title compound was obtained according to the procedure of Example 22 (steps 1 to 4) except that (1S,4S)-2-methyl-2,5-diazabicyclo[2.2.1]heptane was used instead of tert-butyl N-[(3-endo)-8-azabicyclo[3.2.1]octan-3-yl]carbamate.

[0443] Example 87 Synthesis of 2-fluoro-4-[2-[2-fluoro-4-(2-methoxyethyl)phenyl]-5-[(1R,4R)-5-methyl-2,5-diazabicyclo[2.2.1]heptane-2-carbonyl]phenyl]benzonitrile The title compound was obtained according to the procedure of Example 22 (steps 1 to 4) except that (1R,4R)-2-methyl-2,5-diazabicyclo[2.2.1]heptane was used in place of tert-butyl N-[(3-endo)-8-azabicyclo[3.2.1]octan-3-yl]carbamate.

[0444] Example 88 Synthesis of 4-[5-(3,8-diazabicyclo[3.2.1]octane-3-carbonyl)-2-[2-fluoro-4-(2-methoxyethyl)phenyl]phenyl]-2-fluoro-benzonitrile The title compound was obtained according to the procedure of Example 22 (steps 1 to 4) except for using tert-butyl 3,8-diazabicyclo[3.2.1]octane-8-carboxylic acid in place of tert-butyl N-[(3-endo)-8-azabicyclo[3.2.1]octan-3-yl]carbamate.

[0445] Example 89 Synthesis of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-(1,3-benzothiazol-5-yl)phenyl]-2-fluoro-benzonitrile The title compound was obtained according to the procedure of Example 16 (steps 1 to 3), except that 1,3-benzothiazol-5-ylboronic acid was used in place of p-tolylboronic acid.

[0446] Example 90 Synthesis of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-(1-methylpyrazolo[3,4-b]pyridin-5-yl)phenyl]-2-fluoro-benzonitrile The title compound was obtained according to the procedure of Example 16 (steps 1 to 3), except that (1-methylpyrazolo[3,4-b]pyridin-5-yl)boronic acid was used in place of p-tolylboronic acid.

[0447] Example 91 Synthesis of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-(1-methylbenzimidazol-5-yl)phenyl]-2-fluoro-benzonitrile The title compound was obtained according to Example 37 (steps 1 to 3), except that 5-bromo-1-methyl-benzimidazole was used instead of 1-(4-bromo-3-fluoro-phenyl)-2-methyl-propan-2-ol.

[0448] Example 92 Synthesis of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-(1-methylindazol-5-yl)phenyl]-2-fluoro-benzonitrile The title compound was obtained according to the procedure of Example 16 (steps 1 to 3), except that (1-methylindazol-5-yl)boronic acid was used in place of p-tolylboronic acid.

[0449] Example 93 Synthesis of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-(2-methylindazol-5-yl)phenyl]-2-fluoro-benzonitrile The title compound was obtained according to the procedure of Example 16 (steps 1 to 3) except that 2-methyl-5-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)indazole was used in place of p-tolylboronic acid.

[0450] Example 94 Synthesis of 4-[5-[(3S)-3-aminopyrrolidine-1-carbothioyl]-2-[2-fluoro-4-(2-methoxyethyl)phenyl]phenyl]-2-fluoro-benzonitrile According to the procedure of Example 2, the title compound was obtained using 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-methoxyethyl)phenyl]phenyl]-2-fluoro-benzonitrile obtained in Example 20 (step 3) instead of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-(p-tolyl)phenyl]benzonitrile.

[0451] Example 95 Synthesis of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-(6-fluoro-1-methyl-benzimidazol-5-yl)phenyl]-2-fluoro-benzonitrile The title compound was obtained according to the procedure of Example 37 (steps 1 to 3), except that 5-bromo-6-fluoro-1-methyl-benzimidazole was used instead of 1-(4-bromo-3-fluoro-phenyl)-2-methyl-propan-2-ol.

[0452] Example 96 Synthesis of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-(6-fluoro-1-methyl-benzotriazol-5-yl)phenyl]-2-fluoro-benzonitrile (Step 1) 15 mg of tert-butyl N-[(3S)-1-[3-(4-cyano-3-fluoro-phenyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoyl]pyrrolidin-3-yl]carbamate obtained in Example 37 (Step 1) was dissolved in 0.5 mL of 1,4-dioxane. 9.7 mg of 5-bromo-6-fluoro-1-methyl-benzotriazole and PdCl were added at room temperature. 2 1.0 mg of (dppf) and 18 mg of tripotassium phosphate were added, and the mixture was stirred at 125°C for 30 minutes in a microwave reactor. Ethyl acetate was added, and the mixture was placed on NH silica gel and washed with ethyl acetate / methanol. The solvent was evaporated to give tert-butyl N-[(3S)-1-[3-(4-cyano-3-fluorophenyl)-4-(6-fluoro-1-methyl-benzotriazol-5-yl)benzoyl]pyrrolidin-3-yl]carbamate.

[0453] (Step 2) 15 mg of tert-butyl N-[(3S)-1-[3-(4-cyano-3-fluoro-phenyl)-4-(6-fluoro-1-methyl-benzotriazol-5-yl)benzoyl]pyrrolidin-3-yl]carbamate obtained in Step 1 above was dissolved in 0.3 mL of TFA, and the progress of the reaction was confirmed by LCMS, followed by concentration under reduced pressure. The residue was purified by reverse phase HPLC (mobile phase: water / acetonitrile) to obtain the title compound.

[0454] Example 97 Synthesis of 4-[5-[(3-exo)-3-amino-8-azabicyclo[3.2.1]octane-8-carbonyl]-2-(4-fluorophenyl)phenyl]benzonitrile The title compound was obtained according to the procedure of Example 23 (steps 1 to 3), except that 1-bromo-4-fluorobenzene was used instead of 5-bromo-6-fluoro-1-methyl-indole.

[0455] Example 98 Synthesis of 4-[5-[(3-exo)-3-amino-8-azabicyclo[3.2.1]octane-8-carbonyl]-2-(4-chlorophenyl)phenyl]benzonitrile The title compound was obtained according to the procedure described in Example 23 (steps 1 to 3), except that 1-bromo-4-chloro-benzene was used instead of 5-bromo-6-fluoro-1-methyl-indole.

[0456] Example 99 Synthesis of [(3S)-3-aminopyrrolidin-1-yl]-[3-(4-nitrophenyl)-4-(p-tolyl)phenyl]methanone The title compound was obtained according to the procedure of Example 19 (steps 1 to 5), except that 1-bromo-4-nitro-benzene was used instead of 4-bromo-2,6-difluoro-benzonitrile.

[0457] Example 100 Synthesis of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[6-(dimethylamino)-3-pyridyl]phenyl]-2-fluoro-benzonitrile The title compound was obtained according to Example 37 (steps 1 to 3), except that 5-bromo-N,N-dimethylpyridin-2-amine was used instead of 1-(4-bromo-3-fluoro-phenyl)-2-methyl-propan-2-ol.

[0458] Example 101 Synthesis of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-(1-methylbenzotriazol-5-yl)phenyl]-2-fluoro-benzonitrile The title compound was obtained according to Example 37 (steps 1 to 3), except that 5-bromo-1-methyl-benzotriazole was used instead of 1-(4-bromo-3-fluoro-phenyl)-2-methyl-propan-2-ol.

[0459] Example 102 Synthesis of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-(6,7-difluoro-1-methyl-benzimidazol-5-yl)phenyl]-2-fluoro-benzonitrile The title compound was obtained according to the procedure of Example 37 (steps 1 to 3), except that 5-bromo-6,7-difluoro-1-methyl-benzimidazole was used instead of 1-(4-bromo-3-fluoro-phenyl)-2-methyl-propan-2-ol.

[0460] Example 103 Synthesis of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-(1,2-dimethylbenzimidazol-5-yl)phenyl]-2-fluoro-benzonitrile The title compound was obtained according to the procedure of Example 37 (steps 1 to 3), except that 5-bromo-1,2-dimethyl-benzimidazole was used instead of 1-(4-bromo-3-fluoro-phenyl)-2-methyl-propan-2-ol.

[0461] Example 104 Synthesis of 4-[5-[(3-exo)-3-amino-8-azabicyclo[3.2.1]octane-8-carbonyl]-2-(2-naphthyl)phenyl]-2-fluoro-benzonitrile The title compound was obtained according to the procedure of Example 23 (steps 1 to 3) except that 2-bromonaphthalene was used instead of 5-bromo-6-fluoro-1-methyl-indole.

[0462] Example 105 Synthesis of 4-[5-[(3-exo)-3-amino-8-azabicyclo[3.2.1]octane-8-carbonyl]-2-(8-fluoro-7-quinolyl)phenyl]-2-fluoro-benzonitrile The title compound was obtained according to the procedure described in Example 23 (steps 1 to 3) except that 7-bromo-8-fluoroquinoline was used instead of 5-bromo-6-fluoro-1-methyl-indole.

[0463] Example 106 Synthesis of 4-[5-[(3-exo)-3-amino-8-azabicyclo[3.2.1]octane-8-carbonyl]-2-(4-methyl-2,3-dihydro-1,4-benzoxazin7-yl)phenyl]-2-fluoro-benzonitrile The title compound was obtained according to the procedure of Example 23 (steps 1 to 3) except that 7-bromo-4-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazine was used instead of 5-bromo-6-fluoro-1-methyl-indole.

[0464] Example 107 Synthesis of 4-[5-[(3-exo)-3-amino-8-azabicyclo[3.2.1]octane-8-carbonyl]-2-(7-quinonyl)phenyl]-2-fluoro-benzonitrile The title compound was obtained according to the procedure described in Example 23 (steps 1 to 3) except that 7-bromoquinoline was used instead of 5-bromo-6-fluoro-1-methyl-indole.

[0465] Example 108 Synthesis of 4-[5-[(3-exo)-3-amino-8-azabicyclo[3.2.1]octane-8-carbonyl]-2-(6-fluoro-1-methyl-benzimidazol-5-yl)phenyl]-2-fluoro-benzonitrile The title compound was obtained according to the procedure of Example 23 (steps 1 to 3), except that 5-bromo-6-fluoro-1-methyl-benzimidazole was used instead of 5-bromo-6-fluoro-1-methyl-indole.

[0466] Example 109 Synthesis of 4-[5-[(3-exo)-3-amino-8-azabicyclo[3.2.1]octane-8-carbonyl]-2-(6-fluoro-1-methyl-benzotriazol-5-yl)phenyl]-2-fluoro-benzonitrile The title compound was obtained according to the procedure of Example 23 (steps 1 to 3), except that 5-bromo-6-fluoro-1-methyl-benzotriazole was used instead of 5-bromo-6-fluoro-1-methyl-indole.

[0467] Example 110 Synthesis of 4-[5-[(3-exo)-3-amino-8-azabicyclo[3.2.1]octane-8-carbonyl]-2-(4-fluoro-1-methyl-indazol-5-yl)phenyl]-2-fluoro-benzonitrile The title compound was obtained according to the procedure of Example 23 (steps 1 to 3), except that 5-bromo-4-fluoro-1-methyl-indazole was used instead of 5-bromo-6-fluoro-1-methyl-indole.

[0468] Example 111 Synthesis of 4-[5-[(3-exo)-3-amino-8-azabicyclo[3.2.1]octane-8-carbonyl]-2-(2-methylindazol-5-yl)phenyl]benzonitrile The title compound was obtained according to the procedure of Example 23 (steps 1 to 3) except that 5-bromo-2-methyl-2H-indazole was used instead of 5-bromo-6-fluoro-1-methyl-indole.

[0469] Example 112 Synthesis of 2-fluoro-4-[2-[2-fluoro-4-(2-methoxyethyl)phenyl]-5-[(3-exo)-3-(isopropylamino)-8-azabicyclo[3.2.1]octane-8-carbonyl]phenyl]benzonitrile To a solution of 4-[5-[(3-exo)-3-amino-8-azabicyclo[3.2.1]octane-8-carbonyl]-2-[2-fluoro-4-(2-methoxyethyl)phenyl]phenyl]-2-fluoro-benzonitrile obtained in Example 26 (Step 2) in 0.05 mL of dichloromethane, 0.002 mL of acetone was added at 25 ° C., followed by the addition of 8.45 mg of NaBH(OAc) 3 and stirring at room temperature for 1 hour. MeOH was added, the solvent was evaporated, and the residue was purified by reverse phase HPLC (mobile phase: water / acetonitrile) to obtain the title compound.

[0470] Example 113 Synthesis of 2-fluoro-4-[2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]-5-[(3-exo)-3-(isopropylamino)-8-azabicyclo[3.2.1]octane-8-carbonyl]phenyl]benzonitrile According to Example 112, 4-[5-[(3-exo)-3-amino-8-azabicyclo[3.2.1]octane-8-carbonyl]-2-[2-fluoro The title compound was obtained using 4-[5-[(3-exo)-3-amino-8-azabicyclo[3.2.1]octane-8-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile obtained in Example 28 (Step 3) in place of 4-(2-methoxyethyl)phenyl]phenyl]-2-fluoro-benzonitrile.

[0471] Example 114 Synthesis of 4-[5-[(3S)-3-(ethylamino)pyrrolidine-1-carbonyl]-2-(6-fluoro-1-methyl-benzotriazol-5-yl)phenyl]-2-fluoro-benzonitrile (Step 1) 10 mg of tert-butyl N-[(3S)-1-[3-(4-cyano-3-fluoro-phenyl)-4-(6-fluoro-1-methyl-benzotriazol-5-yl)benzoyl]pyrrolidin-3-yl]carbamate obtained in Example 96 (Step 1) was dissolved in 0.5 mL of THF. 0.85 mg of sodium hydride and then 5.58 mg of iodoethane were added at room temperature, and the mixture was stirred overnight at 50°C. The solvent was then evaporated to give (S), tert-butyl (1-(4'-cyano-3'-fluoro-6-(6-fluoro-1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-[1,1'-biphenyl]-3-carbonyl)pyrrolidin-3-yl)(ethyl)carbamate, which was used in the next step without purification.

[0472] (Step 2) In accordance with Example 26 (Step 2), the title compound was obtained using (S), tert-butyl (1-(4'-cyano-3'-fluoro-6-(6-fluoro-1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-[1,1'-biphenyl]-3-carbonyl)pyrrolidin-3-yl)(ethyl)carbamate obtained in Step 1 above in place of [(3-exo)-8-[3-(4-cyano-3-fluoro-phenyl)-4-[2-fluoro-4-(2-methoxyethyl)phenyl]benzoyl]-8-azabicyclo[3.2.1]octan-3-yl]carbamate.

[0473] Example 115 Synthesis of 2-fluoro-4- [2- (6-fluoro-1-methyl-benzotriazol-5-yl) -5- [(3S) -3- (isopropylamino) pyrrolidine-1-carbonyl] phenyl] benzonitrile According to Example 112, instead of 4- [5- [(3-exo) -3-amino-8-azabicyclo [3.2.1] octane-8-carbonyl] -2- [2-fluoro-4- (2-methoxyethyl) phenyl] phenyl] -2-fluoro-benzonitrile, the title compound was obtained using 4- [5- [(3S) -3-aminopyrrolidine-1-carbonyl] -2- (6-fluoro-1-methyl-benzotriazol-5-yl) phenyl] -2-fluoro-benzonitrile obtained in Example 96 (step 2).

[0474] Example 116 Synthesis of 4-[5-[(3S)-3-(cyclobutylamino)pyrrolidine-1-carbonyl]-2-(6-fluoro-1-methyl-benzotriazol-5-yl)phenyl]-2-fluoro-benzonitrile According to the procedure of Example 112, instead of 4-[5-[(3-exo)-3-amino-8-azabicyclo[3.2.1]octane-8-carbonyl]-2-[2-fluoro-4-(2-methoxyethyl)phenyl]phenyl]-2-fluoro-benzonitrile, 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-(6-fluoro-1-methyl-benzotriazol-5-yl)phenyl]-2-fluoro-benzonitrile obtained in Example 96 (step 2) was used, and cyclobutanone was used instead of acetone to obtain the title compound.

[0475] Example 117 Synthesis of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-(1-methylindolin-5-yl)phenyl]-2-fluoro-benzonitrile The title compound was obtained according to Example 37 (steps 1 to 3) except that 5-bromo-1-methyl-indoline was used instead of 1-(4-bromo-3-fluoro-phenyl)-2-methyl-propan-2-ol.

[0476] Example 118 Synthesis of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-(4-methyl-2,3-dihydro-1,4-benzoxazin-7-yl)phenyl]-2-fluoro-benzonitrile The title compound was obtained according to the procedure of Example 37 (steps 1 to 3), except that 7-bromo-4-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazine was used instead of 1-(4-bromo-3-fluoro-phenyl)-2-methyl-propan-2-ol.

[0477] Example 119 Synthesis of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-(3-methyl-2-oxo-1,3-benzoxazol-6-yl)phenyl]-2-fluoro-benzonitrile The title compound was obtained according to the procedure of Example 37 (steps 1 to 3), except that 6-bromo-3-methyl-1,3-benzoxazol-2-one was used instead of 1-(4-bromo-3-fluoro-phenyl)-2-methyl-propan-2-ol.

[0478] Example 120 Synthesis of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-(3-methyl-2-oxo-1,3-benzothiazol-6-yl)phenyl]-2-fluoro-benzonitrile The title compound was obtained according to the procedure of Example 37 (steps 1 to 3), except that 6-bromo-3-methyl-1,3-benzothiazol-2-one was used instead of 1-(4-bromo-3-fluoro-phenyl)-2-methyl-propan-2-ol.

[0479] Example 121 Synthesis of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-(2,3-dihydro-1,4-benzodioxin-6-yl)phenyl]-2-fluoro-benzonitrile The title compound was obtained according to the procedure of Example 16 (steps 1 to 3), except that 2,3-dihydro-1,4-benzodioxan-6-ylboronic acid was used in place of p-tolylboronic acid.

[0480] Example 122 Synthesis of 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-(1,3-benzodioxol-5-yl)phenyl]-2-fluoro-benzonitrile The title compound was obtained according to the procedure of Example 16 (steps 1 to 3), except that 1,3-benzodioxol-5-ylboronic acid was used in place of p-tolylboronic acid.

[0481] Example 123 Synthesis of 4-[5-[(3-endo)-3-amino-8-azabicyclo[3.2.1]octane-8-carbonyl]-2-(6-fluoro-1-methyl-indol-5-yl)phenyl]-2-fluoro-benzonitrile The title compound was obtained according to the procedure of Example 41 (steps 1 to 5) except that 5-bromo-6-fluoro-1-methyl-indole was used instead of 1-(4-bromo-3-fluoro-phenyl)-2-methyl-propan-2-ol.

[0482] Example 124 Synthesis of 4-[5-[(3-endo)-3-amino-8-azabicyclo[3.2.1]octane-8-carbonyl]-2-(6-fluoro-1-methyl-indazol-5-yl)phenyl]-2-fluoro-benzonitrile The title compound was obtained according to the procedure of Example 41 (steps 1 to 5) except that 5-bromo-6-fluoro-1-methyl-indazole was used instead of 1-(4-bromo-3-fluoro-phenyl)-2-methyl-propan-2-ol.

[0483] Example 125 Synthesis of 4-[5-[(3-endo)-3-amino-8-azabicyclo[3.2.1]octane-8-carbonyl]-2-(6-fluoro-1-methyl-benzotriazol-5-yl)phenyl]-2-fluoro-benzonitrile The title compound was obtained according to the procedure of Example 41 (steps 1 to 5) except that 5-bromo-6-fluoro-1-methyl-benzotriazole was used instead of 1-(4-bromo-3-fluoro-phenyl)-2-methyl-propan-2-ol.

[0484] Example 126 Synthesis of 4-[5-[(3-endo)-3-amino-8-azabicyclo[3.2.1]octane-8-carbonyl]-2-(6,7-difluoro1-methyl-benzimidazol-5-yl)phenyl]-2-fluoro-benzonitrile The title compound was obtained according to the procedure of Example 41 (steps 1 to 5) except that 5-bromo-6,7-difluoro-1-methyl-benzimidazole was used instead of 1-(4-bromo-3-fluoro-phenyl)-2-methyl-propan-2-ol.

[0485] Example 127 Synthesis of 4-[5-[(3-exo)-3-amino-9-azabicyclo[3.3.1]nonane-9-carbonyl]-2-[2-fluoro-4-(2-methoxyethyl)phenyl]phenyl]-2-fluoro-benzonitrile The title compound was obtained according to the procedure of Example 22 (steps 1 to 4), except that tert-butyl N-[(3-exo)-9-azabicyclo[3.3.1]nonan-3-yl]carbamate was used in place of tert-butyl N-[(3-endo)-8-azabicyclo[3.2.1]octan-3-yl]carbamate.

[0486] Example 128 Synthesis of 4-[5-[(3-endo)-3-amino-8-azabicyclo[3.2.1]octane-8-carbonyl]-2-(4-methyl-2,3-dihydro-1,4-benzoxazin-7-yl)phenyl]-2-fluoro-benzonitrile The title compound was obtained according to the procedure of Example 41 (steps 1 to 5) except that 7-bromo-4-methyl-3,4-dihydro-2H-benzo[b][1,4]oxazine was used instead of 1-(4-bromo-3-fluoro-phenyl)-2-methyl-propan-2-ol.

[0487] Example 129 Synthesis of 4-[5-[(3-endo)-3-amino-9-azabicyclo[3.3.1]nonane-9-carbonyl]-2-[2-fluoro-4-(2-methoxyethyl)phenyl]phenyl]-2-fluoro-benzonitrile The title compound was obtained according to the procedure of Example 22 (steps 1 to 4), except that tert-butyl N-[(3-endo)-9-azabicyclo[3.3.1]nonan-3-yl]carbamate was used in place of tert-butyl N-[(3-endo)-8-azabicyclo[3.2.1]octan-3-yl]carbamate.

[0488] Example 130 Synthesis of 4-[5-[(3-endo)-3-amino-8-azabicyclo[3.2.1]octane-8-carbonyl]-2-(6-fluoro-1-methyl-benzimidazol-5-yl)phenyl]-2-fluoro-benzonitrile The title compound was obtained according to the procedure of Example 41 (steps 1 to 5) except that 5-bromo-6-fluoro-1-methyl-benzimidazole was used instead of 1-(4-bromo-3-fluoro-phenyl)-2-methyl-propan-2-ol.

[0489] Example 131 Synthesis of 4-[5-[(3-endo)-3-amino-8-azabicyclo[3.2.1]octane-8-carbonyl]-2-[6-(dimethylamino)-3-pyridyl]phenyl]-2-fluoro-benzonitrile The title compound was obtained according to the procedure of Example 41 (steps 1 to 5) except that 5-bromo-N,N-dimethylpyridin-2-amine was used instead of 1-(4-bromo-3-fluoro-phenyl)-2-methyl-propan-2-ol.

[0490] Example 132 Synthesis of 4-[5-[(3-endo)-3-amino-8-azabicyclo[3.2.1]octane-8-carbonyl]-2-(1,3,3-trimethyl-2-oxo-indolin-5-yl)phenyl]-2-fluoro-benzonitrile The title compound was obtained according to the procedure of Example 41 (steps 1 to 5) except that 5-bromo-1,3,3-trimethyl-indolin-2-one was used instead of 1-(4-bromo-3-fluoro-phenyl)-2-methyl-propan-2-ol.

[0491] Example 133 Synthesis of 4-[5-[(3-endo)-3-amino-8-azabicyclo[3.2.1]octane-8-carbonyl]-2-(3-methyl-2-oxo-1,3-benzothiazol-6-yl)phenyl]-2-fluoro-benzonitrile The title compound was obtained according to the procedure of Example 41 (steps 1 to 5) except that 6-bromo-3-methyl-1,3-benzothiazol-2-one was used instead of 1-(4-bromo-3-fluoro-phenyl)-2-methyl-propan-2-ol.

[0492] Example 134 Synthesis of (S)-5'-(3-aminopyrrolidine-1-carbonyl)-3-fluoro-2'-(6-fluoro-1-methyl-1H-indol-5-yl)-[1,1'-biphenyl]-4-carbonitrile The title compound was obtained according to Example 37 (steps 1 to 3) except that 5-bromo-6-fluoro-1-methyl-1H-indole was used instead of 1-(4-bromo-3-fluoro-phenyl)-2-methyl-propan-2-ol.

[0493] Example 135 Synthesis of (S)-5'-(3-aminopyrrolidine-1-carbonyl)-3-fluoro-2'-(6-fluoro-1-methyl-1H-indazol-5-yl)-[1,1'-biphenyl]-4-carbonitrile The title compound was obtained according to Example 37 (steps 1 to 3) using 5-bromo-6-fluoro-1-methyl-1H-indazole instead of 1-(4-bromo-3-fluoro-phenyl)-2-methyl-propan-2-ol.

[0494] Example 136 Synthesis of 5'-((3-endo)-3-amino-8-azabicyclo[3.2.1]octane-8-carbonyl)-3-fluoro-2'-(6-fluoro-1-(2-hydroxy-2-methylpropyl)-1H-indol-5-yl)-[1,1'-biphenyl]-4-carbonitrile (Step 1) 50 mg of 5-bromo-6-fluoro-1H-indole was dissolved in 0.78 mL of DMF. 2 CO 3 151 mg of 2,2-dimethyloxirane and 42 μL of 2,2-dimethyloxirane were added, and the mixture was stirred at 90°C for 16 hours. The mixture was quenched with saturated aqueous NH4Cl, ethyl acetate was added, and the mixture was washed successively with water and saturated brine. The organic layer was dried over anhydrous sodium sulfate, and the solvent was then distilled off. The residue was purified by silica gel column chromatography (mobile phase: hexane / ethyl acetate) to obtain 1-(5-bromo-6-fluoro-indol-1-yl)-2-methyl-propan-2-ol.

[0495] (Step 2) In accordance with Example 41 (Steps 1 to 5), the title compound was obtained using 1-(5-bromo-6-fluoro-indol-1-yl)-2-methyl-propan-2-ol obtained in the above (Step 1) instead of 1-(4-bromo-3-fluoro-phenyl)-2-methyl-propan-2-ol.

[0496] Example 137 Synthesis of 5'-((3-endo)-3-amino-8-azabicyclo[3.2.1]octane-8-carbonyl)-2'-(1,3-dihydroisobenzofuran-5-yl)-3-fluoro-[1,1'-biphenyl]-4-carbonitrile The title compound was obtained according to the procedure described in Example 41 (steps 1 to 5) except that 5-bromo-1,3-dihydroisobenzofuran was used instead of 1-(4-bromo-3-fluoro-phenyl)-2-methyl-propan-2-ol.

[0497] Example 138 Synthesis of 5'-((3-endo)-3-amino-8-azabicyclo[3.2.1]octane-8-carbonyl)-3-fluoro-2'-(3-isopropyl-2-oxo-2,3-dihydrobenzo[d]thiazol-6-yl)-[1,1'-biphenyl]-4-carbonitrile (Step 1) 100 mg of 6-bromo-3H-1,3-benzothiazol-2-one was dissolved in 0.87 mL of DMF. 90 mg of potassium carbonate was added at room temperature, and the mixture was stirred at 0°C for 15 minutes. 0.082 mL of 2-bromopropane was added at room temperature, and the mixture was stirred at 100°C for 3 hours. Saturated NH 4 The mixture was quenched with aqueous Cl solution, ethyl acetate was added, and the mixture was washed successively with water and saturated brine. The organic layer was dried over anhydrous sodium sulfate, and the solvent was evaporated. The residue was purified by silica gel column chromatography (mobile phase: hexane / ethyl acetate) to give 6-bromo-3-isopropyl-1,3-benzothiazol-2-one.

[0498] (Step 2) In accordance with Example 41 (Steps 1 to 5), the title compound was obtained using 6-bromo-3-isopropyl-1,3-benzothiazol-2-one obtained above (Step 1) instead of 1-(4-bromo-3-fluoro-phenyl)-2-methyl-propan-2-ol.

[0499] Example 139 Synthesis of 5'-((3-endo)-3-amino-8-azabicyclo[3.2.1]octane-8-carbonyl)-2'-(1-(tert-butyl)-6-fluoro-1H-benzo[d][1,2,3]triazol-5-yl)-3-fluoro-[1,1'-biphenyl]-4-carbonitrile The title compound was obtained according to the procedure described in Example 41 (steps 1 to 5) except that 5-bromo-1-(tert-butyl)-6-fluoro-1H-benzo[d][1,2,3]triazole was used in place of 1-(4-bromo-3-fluoro-phenyl)-2-methyl-propan-2-ol.

[0500] Example 140 Synthesis of (S)-5'-(3-aminopyrrolidine-1-carbonyl)-2'-(1,3-dihydroisobenzofuran-5-yl)-3-fluoro-[1,1'-biphenyl]-4-carbonitrile The title compound was obtained according to the procedure of Example 37 (steps 1 to 3), except that 5-bromo-1,3-dihydroisobenzofuran was used instead of 1-(4-bromo-3-fluoro-phenyl)-2-methyl-propan-2-ol.

[0501] Example 141 Synthesis of (S)-5'-(3-aminopyrrolidine-1-carbonyl)-3-fluoro-2'-(5-fluoro-3-methyl-2-oxo-2,3-dihydrobenzo[d]thiazol-6-yl)-[1,1'-biphenyl]-4-carbonitrile (Step 1) 200 mg of 5-fluoro-3H-1,3-benzothiazol-2-one was suspended in 1 mL of MeCN. 231 mg of NBS was added at room temperature, and the mixture was stirred at room temperature for 1 hour. The solvent was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (mobile phase: hexane / ethyl acetate) to obtain 6-bromo-5-fluoro-3H-1,3-benzothiazol-2-one.

[0502] (Step 2) 100 mg of 6-bromo-5-fluoro-3H-1,3-benzothiazol-2-one obtained in (Step 1) above was dissolved in 1.3 mL of DMF. 84 mg of potassium carbonate was added at room temperature, and the mixture was stirred at 0°C for 15 minutes. 0.050 mL of iodomethane was added at room temperature, and the mixture was stirred at room temperature for 0.5 hours. Saturated NH 4The mixture was quenched with aqueous Cl solution, ethyl acetate was added, and the mixture was washed successively with water and saturated brine. The organic layer was dried over anhydrous sodium sulfate, and the solvent was evaporated. The residue was purified by silica gel column chromatography (mobile phase: hexane / ethyl acetate) to give 6-bromo-5-fluoro-3-methyl-1,3-benzothiazol-2-one.

[0503] (Step 3) In accordance with Example 37 (Steps 1 to 3), the title compound was obtained using 6-bromo-5-fluoro-3-methyl-1,3-benzothiazol-2-one obtained above (Step 2) instead of 1-(4-bromo-3-fluoro-phenyl)-2-methyl-propan-2-ol.

[0504] Example 142 Synthesis of 5'-((3-endo)-3-amino-8-azabicyclo[3.2.1]octane-8-carbonyl)-3-fluoro-2'-(6-fluoro-1-(2-hydroxy-2-methylpropyl)-1H-indazol-5-yl)-[1,1'-biphenyl]-4-carbonitrile (Step 1) 94 mg of 5-bromo-6-fluoro-1H-indazole was dissolved in 1.5 mL of DMF. 285 mg of cesium carbonate and 0.078 mL of 2,2-dimethyloxirane were added at room temperature, and the mixture was stirred at 90°C for 16 hours. The mixture was quenched with a saturated aqueous NH4Cl solution, ethyl acetate was added, and the mixture was washed successively with water and saturated brine. The organic layer was dried over anhydrous sodium sulfate, and the solvent was then evaporated. The residue was purified by silica gel column chromatography (mobile phase: hexane / ethyl acetate) to obtain 1-(5-bromo-6-fluoro-indazol-1-yl)-2-methyl-propan-2-ol.

[0505] (Step 2) In accordance with Example 41 (Steps 1 to 5), the title compound was obtained using 1-(5-bromo-6-fluoro-indazol-1-yl)-2-methyl-propan-2-ol obtained above (Step 1) instead of 1-(4-bromo-3-fluoro-phenyl)-2-methyl-propan-2-ol.

[0506] Example 143 Synthesis of 4-[5-[(1S,3R,4R)-rel-3-amino-7-azabicyclo[2.2.1]heptane-7-carbonyl]-2-[2-fluoro-4-(2-methoxyethyl)phenyl]phenyl]-2-fluoro-benzonitrile (Step 1) 50 mg of tert-butyl (1S,3R,4R)-rel-3-amino-7-azabicyclo[2.2.1]heptane-7-carboxylate was dissolved in 1.2 mL of THF. 0.066 mL of TEA and 57 mg of 2-nitrobenzenesulfonyl chloride were added at 0°C, and the mixture was stirred at room temperature for 1 hour. Ethyl acetate was added, and the mixture was washed sequentially with water and saturated brine. The organic layer was dried over anhydrous sodium sulfate, and the solvent was then evaporated. The residue was purified by silica gel column chromatography (mobile phase: hexane / ethyl acetate), and the solvent was evaporated. The residue was dissolved in 2 mL of 4 N hydrochloric acid-ethyl acetate solution and stirred at room temperature for 30 minutes. The reaction mixture was concentrated under reduced pressure to give N-[(1S,3R,4R)-rel-7-azabicyclo[2.2.1]heptan-3-yl]-2-nitrobenzenesulfonamide hydrochloride.

[0507] (Step 2) In accordance with Example 22 (Step 3), N-[(1S,3R,4R)-rel-7-[3-(4-cyano-3-fluoro-phenyl)-4-[2-fluoro-4-(2-methoxyethyl)phenyl]benzoyl]-7-azabicyclo[2.2.1]heptan-3-yl]-2-nitrobenzenesulfonamide was obtained using N-[(1S,3R,4R)-rel-7-azabicyclo[2.2.1]heptan-3-yl]-2-nitrobenzenesulfonamide hydrochloride obtained in the above (Step 1) instead of tert-butyl N-[(3-endo)-8-azabicyclo[3.2.1]octan-3-yl]carbamate.

[0508] (Step 3) 20 mg of N-[(1S,3R,4R)-rel-7-[3-(4-cyano-3-fluoro-phenyl)-4-[2-fluoro-4-(2-methoxyethyl)phenyl]benzoyl]-7-azabicyclo[2.2.1]heptan-3-yl]-2-nitrobenzenesulfonamide obtained in the above (Step 2) was dissolved in 0.5 mL of DMF. 2 CO3 21 mg of methylpropional and 12 mg of 4-mercaptobenzoic acid were added and stirred at 40°C for 12 hours. Ethyl acetate was added, and the mixture was washed successively with water and saturated brine. The organic layer was dried over anhydrous sodium sulfate, and the solvent was then distilled off. The residue was purified by reverse phase HPLC (mobile phase: water / acetonitrile) to obtain the title compound.

[0509] Example 144 Synthesis of 5'-((3-endo)-3-amino-8-azabicyclo[3.2.1]octane-8-carbonyl)-2",3,3"-trifluoro-4"-methyl-[1,1':2',1"-terphenyl]-4-carbonitrile The title compound was obtained according to the procedure of Example 41 (steps 1 to 5) except that 1-bromo-2,3-difluoro-4-methyl-benzene was used instead of 1-(4-bromo-3-fluoro-phenyl)-2-methyl-propan-2-ol.

[0510] Example 145 Synthesis of 5'-((3-endo)-3-amino-8-azabicyclo[3.2.1]octane-8-carbonyl)-2'-(6,7-difluoro-1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-fluoro-[1,1'-biphenyl]-4-carbonitrile (Step 1) 200 mg of tert-butyl N-[(3-endo)-8-[3-(4-cyano-3-fluoro-phenyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoyl]-8-azabicyclo[3.2.1]octan-3-yl]carbamate obtained in Example 41, Step 3, 5-bromo-6,7-difluoro-1-methyl-benzotriazole 129 mg of Pd(dba) was dissolved in 1.74 mL of 1,4-dioxane at room temperature. 216.0 mg of the compound, 26.5 mg of X-Phos, and 221 mg of tripotassium phosphate were added, and the mixture was stirred at 125°C for 1 hour in a microwave reactor. The reaction solution was filtered, and the solvent was distilled off. The residue was purified by silica gel column chromatography (mobile phase: ethyl acetate / hexane) to give tert-butyl N-[(3-endo)-8-[3-(4-cyano-3-fluoro-phenyl)-4-(6,7-difluoro-1-methyl-benzotriazol-5-yl)benzoyl]-8-azabicyclo[3.2.1]octan-3-yl]carbamate.

[0511] (Step 2) 210 mg of tert-butyl N-[(3-endo)-8-[3-(4-cyano-3-fluoro-phenyl)-4-(6,7-difluoro-1-methyl-benzotriazol-5-yl)benzoyl]-8-azabicyclo[3.2.1]octan-3-yl]carbamate obtained in Step 1 above was dissolved in 1.60 mL of MeOH. 2.40 mL of 4 N hydrochloric acid-ethyl acetate solution was added at room temperature, and the mixture was stirred at room temperature for 1 hour. The reaction solution was concentrated under reduced pressure, and the solvent was distilled off. The residue was purified by reverse phase HPLC (mobile phase: water / acetonitrile) to obtain the title compound.

[0512] Example 146 Synthesis of (S)-5'-(3-aminopyrrolidine-1-carbonyl)-3-fluoro-2'-(6-fluoro-1-(2-hydroxy-2-methylpropyl)-1H-indol-5-yl)-[1,1'-biphenyl]-4-carbonitrile (Step 1) 60 mg of tert-butyl N-[(3S)-1-[3-(4-cyano-3-fluoro-phenyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoyl]pyrrolidin-3-yl]carbamate obtained in Example 37 Step 1, and 48.1 mg of 1-(5-bromo-6-fluoro-indol-1-yl)-2-methyl-propan-2-ol obtained in Example 136 Step 1 were dissolved in 0.50 mL of 1,4-dioxane. Pd(dba) at room temperature 23.22 mg of the compound, 5.34 mg of X-Phos, and 71.4 mg of tripotassium phosphate were added, and the mixture was stirred at 125 ° C. for 1 hour in a microwave reactor. The reaction solution was filtered, and the solvent was distilled off. The residue was purified by silica gel column chromatography (mobile phase: chloroform / methanol) to give tert-butyl N-[(3S)-1-[3-(4-cyano-3-fluoro-phenyl)-4-[6-fluoro-1-(2-hydroxy-2-methyl-propyl)indol-5-yl]benzoyl]pyrrolidin-3-yl]carbamate.

[0513] (Step 2) 68.0 mg of tert-butyl N-[(3S)-1-[3-(4-cyano-3-fluoro-phenyl)-4-[6-fluoro-1-(2-hydroxy-2-methyl-propyl)indol-5-yl]benzoyl]pyrrolidin-3-yl]carbamate obtained in Step 1 above was dissolved in 1.0 mL of MeOH. 1.0 mL of 12 N hydrochloric acid was added at room temperature, and the mixture was stirred at room temperature for 1 hour. 6.00 mL of 2 N aqueous sodium hydroxide solution and chloroform were added, and the mixture was washed sequentially with water and saturated brine, dried over anhydrous sodium sulfate, and the solvent was then evaporated. The residue was purified by reverse phase HPLC (mobile phase: water / acetonitrile) to obtain the title compound.

[0514] Example 147 Synthesis of (S)-5'-(3-aminopyrrolidine-1-carbonyl)-3-fluoro-2'-(6-fluoro-1-(2-hydroxy-2-methylpropyl)-1H-indazol-5-yl)-[1,1'-biphenyl]-4-carbonitrile (Step 1) 70 mg of tert-butyl N-[(3S)-1-[3-(4-cyano-3-fluoro-phenyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoyl]pyrrolidin-3-yl]carbamate obtained in Example 37 Step 1, and 56.3 mg of 1-(5-bromo-6-fluoro-indazol-1-yl)-2-methyl-propan-2-ol obtained in Example 142 Step 1 were dissolved in 0.50 mL of 1,4-dioxane. Pd(dba) at room temperature 23.76 mg of the compound, 6.23 mg of X-Phos, and 83.3 mg of tripotassium phosphate were added, and the mixture was stirred at 125 ° C. for 1 hour in a microwave reactor. The reaction solution was filtered, and the solvent was distilled off. The residue was purified by silica gel column chromatography (mobile phase: chloroform / methanol) to give tert-butyl N-[(3S)-1-[3-(4-cyano-3-fluoro-phenyl)-4-[6-fluoro-1-(2-hydroxy-2-methyl-propyl)indazol-5-yl]benzoyl]pyrrolidin-3-yl]carbamate.

[0515] (Step 2) 70.0 mg of tert-butyl N-[(3S)-1-[3-(4-cyano-3-fluoro-phenyl)-4-[6-fluoro-1-(2-hydroxy-2-methyl-propyl)indazol-5-yl]benzoyl]pyrrolidin-3-yl]carbamate obtained in Step 1 above was dissolved in 1.0 mL of MeOH. 1.0 mL of 12 N hydrochloric acid was added at room temperature, and the mixture was stirred at room temperature for 1 hour. 6.00 mL of 2 N aqueous sodium hydroxide solution and chloroform were added, and the mixture was washed sequentially with water and saturated brine, dried over anhydrous sodium sulfate, and the solvent was then evaporated. The residue was purified by reverse phase HPLC (mobile phase: water / acetonitrile) to obtain the title compound.

[0516] Example 148 Synthesis of 5'-((3-endo)-3-amino-8-azabicyclo[3.2.1]octane-8-carbonyl)-3-fluoro-2'-(quinoxalin-6-yl)-[1,1'-biphenyl]-4-carbonitrile The title compound was obtained according to the procedure described in Example 41 (steps 1 to 5) except that 6-bromoquinoxaline was used instead of 1-(4-bromo-3-fluoro-phenyl)-2-methyl-propan-2-ol.

[0517] Example 149 Synthesis of 5'-((3-endo)-3-amino-8-azabicyclo[3.2.1]octane-8-carbonyl)-3-fluoro-2'-(isoquinolin-6-yl)-[1,1'-biphenyl]-4-carbonitrile The title compound was obtained according to the procedure described in Example 41 (steps 1 to 5) except that 6-bromoisoquinoline was used instead of 1-(4-bromo-3-fluoro-phenyl)-2-methyl-propan-2-ol.

[0518] Example 150 Synthesis of 5'-((3-endo)-3-amino-8-azabicyclo[3.2.1]octane-8-carbonyl)-3-fluoro-2'-(isoquinolin-7-yl)-[1,1'-biphenyl]-4-carbonitrile The title compound was obtained according to the procedure described in Example 41 (steps 1 to 5) except that 7-bromoisoquinoline was used instead of 1-(4-bromo-3-fluoro-phenyl)-2-methyl-propan-2-ol.

[0519] Example 151 Synthesis of 5'-((3-endo)-3-amino-8-azabicyclo[3.2.1]octane-8-carbonyl)-3-fluoro-2'-(quinolin-6-yl)-[1,1'-biphenyl]-4-carbonitrile The title compound was obtained according to the procedure described in Example 41 (steps 1 to 5) except that 6-bromoquinoline was used instead of 1-(4-bromo-3-fluoro-phenyl)-2-methyl-propan-2-ol.

[0520] Example 152 Synthesis of 5'-((3-endo)-3-amino-8-azabicyclo[3.2.1]octane-8-carbonyl)-3-fluoro-2'-(quinazolin-7-yl)-[1,1'-biphenyl]-4-carbonitrile The title compound was obtained according to the procedure described in Example 41 (steps 1 to 5) except that 7-bromoquinazoline was used instead of 1-(4-bromo-3-fluoro-phenyl)-2-methyl-propan-2-ol.

[0521] Example 153 Synthesis of 5'-((3-endo)-3-amino-8-azabicyclo[3.2.1]octane-8-carbonyl)-3-fluoro-2'-(quinazolin-6-yl)-[1,1'-biphenyl]-4-carbonitrile The title compound was obtained according to the procedure described in Example 41 (steps 1 to 5) except that 6-bromoquinazoline was used instead of 1-(4-bromo-3-fluoro-phenyl)-2-methyl-propan-2-ol.

[0522] Example 154 Synthesis of 5'-((3-endo)-3-amino-8-azabicyclo[3.2.1]octane-8-carbonyl)-3-fluoro-2'-(phthalazin-6-yl)-[1,1'-biphenyl]-4-carbonitrile The title compound was obtained according to the procedure described in Example 41 (steps 1 to 5) except that 6-bromophthalazine was used instead of 1-(4-bromo-3-fluoro-phenyl)-2-methyl-propan-2-ol.

[0523] Example 155 Synthesis of 5'-((1R,2R,4S)-rel-2-amino-7-azabicyclo[2.2.1]heptane-7-carbonyl)-2",3-difluoro-4"-(2-methoxyethyl)-[1,1':2',1"-terphenyl]-4-carbonitrile-isomer-B (Step 1) 550 mg of tert-butyl (1S,3R,4R)-rel-3-amino-7-azabicyclo[2.2.1]heptane-7-carboxylate was dissolved in 13.0 mL of THF. 0.720 mL of TEA and 829 mg of 2,4-dinitrobenzenesulfonyl chloride were added at 0°C, and the mixture was stirred at room temperature for 1 hour. Ethyl acetate was added, and the mixture was washed successively with water and saturated brine, dried over anhydrous sodium sulfate, and then the solvent was evaporated. The residue was purified by silica gel column chromatography (mobile phase: hexane / ethyl acetate) to obtain tert-butyl (1S,3R,4R)-rel-3-[(2,4-dinitrophenyl)sulfonylamino]-7-azabicyclo[2.2.1]heptane-7-carboxylate.

[0524] (Step 2) 440 mg of the tert-butyl (1S,3R,4R)-rel-3-[(2,4-dinitrophenyl)sulfonylamino]-7-azabicyclo[2.2.1]heptane-7-carboxylate obtained in Step 1 above was subjected to chiral separation using SFC (apparatus: Thar SFC prep 80 system, column: CHIRALPAK IE 20 x 250 mm, flow rate: 50 g / min, mobile phase: CO2 / MeOH=90 / 10) to obtain (1S,3R,4R)-rel-3-[(2,4-dinitrophenyl)sulfonylamino]-7-azabicyclo[2.2.1]heptane-7-carboxylate-isomer-A (faster isomer), and (1S,3R,4R)-rel-3-[(2,4-dinitrophenyl)sulfonylamino]-7-azabicyclo[2.2.1]heptane-7-carboxylate-isomer-B (slower isomer), respectively.

[0525] Furthermore, each isomer was analyzed under the following HPLC conditions. Column: CHIRALPAK IE 4.6 x 150 mm Mobile phase: hexane (0.1% triethylamine) / ethanol = 85 / 15 Flow rate: 1.0 mL / min Retention time of each isomer: (1S,3R,4R)-rel-3-[(2,4-dinitrophenyl)sulfonylamino]-7-azabicyclo[2.2.1]heptane-7-carboxylate-isomer-A: 10.903 min (faster isomer) (1S,3R,4R)-rel-3-[(2,4-dinitrophenyl)sulfonylamino]-7-azabicyclo[2.2.1]heptane-7-carboxylate-isomer-B: 14.028 min (slower isomer) (Step 3) 200 mg of (1S,3R,4R)-rel-3-[(2,4-dinitrophenyl)sulfonylamino]-7-azabicyclo[2.2.1]heptane-7-carboxylate isomer-B obtained in Step 2 above was dissolved in 1.00 mL of ethyl acetate, and 2.00 mL of a 4 N hydrochloric acid-ethyl acetate solution was added at room temperature, followed by stirring at room temperature for 2 hours. The reaction solution was concentrated under reduced pressure to give N-((1R,2R,4S)-rel-7-azabicyclo[2.2.1]heptane-2-yl)-2,4-dinitrobenzenesulfonamide isomer-B hydrochloride.

[0526] (Step 4) 8 mg of 3-(4-cyano-3-fluoro-phenyl)-4-[2-fluoro-4-(2-methoxyethyl)phenyl]benzoic acid obtained in Step 2 of Example 22 and 8.47 mg of N-((1R,2R,4S)-rel-7-azabicyclo[2.2.1]heptan-2-yl)-2,4-dinitrobenzenesulfonamide-isomer-B hydrochloride obtained in Step 3 above were dissolved in 0.30 mL of THF. 8.49 μL of TEA and 15.5 mg of HATU were added at room temperature, and the mixture was stirred at 50° C. for 1 hour. The solvent was evaporated under reduced pressure from the reaction solution. The residue was purified by silica gel column chromatography (mobile phase: hexane / ethyl acetate) to give N-[(1S,3R,4R)-rel-7-[3-(4-cyano-3-fluoro-phenyl)-4-[2-fluoro-4-(2-methoxyethyl)phenyl]benzoyl]-7-azabicyclo[2.2.1]heptan-3-yl]-2,4-dinitrobenzenesulfonamide-isomer-B.

[0527] (Step 5) 14.5 mg of N-[(1S,3R,4R)-rel-7-[3-(4-cyano-3-fluoro-phenyl)-4-[2-fluoro-4-(2-methoxyethyl)phenyl]benzoyl]-7-azabicyclo[2.2.1]heptan-3-yl]-2,4-dinitrobenzenesulfonamide-isomer-B obtained in Step 4 above was dissolved in 1 mL of DCM. 2.83 μL of mercaptoacetic acid and 7.49 μL of TEA were added at 0°C, and the mixture was stirred at room temperature for 2 hours. Chloroform was added, the mixture was washed with 4 N aqueous sodium hydroxide, dried over anhydrous sodium sulfate, and the solvent was evaporated. The residue was purified by reverse phase HPLC (mobile phase: water / acetonitrile) to obtain the title compound.

[0528] Example 156 Synthesis of 5'-((1R,2R,4S)-rel-2-amino-7-azabicyclo[2.2.1]heptane-7-carbonyl)-2",3-difluoro-4"-(2-methoxyethyl)-[1,1':2',1"-terphenyl]-4-carbonitrile-isomer-A (Step 1) 200 mg of (1S,3R,4R)-rel-3-[(2,4-dinitrophenyl)sulfonylamino]-7-azabicyclo[2.2.1]heptane-7-carboxylate-isomer-A obtained in Step 2 of Example 155 was dissolved in 1.00 mL of ethyl acetate, and 2.00 mL of a 4 N hydrochloric acid-ethyl acetate solution was added at room temperature, followed by stirring at room temperature for 2 hours. The reaction solution was concentrated under reduced pressure to obtain N-((1R,2R,4S)-rel-7-azabicyclo[2.2.1]heptan-2-yl)-2,4-dinitrobenzenesulfonamide-isomer-A hydrochloride.

[0529] (Step 2) 8 mg of 3-(4-cyano-3-fluoro-phenyl)-4-[2-fluoro-4-(2-methoxyethyl)phenyl]benzoic acid obtained in Step 2 of Example 22 and 8.47 mg of N-((1r,2r,4s)-rel-7-azabicyclo[2.2.1]heptan-2-yl)-2,4-dinitrobenzenesulfonamide-isomer-A hydrochloride obtained in Step 1 above were dissolved in 0.30 mL of THF. 8.49 μL of TEA and 15.5 mg of HATU were added at room temperature, and the mixture was stirred at 50° C. for 1 hour. The solvent was evaporated under reduced pressure from the reaction solution. The residue was purified by silica gel column chromatography (mobile phase: hexane / ethyl acetate) to give N-[(1S,3R,4R)-rel-7-[3-(4-cyano-3-fluoro-phenyl)-4-[2-fluoro-4-(2-methoxyethyl)phenyl]benzoyl]-7-azabicyclo[2.2.1]heptan-3-yl]-2,4-dinitrobenzenesulfonamide-isomer-A.

[0530] (Step 3) 14.5 mg of N-[(1S,3R,4R)-rel-7-[3-(4-cyano-3-fluoro-phenyl)-4-[2-fluoro-4-(2-methoxyethyl)phenyl]benzoyl]-7-azabicyclo[2.2.1]heptan-3-yl]-2,4-dinitrobenzenesulfonamide-isomer-A obtained in Step 2 above was dissolved in 1 mL of DCM. 2.83 μL of mercaptoacetic acid and 7.49 μL of TEA were added at 0°C, and the mixture was stirred at room temperature for 2 hours. Chloroform was added, the mixture was washed with 4 N aqueous sodium hydroxide, dried over anhydrous sodium sulfate, and the solvent was evaporated. The residue was purified by reverse phase HPLC (mobile phase: water / acetonitrile) to obtain the title compound.

[0531] Example 157 Synthesis of 5'-((3-endo)-3-amino-8-azabicyclo[3.2.1]octane-8-carbonyl)-3-fluoro-2'-(3-methylimidazo[1,5-a]pyridin-7-yl)-[1,1'-biphenyl]-4-carbonitrile The title compound was obtained according to the procedure described in Example 41 (steps 1 to 5) except that 7-bromo-3-methyl-imidazo[1,5-a]pyridine was used instead of 1-(4-bromo-3-fluoro-phenyl)-2-methyl-propan-2-ol.

[0532] Example 158 Synthesis of 5'-((3-endo)-3-amino-8-azabicyclo[3.2.1]octane-8-carbonyl)-3-fluoro-2'-(3-methylpyrazolo[1,5-a]pyrimidin-6-yl)-[1,1'-biphenyl]-4-carbonitrile The title compound was obtained according to the procedure described in Example 41 (steps 1 to 5) except that 6-bromo-3-methyl-pyrazolo[1,5-a]pyrimidine was used instead of 1-(4-bromo-3-fluoro-phenyl)-2-methyl-propan-2-ol.

[0533] Example 159 Synthesis of 5'-((3-endo)-3-amino-8-azabicyclo[3.2.1]octane-8-carbonyl)-3-fluoro-2'-(6-fluoro-2-(2-hydroxy-2-methylpropyl)-2H-indazol-5-yl)-[1,1'-biphenyl]-4-carbonitrile (Step 1) 94 mg of 5-bromo-6-fluoro-1H-indazole was dissolved in 1.5 mL of DMF. 285 mg of cesium carbonate and 0.078 mL of 2,2-dimethyloxirane were added at room temperature, and the mixture was stirred at 90°C for 16 hours. Saturated NH 4 The mixture was quenched with aqueous Cl solution, ethyl acetate was added, and the mixture was washed successively with water and saturated brine. The organic layer was dried over anhydrous sodium sulfate, and the solvent was evaporated. The residue was purified by silica gel column chromatography (mobile phase: hexane / ethyl acetate) to give 1-(5-bromo-6-fluoro-indazol-2-yl)-2-methyl-propan-2-ol.

[0534] (Step 2) In accordance with Example 41 (Steps 1 to 5), the title compound was obtained using 1-(5-bromo-6-fluoro-indazol-2-yl)-2-methyl-propan-2-ol obtained in Step 1 above instead of 1-(4-bromo-3-fluoro-phenyl)-2-methyl-propan-2-ol.

[0535] Example 160 Synthesis of 5'-((3-endo)-3-amino-8-azabicyclo[3.2.1]octane-8-carbonyl)-2'-(1-ethyl-6-fluoro-1H-benzo[d][1,2,3]triazol-5-yl)-3-fluoro-[1,1'-biphenyl]-4-carbonitrile The title compound was obtained according to the procedure described in Example 41 (steps 1 to 5) except that 5-bromo-1-ethyl-6-fluoro-benzotriazole was used instead of 1-(4-bromo-3-fluoro-phenyl)-2-methyl-propan-2-ol.

[0536] Example 161 Synthesis of 5'-((3-endo)-3-amino-8-azabicyclo[3.2.1]octane-8-carbonyl)-2'-(6,7-difluoro-1-(2-hydroxy-2-methylpropyl)-1H-benzo[d][1,2,3]triazol-5-yl)-3-fluoro-[1,1'-biphenyl]-4-carbonitrile (Step 1) 6.20 g of 1-(2,3-difluoro-6-nitro-anilino)-2-methyl-propan-2-ol was dissolved in 84.0 mL of DMF. 5.80 g of NBS was added at room temperature, and the mixture was stirred at 90°C for 1 hour. Ethyl acetate was added, and the mixture was washed successively with water and saturated brine, dried over anhydrous sodium sulfate, and then the solvent was evaporated. The residue was purified by silica gel column chromatography (mobile phase: hexane / ethyl acetate) to obtain 1-(4-bromo-2,3-difluoro-6-nitro-anilino)-2-methyl-propan-2-ol.

[0537] (Step 2) 5.67 g of 1-(4-bromo-2,3-difluoro-6-nitro-anilino)-2-methyl-propan-2-ol obtained in Step 1 above was dissolved in 87.2 mL of ethanol. 5.67 g of ammonium chloride, 5.67 g of iron, and 87.2 mL of water were added at room temperature, and the mixture was stirred at 60°C overnight. The reaction solution was filtered through Celite and washed with ethyl acetate. The filtrate was concentrated under reduced pressure, and ethyl acetate was added. The mixture was washed sequentially with water and saturated brine, dried over anhydrous sodium sulfate, and the solvent was distilled off. The residue was purified by silica gel column chromatography (mobile phase: hexane / ethyl acetate) to obtain 1-(6-amino-4-bromo-2,3-difluoro-anilino)-2-methyl-propan-2-ol.

[0538] (Step 3) 4.36 g of 1-(6-amino-4-bromo-2,3-difluoro-anilino)-2-methyl-propan-2-ol obtained in Step 2 above was dissolved in 28.4 mL of water and 28.4 mL of THF. 28.4 mL of 12N hydrochloric acid and 1.80 g of sodium nitrite were added at 0°C, and the mixture was stirred at room temperature for 1 hour. Ethyl acetate was added, and the mixture was washed successively with water and saturated brine, dried over anhydrous sodium sulfate, and the solvent was distilled off. The residue was purified by silica gel column chromatography (mobile phase: hexane / ethyl acetate) to obtain 1-(5-bromo-6,7-difluoro-benzotriazol-1-yl)-2-methyl-propan-2-ol.

[0539] (Step 4) 50 mg of tert-butyl N-[(3-endo)-8-[3-(4-cyano-3-fluoro-phenyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoyl]-8-azabicyclo[3.2.1]octan-3-yl]carbamate obtained in Step 3 of Example 41 and 39.9 mg of 1-(5-bromo-6,7-difluoro-benzotriazol-1-yl)-2-methyl-propan-2-ol obtained in Step 3 above were dissolved in 0.50 mL of 1,4-dioxane. Pd(dba) 2 2.50 mg of the compound, 4.14 mg of X-Phos, and 55.3 mg of tripotassium phosphate were added, and the mixture was stirred at 125°C in a microwave reactor for 1 hour. The reaction solution was filtered, and the solvent was distilled off. The residue was purified by silica gel column chromatography (mobile phase: chloroform / methanol) to give tert-butyl N-[(3-endo)-8-[3-(4-cyano-3-fluoro-phenyl)-4-[6,7-difluoro-1-(2-hydroxy-2-methyl-propyl)benzotriazol-5-yl]benzoyl]-8-azabicyclo[3.2.1]octan-3-yl]carbamate.

[0540] (Step 5) 55.0 mg of tert-butyl N-[(3-endo)-8-[3-(4-cyano-3-fluoro-phenyl)-4-[6,7-difluoro-1-(2-hydroxy-2-methyl-propyl)benzotriazol-5-yl]benzoyl]-8-azabicyclo[3.2.1]octan-3-yl]carbamate obtained in Step 4 above was dissolved in 1.0 mL of MeOH. 1.0 mL of 12 N hydrochloric acid was added at room temperature, and the mixture was stirred at room temperature for 1 hour. 6.00 mL of 2 N aqueous sodium hydroxide solution and chloroform were added, and the mixture was washed sequentially with water and saturated brine, dried over anhydrous sodium sulfate, and the solvent was then evaporated. The residue was purified by reverse-phase HPLC (mobile phase: water / acetonitrile) to obtain the title compound.

[0541] Example 162 Synthesis of (S)-5'-(3-aminopyrrolidine-1-carbonyl)-2'-(6,7-difluoro-1-(2-hydroxy-2-methylpropyl)-1H-benzo[d][1,2,3]triazol-5-yl)-3-fluoro-[1,1'-biphenyl]-4-carbonitrile (Step 1) 100 mg of tert-butyl N-[(3S)-1-[3-(4-cyano-3-fluoro-phenyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoyl]pyrrolidin-3-yl]carbamate obtained in Step 1 of Example 37 and 85.8 mg of 1-(5-bromo-6,7-difluoro-benzotriazol-1-yl)-2-methyl-propan-2-ol obtained in Step 3 of Example 161 were dissolved in 1,4-dioxane. Dissolved in 0.934 mL of Pd(dba) at room temperature. 2 5.37 mg of the compound, 8.90 mg of X-Phos, and 119 mg of tripotassium phosphate were added, and the mixture was stirred at 125°C in a microwave reactor for 1 hour. The reaction solution was filtered, and the solvent was distilled off. The residue was purified by silica gel column chromatography (mobile phase: chloroform / methanol) to give tert-butyl N-[(3S)-1-[3-(4-cyano-3-fluoro-phenyl)-4-[6,7-difluoro-1-(2-hydroxy-2-methyl-propyl)benzotriazol-5-yl]benzoyl]pyrrolidin-3-yl]carbamate.

[0542] (Step 2) 99.8 mg of tert-butyl N-[(3S)-1-[3-(4-cyano-3-fluoro-phenyl)-4-[6,7-difluoro-1-(2-hydroxy-2-methyl-propyl)benzotriazol-5-yl]benzoyl]pyrrolidin-3-yl]carbamate obtained in Step 1 above was dissolved in 1.0 mL of MeOH. 1.0 mL of 12 N hydrochloric acid was added at room temperature, and the mixture was stirred at room temperature for 1 hour. 6.00 mL of 2 N aqueous sodium hydroxide solution and chloroform were added, and the mixture was washed sequentially with water and saturated brine, dried over anhydrous sodium sulfate, and the solvent was then evaporated. The residue was purified by reverse phase HPLC (mobile phase: water / acetonitrile) to obtain the title compound.

[0543] Example 163 Synthesis of 2",3-difluoro-4"-(2-methoxyethyl)-5'-(piperazine-1-carbonyl)-[1,1':2',1''-terphenyl]-4-carbonitrile The title compound was obtained according to the procedure of Example 22 (steps 1 to 4) except that tert-butyl piperazine-1-carboxylate was used instead of tert-butyl N-[(3-endo)-8-azabicyclo[3.2.1]octan-3-yl]carbamate.

[0544] Example 164 Synthesis of (R)-5'-(3-aminopiperidine-1-carbonyl)-2",3-difluoro-4"-(2-methoxyethyl)-[1,1':2',1''-terphenyl]-4-carbonitrile The title compound was obtained according to the procedure of Example 22 (steps 1 to 4), except that tert-butyl N-[(3R)-3-piperidyl]carbamate was used in place of tert-butyl N-[(3-endo)-8-azabicyclo[3.2.1]octan-3-yl]carbamate.

[0545] Example 165 Synthesis of 5'-(4-aminoazepane-1-carbonyl)-2",3-difluoro-4"-(2-methoxyethyl)-[1,1':2',1''-terphenyl]-4-carbonitrile The title compound was obtained according to the procedure of Example 22 (steps 1 to 4), except that tert-butyl N-(azepan-4-yl)carbamate was used instead of tert-butyl N-[(3-endo)-8-azabicyclo[3.2.1]octan-3-yl]carbamate.

[0546] Example 166 Synthesis of 5'-((1S,2S,4R)-rel-2-amino-7-azabicyclo[2.2.1]heptane-7-carbonyl)-2",3-difluoro-4"-(2-hydroxy-2-methylpropyl)-[1,1':2',1"-terphenyl]-4-carbonitrile-isomer-B (Step 1) 500 mg of tert-butyl 3-(4-cyano-3-fluoro-phenyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate obtained in Step 1 of Example 41 and 379 mg of 1-(4-bromo-3-fluoro-phenyl)-2-methyl-propan-2-ol obtained in Step 1 of Example 28 were dissolved in 5.9 mL of 1,4-dioxane at room temperature. 2 68 mg of the compound, 113 mg of X-Phos, and 752 mg of tripotassium phosphate were added, and the mixture was stirred overnight at 100° C. The solvent was evaporated, and the residue was purified by silica gel column chromatography (mobile phase: hexane / ethyl acetate) to obtain tert-butyl 3-(4-cyano-3-fluoro-phenyl)-4-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]benzoate.

[0547] (Step 2) 300 mg of tert-butyl 3-(4-cyano-3-fluoro-phenyl)-4-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]benzoate obtained in Step 1 above was dissolved in 0.9 mL of THF. 0.9 mL of 12 N hydrochloric acid was added at 0°C, and the mixture was stirred at room temperature for 2 hours. MTBE was added, the mixture was washed with water, dried over anhydrous sodium sulfate, and the solvent was evaporated to give 3-(4-cyano-3-fluoro-phenyl)-4-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]benzoic acid.

[0548] (Step 3) 10 mg of 3-(4-cyano-3-fluoro-phenyl)-4-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]benzoic acid obtained in Step 2 above and 10.2 mg of N-((1R,2R,4S)-rel-7-azabicyclo[2.2.1]heptan-2-yl)-2,4-dinitrobenzenesulfonamide-isomer-B hydrochloride obtained in Step 3 of Example 155 were dissolved in 0.12 mL of THF. 0.014 mL of TEA and 18.7 mg of HATU were added at room temperature, and the mixture was stirred at 50° C. for 1 hour. The reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (mobile phase: hexane / ethyl acetate) to give N-[(1S,3R,4R)-rel-7-[3-(4-cyano-3-fluoro-phenyl)-4-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]benzoyl]-7-azabicyclo[2.2.1]heptan-3-yl]-2,4-dinitrobenzenesulfonamide-isomer-B.

[0549] (Step 4) 15 mg of N-[(1S,3R,4R)-rel-7-[3-(4-cyano-3-fluoro-phenyl)-4-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]benzoyl]-7-azabicyclo[2.2.1]heptan-3-yl]-2,4-dinitrobenzenesulfonamide-isomer-B obtained in Step 3 above was dissolved in 0.2 mL of DCM. 2 μL of mercaptoacetic acid and 8.6 μL of TEA were added at 0°C, and the mixture was stirred at room temperature for 2 hours. Ethyl acetate was added, and the mixture was washed sequentially with water and saturated brine. The organic layer was dried over anhydrous sodium sulfate, and the solvent was then evaporated. The residue was purified by reverse-phase HPLC (mobile phase: water / acetonitrile) to obtain the title compound.

[0550] Example 167 Synthesis of (S)-5'-(3-aminopyrrolidine-1-carbonyl)-2'-(6,7-difluoro-1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-fluoro-[1,1'-biphenyl]-4-carbonitrile (Step 1) 60 mg of tert-butyl N-[(3S)-1-[3-(4-cyano-3-fluoro-phenyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoyl]pyrrolidin-3-yl]carbamate obtained in Step 1 of Example 37 and 41.7 mg of 5-bromo-6,7-difluoro-1-methyl-benzotriazole were dissolved in 0.56 mL of 1,4-dioxane. Pd(dba) 2 3.22 mg of the compound, 5.34 mg of X-Phos, and 71.4 mg of tripotassium phosphate were added, and the mixture was stirred at 125°C for 1 hour in a microwave reaction apparatus. The reaction solution was filtered, and the solvent was distilled off. The residue was purified by silica gel column chromatography (mobile phase: chloroform / methanol) to give tert-butyl N-[(3S)-1-[3-(4-cyano-3-fluoro-phenyl)-4-(6,7-difluoro-1-methyl-benzotriazol-5-yl)benzoyl]pyrrolidin-3-yl]carbamate.

[0551] (Step 2) 20 mg of tert-butyl N-[(3S)-1-[3-(4-cyano-3-fluoro-phenyl)-4-(6,7-difluoro-1-methyl-benzotriazol-5-yl)benzoyl]pyrrolidin-3-yl]carbamate obtained in Step 1 above was dissolved in 0.40 mL of TFA and stirred at room temperature for 5 minutes. After confirming the completion of the reaction by LCMS, 1.60 mL of DMSO was added, and the mixture was purified by reverse phase HPLC (mobile phase: water / acetonitrile) to obtain the title compound.

[0552] Example 168 Synthesis of 5'-((3-endo)-3-amino-8-azabicyclo[3.2.1]octane-8-carbonyl)-3-fluoro-2'-(6-fluoro-1-propyl-1H-benzo[d][1,2,3]triazol-5-yl)-[1,1'-biphenyl]-4-carbonitrile The title compound was obtained according to the procedure described in Example 41 (steps 1 to 5) except that 5-bromo-6-fluoro-1-propyl-benzotriazole was used instead of 1-(4-bromo-3-fluoro-phenyl)-2-methyl-propan-2-ol.

[0553] Example 169 Synthesis of (S)-5'-(3-aminopyrrolidine-1-carbonyl)-2'-(6,7-difluoro-1-(2-methoxyethyl)-1H-benzo[d][1,2,3]triazol-5-yl)-3-fluoro-[1,1'-biphenyl]-4-carbonitrile (Step 1) 5-Bromo-6,7-difluoro-1-(2-methoxyethyl)benzotriazole was obtained by using 2,3-difluoro-N-(2-methoxyethyl)-6-nitro-aniline instead of 1-(2,3-difluoro-6-nitro-anilino)-2-methyl-propan-2-ol in accordance with Example 161 (Steps 1 to 3).

[0554] (Step 2) In accordance with Example 37 (Steps 1 to 3), the title compound was obtained using 5-bromo-6,7-difluoro-1-(2-methoxyethyl)benzotriazole obtained in Step 1 above instead of 1-(4-bromo-3-fluoro-phenyl)-2-methyl-propan-2-ol.

[0555] Example 170 Synthesis of (S)-5'-(3-aminopyrrolidine-1-carbonyl)-3-fluoro-2'-(6-fluoro-1-(2-hydroxyethyl)-1H-indol-5-yl)-[1,1'-biphenyl]-4-carbonitrile The title compound was obtained according to Example 37 (steps 1 to 3) except that 2-(5-bromo-6-fluoro-indol-1-yl)ethanol was used instead of 1-(4-bromo-3-fluoro-phenyl)-2-methyl-propan-2-ol.

[0556] Example 171 Synthesis of 5'-((1R,2R,4S)-rel-2-amino-7-azabicyclo[2.2.1]heptane-7-carbonyl)-3-fluoro-2'-(6-fluoro-1-(2-hydroxy-2-methylpropyl)-1H-indol-5-yl)-[1,1'-biphenyl]-4-carbonitrile-isomer-B (Step 1) 2.3 g of tert-butyl 3-(4-cyano-3-fluoro-phenyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate obtained in Step 1 of Example 41 and 2.02 g of 1-(5-bromo-6-fluoro-indol-1-yl)-2-methyl-propan-2-ol obtained in Step 1 of Example 136 were dissolved in 1,4-dioxane. Dissolved in 18.1 mL of Pd(dba) at room temperature. 2 250 mg of the above, 414 mg of X-Phos, and 3.46 g of tripotassium phosphate were added and stirred overnight at 100°C. The solvent was distilled off, and the residue was purified by silica gel column chromatography (mobile phase: hexane / ethyl acetate), and the solvent was distilled off. The residue was dissolved in 40.0 mL of THF. 30.0 mL of 12 N hydrochloric acid was added at 0°C, and the mixture was stirred at room temperature for 2 hours. MTBE was added, the mixture was washed with water, dried over anhydrous sodium sulfate, and the solvent was distilled off to obtain 3-(4-cyano-3-fluoro-phenyl)-4-[6-fluoro-1-(2-hydroxy-2-methyl-propyl)indol-5-yl]benzoic acid.

[0557] (Step 2) 8 mg of 3-(4-cyano-3-fluoro-phenyl)-4-[6-fluoro-1-(2-hydroxy-2-methyl-propyl)indol-5-yl]benzoic acid obtained in Step 1 above and 7.47 mg of N-((1R,2R,4S)-rel-7-azabicyclo[2.2.1]heptan-2-yl)-2,4-dinitrobenzenesulfonamide-isomer-B hydrochloride obtained in Step 3 of Example 155 were dissolved in 0.30 mL of THF. 0.00748 mL of TEA and 13.6 mg of HATU were added at room temperature, and the mixture was stirred at 50° C. for 1 hour. The reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (mobile phase: hexane / ethyl acetate) to give N-[(1S,3R,4R)-rel-7-[3-(4-cyano-3-fluoro-phenyl)-4-[6-fluoro-1-(2-hydroxy-2-methyl-propyl)indol-5-yl]benzoyl]-7-azabicyclo[2.2.1]heptan-3-yl]-2,4-dinitrobenzenesulfonamide-isomer-B.

[0558] (Step 3) 13.8 mg of N-[(1S,3R,4R)-rel-7-[3-(4-cyano-3-fluoro-phenyl)-4-[6-fluoro-1-(2-hydroxy-2-methyl-propyl)indol-5-yl]benzoyl]-7-azabicyclo[2.2.1]heptan-3-yl]-2,4-dinitrobenzenesulfonamide-isomer-B obtained in Step 2 above was dissolved in 1.0 mL of DCM. 2.49 μL of mercaptoacetic acid and 7.48 μL of TEA were added at 0°C, and the mixture was stirred at room temperature for 1 hour. Chloroform and 4 N sodium hydroxide were added, and the mixture was washed sequentially with water and saturated brine. The organic layer was dried over anhydrous sodium sulfate, and the solvent was then evaporated. The residue was purified by reverse-phase HPLC (mobile phase: water / acetonitrile) to obtain the title compound.

[0559] Example 172 Synthesis of (S)-5'-(3-aminopyrrolidine-1-carbonyl)-2'-(6,7-difluoro-1-(2-hydroxy-2-methylpropyl)-1H-indol-5-yl)-3-fluoro-[1,1'-biphenyl]-4-carbonitrile (Step 1) 300 mg of 5-bromo-6,7-difluoro-1H-indole was dissolved in 4.31 mL of DMF. 2 CO 3 843 mg of the above and 0.230 mL of 2,2-dimethyloxirane were added, and the mixture was stirred at 80°C for 3 hours. The reaction solution was filtered, and the solvent was distilled off. Ethyl acetate was added, and the mixture was washed successively with a saturated aqueous ammonium chloride solution, water, and saturated brine, dried over anhydrous sodium sulfate, and the solvent was distilled off. The residue was purified by silica gel column chromatography (mobile phase: hexane / ethyl acetate) to obtain 1-(5-bromo-6,7-difluoro-indol-1-yl)-2-methyl-propan-2-ol.

[0560] (Step 2) 210 mg of tert-butyl 3-(4-cyano-3-fluoro-phenyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate obtained in Step 1 of Example 41 and 196 mg of 1-(5-bromo-6,7-difluoro-indol-1-yl)-2-methyl-propan-2-ol obtained in Step 1 above were dissolved in 1.65 mL of 1,4-dioxane. 2 22.8 mg of the compound, 37.8 mg of X-Phos, and 316 mg of tripotassium phosphate were added and stirred overnight at 100°C. The solvent was evaporated, and the residue was purified by silica gel column chromatography (mobile phase: hexane / ethyl acetate), and the solvent was evaporated. The residue was dissolved in 2.63 mL of THF. 2.1 mL of 12 N hydrochloric acid was added at 0°C, and the mixture was stirred at room temperature for 2 hours. MTBE was added, and the mixture was washed with water and dried over anhydrous sodium sulfate, and the solvent was evaporated to give 3-(4-cyano-3-fluoro-phenyl)-4-[6,7-difluoro-1-(2-hydroxy-2-methyl-propyl)indol-5-yl]benzoic acid.

[0561] (Step 3) 30 mg of 3-(4-cyano-3-fluoro-phenyl)-4-[6,7-difluoro-1-(2-hydroxy-2-methyl-propyl)indol-5-yl]benzoic acid obtained in Step 2 above and 13.2 mg of tert-butyl N-[(3S)-pyrrolidin-3-yl]carbamate were dissolved in 0.323 mL of THF. 0.027 mL of TEA and 49.1 mg of HATU were added at room temperature, and the mixture was stirred at 50°C for 1 hour. The solvent was evaporated under reduced pressure from the reaction solution. The residue was purified by silica gel column chromatography (mobile phase: hexane / ethyl acetate) to give tert-butyl N-[(3S)-1-[3-(4-cyano-3-fluoro-phenyl)-4-[6,7-difluoro-1-(2-hydroxy-2-methyl-propyl)indol-5-yl]benzoyl]pyrrolidin-3-yl]carbamate.

[0562] (Step 4) 40 mg of tert-butyl N-[(3S)-1-[3-(4-cyano-3-fluoro-phenyl)-4-[6,7-difluoro-1-(2-hydroxy-2-methyl-propyl)indol-5-yl]benzoyl]pyrrolidin-3-yl]carbamate obtained in Step 3 above was dissolved in 0.80 mL of MeOH. 0.80 mL of 4 N hydrochloric acid-1,4-dioxane solution was added at room temperature, and the mixture was stirred at room temperature for 1 hour. 1.6 mL of chloroform and 2 N aqueous sodium hydroxide solution was added, washed with water, dried over anhydrous sodium sulfate, and the solvent was evaporated. The residue was purified by reverse phase HPLC (mobile phase: water / acetonitrile) to obtain the title compound.

[0563] Example 173 Synthesis of 5'-(7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-3-fluoro-2'-(6-fluoro-1-(2-hydroxy-2-methylpropyl)-1H-indol-5-yl)-[1,1'-biphenyl]-4-carbonitrile 3-(4-cyano-3-fluoro-phenyl)-4-[6-fluoro-1-(2-hydroxy-2-methyl-propyl)indol-5-yl]benzoic acid obtained in Example 171 Step 1 was dissolved in 0.3 mL of THF. 3.80 mg of tert-butyl N-(3-azabicyclo[2.2.1]heptan-7-yl)carbamate, 0.0075 mL of TEA, and 13.6 mg of HATU were added at room temperature and stirred at 50 ° C. for 3 hours. After confirming the completion of the reaction by LCMS, the reaction solution was concentrated. 0.20 mL of TFA was added to the residue, and the mixture was stirred at room temperature for 5 minutes. After confirming the completion of the reaction by LCMS, 0.8 mL of DMSO was added to the reaction solution, and the mixture was purified by reverse-phase HPLC (mobile phase: water / acetonitrile) to obtain the title compound.

[0564] Example 174 Synthesis of 5'-(7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-2",3-difluoro-4"-(2-hydroxy-2-methylpropyl)-[1,1':2',1"-terphenyl]-4-carbonitrile (Step 1) 100 mg of 3-(4-cyano-3-fluoro-phenyl)-4-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]benzoic acid obtained in Step 2 of Example 166 was dissolved in 0.982 mL of THF. 52.1 mg of tert-butyl N-(3-azabicyclo[2.2.1]heptane-7-yl)carbamate, 0.103 mL of TEA, and 187 mg of HATU were added at room temperature, and the mixture was stirred at 50°C for 3 hours. The residue was purified by silica gel column chromatography (mobile phase: hexane / ethyl acetate) to give tert-butyl N-[3-[3-(4-cyano-3-fluoro-phenyl)-4-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]benzoyl]-3-azabicyclo[2.2.1]heptan-7-yl]carbamate.

[0565] (Step 2) 30 mg of tert-butyl N-[3-[3-(4-cyano-3-fluoro-phenyl)-4-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]benzoyl]-3-azabicyclo[2.2.1]heptan-7-yl]carbamate obtained in Step 1 above was dissolved in 0.5 mL of MeOH, and 0.5 mL of 12 N hydrochloric acid was added at room temperature. After stirring at room temperature for 0.5 hours, water and 3.0 mL of 2 N aqueous sodium hydroxide solution were added. Extraction was performed with chloroform, and the solvent was evaporated. The residue was purified by reverse phase HPLC (mobile phase: water / acetonitrile) to obtain the title compound.

[0566] Example 175 Synthesis of 5'-((1S,2S,4R)-rel-2-amino-7-azabicyclo[2.2.1]heptane-7-carbonyl)-2'-(6,7-difluoro-1-methyl-1H-benzo[d][1,2,3]triazol-5-yl)-3-fluoro-[1,1'-biphenyl]-4-carbonitrile-isomer-B (Step 1) 90 mg of tert-butyl 3-(4-cyano-3-fluoro-phenyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate obtained in Step 1 of Example 41 and 68.6 mg of 5-bromo-6,7-difluoro-1-methyl-benzotriazole were dissolved in 0.71 mL of 1,4-dioxane. Pd(dba) 2 9.8 mg of the compound, 16 mg of X-Phos, and 135 mg of tripotassium phosphate were added and stirred overnight at 100°C. The solvent was evaporated, and the residue was purified by silica gel column chromatography (mobile phase: hexane / ethyl acetate), and the solvent was evaporated. The residue was dissolved in 1.0 mL of TFA and stirred at room temperature for 2 hours. MTBE was added, the mixture was washed with water, dried over anhydrous sodium sulfate, and the solvent was evaporated to give 3-(4-cyano-3-fluoro-phenyl)-4-(6,7-difluoro-1-methyl-benzotriazol-5-yl)benzoic acid.

[0567] (Step 2) 30 mg of 3-(4-cyano-3-fluoro-phenyl)-4-(6,7-difluoro-1-methyl-benzotriazol-5-yl)benzoic acid obtained in Step 1 above and 30.6 mg of N-((1R,2R,4S)-rel-7-azabicyclo[2.2.1]heptan-2-yl)-2,4-dinitrobenzenesulfonamide-isomer-B hydrochloride obtained in Step 3 of Example 155 were dissolved in 0.367 mL of THF. 0.042 mL of TEA and 55.9 mg of HATU were added at room temperature, and the mixture was stirred at 50° C. for 1 hour. The reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (mobile phase: hexane / ethyl acetate) to give N-[(1R,3S,4S)-rel-7-[3-(4-cyano-3-fluoro-phenyl)-4-(6,7-difluoro-1-methyl-benzotriazol-5-yl)benzoyl]-7-azabicyclo[2.2.1]heptan-3-yl]-2,4-dinitrobenzenesulfonamide-isomer-B.

[0568] (Step 3) 51 mg of N-[(1R,3S,4S)-rel-7-[3-(4-cyano-3-fluoro-phenyl)-4-(6,7-difluoro-1-methyl-benzotriazol-5-yl)benzoyl]-7-azabicyclo[2.2.1]heptan-3-yl]-2,4-dinitrobenzenesulfonamide-isomer-B obtained in Step 2 above was dissolved in 0.70 mL of DCM. 5.8 μL of mercaptoacetic acid and 29.1 μL of TEA were added at 0 °C, and the mixture was stirred at room temperature for 2 hours. Ethyl acetate was added, and the mixture was washed sequentially with water and saturated brine. The organic layer was dried over anhydrous sodium sulfate, and the solvent was then evaporated. The residue was purified by reverse-phase HPLC (mobile phase: water / acetonitrile) to obtain the title compound.

[0569] Example 176 Synthesis of 5'-((1S,2S,4R)-rel-2-amino-7-azabicyclo[2.2.1]heptane-7-carbonyl)-3-fluoro-2'-(6-fluoro-1-(2-hydroxy-2-methylpropyl)-1H-indazol-5-yl)-[1,1'-biphenyl]-4-carbonitrile-isomer-B (Step 1) 2.3 g of tert-butyl 3-(4-cyano-3-fluoro-phenyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate obtained in Step 1 of Example 41 and 2.03 g of 1-(5-bromo-6-fluoro-1H-indazol-1-yl)-2-methylpropan-2-ol obtained in Step 1 of Example 142 were dissolved in 1,4-dioxane. Dissolved in 18.7 mL of Pd(dba) at room temperature. 2 250 mg of the above, 414 mg of X-Phos, and 3.46 g of tripotassium phosphate were added and stirred overnight at 100°C. The solvent was distilled off, and the residue was purified by silica gel column chromatography (mobile phase: hexane / ethyl acetate), and the solvent was distilled off. The residue was dissolved in 10.0 mL of THF. 10.0 mL of 12 N hydrochloric acid was added at 0°C, and the mixture was stirred at room temperature for 2 hours. MTBE was added, the mixture was washed with water, dried over anhydrous sodium sulfate, and the solvent was distilled off to obtain 3-(4-cyano-3-fluoro-phenyl)-4-[6-fluoro-1-(2-hydroxy-2-methyl-propyl)indazol-5-yl]benzoic acid.

[0570] (Step 2) 30 mg of 3-(4-cyano-3-fluoro-phenyl)-4-[6-fluoro-1-(2-hydroxy-2-methyl-propyl)indazol-5-yl]benzoic acid obtained in Step 1 above and 27.9 mg of N-((1R,2R,4S)-rel-7-azabicyclo[2.2.1]heptan-2-yl)-2,4-dinitrobenzenesulfonamide-isomer-B hydrochloride obtained in Step 3 of Example 155 were dissolved in 0.34 mL of THF. 0.038 mL of TEA and 51.0 mg of HATU were added at room temperature, and the mixture was stirred at 50° C. for 1 hour. The reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (mobile phase: hexane / ethyl acetate) to give N-[(1S,3R,4R)-rel-7-[3-(4-cyano-3-fluoro-phenyl)-4-[6-fluoro-1-(2-hydroxy-2-methyl-propyl)indazol-5-yl]benzoyl]-7-azabicyclo[2.2.1]heptan-3-yl]-2,4-dinitrobenzenesulfonamide-isomer-B.

[0571] (Step 3) 45 mg of N-[(1S,3R,4R)-rel-7-[3-(4-cyano-3-fluoro-phenyl)-4-[6-fluoro-1-(2-hydroxy-2-methyl-propyl)indazol-5-yl]benzoyl]-7-azabicyclo[2.2.1]heptan-3-yl]-2,4-dinitrobenzenesulfonamide-isomer-B obtained in Step 2 above was dissolved in 0.58 mL of DCM. 4.9 μL of mercaptoacetic acid and 24 μL of TEA were added at 0 °C, and the mixture was stirred at room temperature for 2 hours. Ethyl acetate was added, and the mixture was washed sequentially with water and saturated brine. The organic layer was dried over anhydrous sodium sulfate, and the solvent was then evaporated. The residue was purified by reverse-phase HPLC (mobile phase: water / acetonitrile) to obtain the title compound.

[0572] Example 177 Synthesis of 5'-((1S,2S,4R)-rel-2-amino-7-azabicyclo[2.2.1]heptane-7-carbonyl)-2'-(6,7-difluoro-1-(2-hydroxy-2-methylpropyl)-1H-benzo[d][1,2,3]triazol-5-yl)-3-fluoro-[1,1'-biphenyl]-4-carbonitrile-isomer-B (Step 1) 3.2 g of tert-butyl 3-(4-cyano-3-fluoro-phenyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoate obtained in Step 1 of Example 41, and 1-(5-bromo-6,7-difluoro-benzotriazol-1-yl)-2-methyl-propan-2-ol obtained in Step 3 of Example 161 3.01 g of Pd(dba) was dissolved in 25.2 mL of 1,4-dioxane at room temperature. 2 348 mg of the above, 577 mg of X-Phos, and 4.81 g of tripotassium phosphate were added and stirred overnight at 100°C. The solvent was evaporated, and the residue was purified by silica gel column chromatography (mobile phase: hexane / ethyl acetate), and the solvent was evaporated. The residue was dissolved in 15.0 mL of THF. 15.0 mL of 12 N hydrochloric acid was added at 0°C, and the mixture was stirred at room temperature for 2 hours. MTBE was added, the mixture was washed with water, dried over anhydrous sodium sulfate, and the solvent was evaporated to give 3-(4-cyano-3-fluoro-phenyl)-4-[6,7-difluoro-1-(2-hydroxy-2-methyl-propyl)benzotriazol-5-yl]benzoic acid.

[0573] (Step 2) 30 mg of 3-(4-cyano-3-fluoro-phenyl)-4-[6,7-difluoro-1-(2-hydroxy-2-methyl-propyl)benzotriazol-5-yl]benzoic acid obtained in Step 1 above and 26.8 mg of N-((1S,2S,4R)-rel-7-azabicyclo[2.2.1]heptan-2-yl)-2,4-dinitrobenzenesulfonamide-isomer-B hydrochloride obtained in Step 3 of Example 155 were dissolved in 0.33 mL of THF. 0.037 mL of TEA and 48.9 mg of HATU were added at room temperature, and the mixture was stirred at 50° C. for 1 hour. The reaction solution was concentrated under reduced pressure, and the residue was purified by silica gel column chromatography (mobile phase: hexane / ethyl acetate) to give N-[(1S,2S,4R)-rel-7-[3-(4-cyano-3-fluoro-phenyl)-4-[6,7-difluoro-1-(2-hydroxy-2-methyl-propyl)benzotriazol-5-yl]benzoyl]-7-azabicyclo[2.2.1]heptan-3-yl]-2,4-dinitrobenzenesulfonamide-isomer-B.

[0574] (Step 3) 43 mg of N-[(1S,2S,4R)-rel-7-[3-(4-cyano-3-fluoro-phenyl)-4-[6,7-difluoro-1-(2-hydroxy-2-methyl-propyl)benzotriazol-5-yl]benzoyl]-7-azabicyclo[2.2.1]heptan-3-yl]-2,4-dinitrobenzenesulfonamide-isomer-B obtained in Step 2 above was dissolved in 0.54 mL of DCM. 4.5 μL of mercaptoacetic acid and 22.7 μL of TEA were added at 0 °C, and the mixture was stirred at room temperature for 2 hours. Ethyl acetate was added, and the mixture was washed sequentially with water and saturated brine. The organic layer was dried over anhydrous sodium sulfate, and the solvent was then evaporated. The residue was purified by reverse-phase HPLC (mobile phase: water / acetonitrile) to obtain the title compound.

[0575] Example 178 Synthesis of 5'-((3-endo)-3-amino-8-azabicyclo[3.2.1]octane-8-carbonyl)-2'-(3-bromo-6-fluo...

Claims

1. The following general formula (I) [In the formula, ring A represents a nitrogen-containing saturated heterocyclic group having 1 to 3 nitrogen atoms, 0 to 1 sulfur atom and 0 to 2 oxygen atoms as heteroatoms, and being a 4- to 14-membered monocyclic, bridged cyclic or spirocyclic group; ring B represents an unsaturated hydrocarbon group having 5 to 14 members which is monocyclic or bicyclic, or may be substituted with an oxo group, and having 0 to 4 nitrogen atoms, 0 to 2 sulfur atoms and 0 to 3 oxygen atoms as heteroatoms, and having at least 1 of nitrogen atom, sulfur atom and oxygen atom, and representing an unsaturated heterocyclic group having 5 to 14 members which is monocyclic or bicyclic; R1 represents a nitro group or a cyano group; R2 represents a halogen atom; R3 represents an amino group, a mono- or di(C1-C6 alkyl)amino group, a (C3-C7 cycloalkyl)amino group, or a C1-C6 alkyl group; R4 represents a halogen atom, a nitro group, a cyano group, a carboxy group, a C1-C8 alkyl group which may have a substituent, a C2-C6 alkenyl group which may have a substituent, a C1-C6 alkoxy group which may have a substituent, a C3-C7 cycloalkyl group which may have a substituent, a mono- or di(C1-C6 alkyl)amino group, or a carbamoyl group which may have a substituent. When at least 1 of R4 is a C1-C8 alkyl group having a substituent, a C2-C6 alkenyl group having a substituent, a C1-C6 alkoxy group having a substituent, a C3-C7 cycloalkyl group having a substituent, or a carbamoyl group having a substituent, the substituent represents a halogen atom, a carboxy group, a C1-C6 alkoxy group, a hydroxyl group, a C1-C6 alkyl group which may have a hydroxyl group as a substituent, an unsaturated hydrocarbon group which is monocyclic and has 5 to 10 members, a carbamoyl group which may have a C1-C6 alkyl group or an unsaturated hydrocarbon group which is monocyclic and has 5 to 10 members as a substituent, a (C2-C7 acyl)oxy group, an amino group which may have a C1-C6 alkyl group or a C2-C7 acyl group as a substituent, a C3-C7 cycloalkyl group which may have a hydroxyl group as a substituent, or a (C1-C6 alkoxy)(C1-C6 alkyl) group. When a plurality of such substituents exist, they may be the same or different.R5 and R6 are the same or different and each represents a hydrogen atom or a C1-C6 alkyl group, or R5 and R6 may combine together to form an oxo group or a thioxo group. When R5 and R6 are the same or different and each represents a hydrogen atom or a C1-C6 alkyl group, at least one of R5 and R6 is a hydrogen atom. l represents an integer of 0 to 2, m represents an integer of 0 to 2, and n represents an integer of 0 to 5. When l is 2, the two R2s may be the same or different. When m is 2, the two R3s may be the same or different. When n is from 2 to 5, the 2 to 5 R4s may be the same or different. ] A biphenyl compound represented by or a salt thereof, and an antitumor agent characterized by being used in combination with another antitumor agent.

2. The antitumor agent according to claim 1, wherein the biphenyl compound satisfies the following conditions in the general formula (I): Ring A is a pyrrolidinyl group, a piperidinyl group, a piperazinyl group, an azepanyl group, a diazepanyl group, , a 2,7-diazaspiro[3.4]octanyl group, 3,7-diazaspiro[3.4]octanyl group, 2,7-diazaspiro[3.5]nonanyl group, 2,8-diazaspiro[3.5]nonanyl group, 3,7-diazaspiro[3.5]nonanyl group, 3,8-diazaspiro[4.4]nonanyl group, 3,8-diazaspiro[4.5]decanyl group, or 9-oxa-diazaspiro[3.5]nonanyl group, and ring B is a phenyl group, naphthyl group, pyridyl group, pyrazolopyridyl group, pyrazolopyrimidinyl group, indolyl group, indolinyl group, 2-oxo-indolinyl group, indazolyl group, benzimidazolyl group, benzisoxazolyl group, benzothiazolyl group, benzotriazolyl group, imidazopyridinyl group, quinolinyl group, isoquinolinyl group, quinoxalinyl group, quinazolinyl group, phthalazinyl group, 2-oxo-2,3-dihydrobenzo[d]oxazolyl group, 1,3-dihydroisobenzofuranyl group, dihydrobenzoxazinyl group, benzodioxolyl group, dihydrobenzodioxinyl group, or 2-oxo-2,is a 3-dihydrobenzothiazolyl group, R1 is a nitro group or a cyano group, R2 is a fluorine atom, and the R2 is present at the ortho position to R1 on the phenyl group, R3 is an amino group, a methylamino group, an ethylamino group, an isopropylamino group, a dimethylamino group, a cyclobutylamino group, or a methyl group (when a plurality of R3 are present, these R3 may be the same or different), R4 is a fluorine atom, a chlorine atom, a bromine atom, an iodine atom, a nitro group, a cyano group, a carboxy group, a methyl group, an ethyl group, an n-propyl group, an isopropyl group, a tert-butyl group, a difluoromethyl group, a trifluoromethyl group, a fluoroethyl group, an aminoethyl group, a hydroxymethyl group, a hydroxyethyl group, a hydroxypropyl group, a hydroxydimethylethyl group, a hydroxymethylpropyl group, a hydroxymethylbutyl group, a hydroxyethylbutyl group, a carboxymethyl group, a carbamoylmethyl group, a methylcarbamoylmethyl group, a dimethylcarbamoylmethyl group, an acetylaminoethyl group, a methoxyethyl group, a hydroxycyclopropylmethyl group, a hydroxycyclopropylethyl group, a hydroxycyclobutylmethyl group, a methylcarbonyloxyethyl group, an isobutenyl group, a methoxy group, a hydroxypropoxy group, a cyclopropyl group, a hydroxymethylcyclopropyl group, a methoxymethylcyclopropyl group, a hydroxycyclopropylcyclopropyl group, a phenylcarbamoylcyclopropyl group, a benzyloxy group, a dimethylamino group, a carbamoyl group, a methylcarbamoyl group, or a dimethylcarbamoyl group (when a plurality of R4 are present, these R4 may be the same or different), R5 and R6 are the same or different and each represents a hydrogen atom or a C1-C6 alkyl group, or R5 and R6 may together form an oxo group or a thioxo group, when R5 and R6 are the same or different and each represents a hydrogen atom or a C1-C6 alkyl group, at least one of R5 and R6 is a hydrogen atom, n represents an integer of 0 to 3, when n is 2 to 3, two to three R4 may be the same or different., 3. The antitumor agent according to claim 1 or 2, wherein the biphenyl compound is selected from the following (1) to (7).(1) 4-[5-[(3S)-3-aminopyrrolidine-1-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile (2) 4-[5-[(3-endo)-3-amino-8-azabicyclo[3.2.1]octane-8-carbonyl]-2-[2-fluoro-4-(2-hydroxy-2-methyl-propyl)phenyl]phenyl]-2-fluoro-benzonitrile (3) 5'-((1S,2S,4R)-rel-2-amino-7-azabicyclo[2.2.1]heptane-7-carbonyl)-2'',3-difluoro-4''-(2-hydroxy-2-methylpropyl)-[1,1':2',1''-terphenyl]-4-carbonitrile-isomer-B (4) 5'-((1S,2S,4R)-rel-2-amino-7-azabicyclo[2.2.1]heptane-7-carbonyl)-2'-(6,7-difluoro-1-(2-hydroxy-2-methylpropyl)-1H-benzo[d][1,2,3]triazol-5-yl)-3-fluoro-[1,1'-biphenyl]-4-carbonitrile-isomer-B (5) 5'-((1S,2S,4R)-rel-2-amino-7-azabicyclo[2.2.1]heptane-7-carbonyl)-2'-(1-(2-ethyl-2-hydroxybutyl)-6,7-difluoro-1H-benzo[d][1,2,3]triazol-5-yl)-3-fluoro-[1,1'-biphenyl]-4-carbonitrile-isomer-X (6) 5'-((1S,2S,4R)-rel-2-amino-7-azabicyclo[2.2.1]heptane-7-carbonyl)-2'-(7-bromo-6-fluoro-1-(2-hydroxy-2-methylpropyl)-1H-benzo[d][1,2,3]triazol-5-yl)-3-fluoro-[1,1'-biphenyl]-4-carbonitrile-isomer-X (7) 5'-(((1S,2S,4R)-rel-2-amino-7-azabicyclo[2.2.1]heptane-7-yl)methyl)-2'-(6,7-difluoro-1-(2-hydroxy-2-methylpropyl)-1H-benzo[d][1,2,3]triazol-5-yl)-3-fluoro-[1,1'-biphenyl]-4-carbonitrile-isomer-X.

4. The antitumor agent according to any one of claims 1 to 3, wherein the other antitumor agent is at least one selected from antimetabolites, antitumor antibiotics, molecular target drugs, platinum-based drugs, and plant alkaloid drugs.

5. The antitumor agent according to any one of claims 1 to 3, wherein the other antitumor agent is at least one selected from cytarabine, azacitidine, decitabine, guadecitabine, daunorubicin, tretinoin (ATRA), RG7388, carboplatin, cisplatin, paclitaxel, irinotecan (SN-38), and etoposide.

6. The following general formula (I) [In the formula, ring A represents a nitrogen-containing saturated heterocyclic group having 1 to 3 nitrogen atoms, 0 to 1 sulfur atom, and 0 to 2 oxygen atoms as heteroatoms, and being a monocyclic, bridged cyclic or spiro cyclic 4- to 14-membered ring; ring B represents a monocyclic or bicyclic unsaturated hydrocarbon group having 5 to 14 members, or may be substituted with an oxo group, having 0 to 4 nitrogen atoms, 0 to 2 sulfur atoms, and 0 to 3 oxygen atoms as heteroatoms, and having at least 1 of nitrogen atom, sulfur atom, and oxygen atom, and being a monocyclic or bicyclic 5- to 14-membered unsaturated heterocyclic group; R1 represents a nitro group or a cyano group; R2 represents a halogen atom; R3 represents an amino group, a mono- or di-(C1-C6 alkyl)amino group, a (C3-C7 cycloalkyl)amino group, or a C1-C6 alkyl group; R4 represents a halogen atom, a nitro group, a cyano group, a carboxy group, a C1-C8 alkyl group which may have a substituent, a C2-C6 alkenyl group which may have a substituent, a C1-C6 alkoxy group which may have a substituent, a C3-C7 cycloalkyl group which may have a substituent, a mono- or di-(C1-C6 alkyl)amino group, or a carbamoyl group which may have a substituent. When at least one of R4 is a C1-C8 alkyl group having a substituent, a C2-C6 alkenyl group having a substituent, a C1-C6 alkoxy group having a substituent, a C3-C7 cycloalkyl group having a substituent, or a carbamoyl group having a substituent, the substituent represents a halogen atom, a carboxy group, a C1-C6 alkoxy group, a hydroxyl group, a C1-C6 alkyl group which may have a hydroxyl group as a substituent, a monocyclic unsaturated hydrocarbon group having 5 to 10 members, a carbamoyl group which may have a C1-C6 alkyl group or a monocyclic unsaturated hydrocarbon group having 5 to 10 members as a substituent, a (C2-C7 acyl)oxy group, an amino group which may have a C1-C6 alkyl group or a C2-C7 acyl group as a substituent, a C3-C7 cycloalkyl group which may have a hydroxyl group as a substituent, or a (C1-C6 alkoxy)(C1-C6 alkyl) group. When a plurality of the substituents exist, they may be the same or different.R5 and R6 are the same or different and each represents a hydrogen atom or a C1-C6 alkyl group, or R5 and R6 may together form an oxo group or a thioxo group. When R5 and R6 are the same or different and each represents a hydrogen atom or a C1-C6 alkyl group, at least one of R5 and R6 is a hydrogen atom. l represents an integer of 0 to 2, m represents an integer of 0 to 2, and n represents an integer of 0 to 5. When l is 2, the two R2s may be the same or different. When m is 2, the two R3s may be the same or different. When n is 2 to 5, the 2 to 5 R4s may be the same or different.], an antitumor effect enhancer for other antitumor agents, which contains a biphenyl compound represented by the formula or a salt thereof as an active ingredient.

7. An antitumor agent containing a biphenyl compound or a salt thereof for treating cancer patients administered with other antitumor agents, wherein the biphenyl compound has the following general formula (I) [In the formula, ring A represents a nitrogen-containing saturated heterocyclic group having 1 to 3 nitrogen atoms, 0 to 1 sulfur atom and 0 to 2 oxygen atoms as heteroatoms, and being a monocyclic, bridged cyclic or spirocyclic 4- to 14-membered ring; ring B represents an unsaturated hydrocarbon group which is monocyclic or bicyclic and has 5 to 14 members, or may be substituted with an oxo group, and has 0 to 4 nitrogen atoms, 0 to 2 sulfur atoms and 0 to 3 oxygen atoms as heteroatoms, and has at least 1 of nitrogen atom, sulfur atom and oxygen atom, and represents an unsaturated heterocyclic group which is monocyclic or bicyclic and has 5 to 14 members; R1 represents a nitro group or a cyano group; R2 represents a halogen atom; R3 represents an amino group, a mono- or di(C1-C6 alkyl)amino group, a (C3-C7 cycloalkyl)amino group, or a C1-C6 alkyl group; R4 represents a halogen atom, a nitro group, a cyano group, a carboxy group, a C1-C8 alkyl group which may have a substituent, a C2-C6 alkenyl group which may have a substituent, a C1-C6 alkoxy group which may have a substituent, a C3-C7 cycloalkyl group which may have a substituent, a mono- or di(C1-C6 alkyl)amino group, or a carbamoyl group which may have a substituent. When at least 1 of R4 is a C1-C8 alkyl group having a substituent, a C2-C6 alkenyl group having a substituent, a C1-C6 alkoxy group having a substituent, a C3-C7 cycloalkyl group having a substituent, or a carbamoyl group having a substituent, the substituent represents a halogen atom, a carboxy group, a C1-C6 alkoxy group, a hydroxyl group, a C1-C6 alkyl group which may have a hydroxyl group as a substituent, an unsaturated hydrocarbon group which is monocyclic and has 5 to 10 members, a carbamoyl group which may have a C1-C6 alkyl group or an unsaturated hydrocarbon group which is monocyclic and has 5 to 10 members as a substituent, a (C2-C7 acyl)oxy group, an amino group which may have a C1-C6 alkyl group or a C2-C7 acyl group as a substituent, a C3-C7 cycloalkyl group which may have a hydroxyl group as a substituent, or a (C1-C6 alkoxy)(C1-C6 alkyl) group. When there are a plurality of such substituents, they may be the same or different.R5 and R6 are the same or different and each represents a hydrogen atom or a C1-C6 alkyl group, or R5 and R6 may combine together to form an oxo group or a thioxo group. When R5 and R6 are the same or different and each represents a hydrogen atom or a C1-C6 alkyl group, at least one of R5 and R6 is a hydrogen atom. l represents an integer of 0 to 2, m represents an integer of 0 to 2, and n represents an integer of 0 to 5. When l is 2, the two R2s may be the same or different. When m is 2, the two R3s may be the same or different. When n is 2 to 5, the 2 to 5 R4s may be the same or different. ] An antitumor agent which is a compound represented by 8. An antitumor agent comprising a biphenyl compound or a salt thereof and another antitumor agent, wherein the biphenyl compound has the following general formula (I) [wherein, ring A represents a nitrogen-containing saturated heterocyclic group having 1 to 3 nitrogen atoms, 0 to 1 sulfur atom and 0 to 2 oxygen atoms as heteroatoms, and being a monocyclic, bridged cyclic or spirocyclic 4- to 14-membered ring; ring B represents a monocyclic or bicyclic unsaturated hydrocarbon group having 5 to 14 members, or may be substituted with an oxo group, having 0 to 4 nitrogen atoms, 0 to 2 sulfur atoms and 0 to 3 oxygen atoms as heteroatoms, and having at least 1 of nitrogen atom, sulfur atom and oxygen atom, and being a monocyclic or bicyclic unsaturated heterocyclic group having 5 to 14 members; R1 represents a nitro group or a cyano group; R2 represents a halogen atom; R3 represents an amino group, a mono- or di(C1-C6 alkyl)amino group, a (C3-C7 cycloalkyl)amino group, or a C1-C6 alkyl group; R4 represents a halogen atom, a nitro group, a cyano group, a carboxy group, a C1-C8 alkyl group which may have a substituent, a C2-C6 alkenyl group which may have a substituent, a C1-C6 alkoxy group which may have a substituent, a C3-C7 cycloalkyl group which may have a substituent, a mono- or di(C1-C6 alkyl)amino group, or a carbamoyl group which may have a substituent. When at least one of R4 is a C1-C8 alkyl group having a substituent, a C2-C6 alkenyl group having a substituent, a C1-C6 alkoxy group having a substituent, a C3-C7 cycloalkyl group having a substituent, or a carbamoyl group having a substituent, the substituent represents a halogen atom, a carboxy group, a C1-C6 alkoxy group, a hydroxyl group, a C1-C6 alkyl group which may have a hydroxyl group as a substituent, a monocyclic unsaturated hydrocarbon group having 5 to 10 members, a carbamoyl group which may have a C1-C6 alkyl group or a monocyclic unsaturated hydrocarbon group having 5 to 10 members as a substituent, a (C2-C7 acyl)oxy group, an amino group which may have a C1-C6 alkyl group or a C2-C7 acyl group as a substituent, a C3-C7 cycloalkyl group which may have a hydroxyl group as a substituent, or a (C1-C6 alkoxy)(C1-C6 alkyl) group. When a plurality of the substituents are present, they may be the same or different.R5 and R6 are the same or different and each represents a hydrogen atom or a C1-C6 alkyl group, or R5 and R6 may together form an oxo group or a thioxo group. When R5 and R6 are the same or different and each represents a hydrogen atom or a C1-C6 alkyl group, at least one of R5 and R6 is a hydrogen atom. l represents an integer of 0 to 2, m represents an integer of 0 to 2, and n represents an integer of 0 to 5. When l is 2, the two R2s may be the same or different. When m is 2, the two R3s may be the same or different. When n is 2 to 5, the 2 to 5 R4s may be the same or different. ] An antitumor agent which is a compound represented by 9. The following general formula (I) [In the formula, ring A represents a nitrogen-containing saturated heterocyclic group having 1 to 3 nitrogen atoms, 0 to 1 sulfur atom, and 0 to 2 oxygen atoms as heteroatoms, and being a monocyclic, bridged cyclic or spiro cyclic 4- to 14-membered ring; ring B represents an unsaturated hydrocarbon group which is monocyclic or bicyclic and has 5 to 14 members, or may be substituted with an oxo group, and has 0 to 4 nitrogen atoms, 0 to 2 sulfur atoms, and 0 to 3 oxygen atoms as heteroatoms, and has at least 1 of nitrogen atom, sulfur atom, and oxygen atom, and represents an unsaturated heterocyclic group which is monocyclic or bicyclic and has 5 to 14 members; R1 represents a nitro group or a cyano group; R2 represents a halogen atom; R3 represents an amino group, a mono- or di(C1-C6 alkyl)amino group, a (C3-C7 cycloalkyl)amino group, or a C1-C6 alkyl group; R4 represents a halogen atom, a nitro group, a cyano group, a carboxy group, a C1-C8 alkyl group which may have a substituent, a C2-C6 alkenyl group which may have a substituent, a C1-C6 alkoxy group which may have a substituent, a C3-C7 cycloalkyl group which may have a substituent, a mono- or di(C1-C6 alkyl)amino group, or a carbamoyl group which may have a substituent. When at least 1 of R4 is a C1-C8 alkyl group having a substituent, a C2-C6 alkenyl group having a substituent, a C1-C6 alkoxy group having a substituent, a C3-C7 cycloalkyl group having a substituent, or a carbamoyl group having a substituent, the substituent represents a halogen atom, a carboxy group, a C1-C6 alkoxy group, a hydroxyl group, a C1-C6 alkyl group which may have a hydroxyl group as a substituent, an unsaturated hydrocarbon group which is monocyclic and has 5 to 10 members, a carbamoyl group which may have a C1-C6 alkyl group or an unsaturated hydrocarbon group which is monocyclic and has 5 to 10 members as a substituent, a (C2-C7 acyl)oxy group, an amino group which may have a C1-C6 alkyl group or a C2-C7 acyl group as a substituent, a C3-C7 cycloalkyl group which may have a hydroxyl group as a substituent, or a (C1-C6 alkoxy)(C1-C6 alkyl) group. When there are a plurality of the substituents, they may be the same or different.R5 and R6 are the same or different and each represents a hydrogen atom or a C1-C6 alkyl group, or R5 and R6 may together form an oxo group or a thioxo group. When R5 and R6 are the same or different and each represents a hydrogen atom or a C1-C6 alkyl group, at least one of R5 and R6 is a hydrogen atom. l represents an integer of 0 to 2, m represents an integer of 0 to 2, and n represents an integer of 0 to 5. When l is 2, the two R2s may be the same or different. When m is 2, the two R3s may be the same or different. When n is 2 to 5, the 2 to 5 R4s may be the same or different. A pharmaceutical composition for preventing and / or treating tumors, comprising a biphenyl compound represented by the formula or a salt thereof and another antitumor agent.

10. A biphenyl compound or a salt thereof for enhancing the antitumor effect of another antitumor agent, which has the following general formula (I) [In the formula, ring A represents a nitrogen-containing saturated heterocyclic group having 1 to 3 nitrogen atoms, 0 to 1 sulfur atom and 0 to 2 oxygen atoms as heteroatoms, and being a 4- to 14-membered monocyclic, bridged cyclic or spirocyclic group; ring B represents an unsaturated hydrocarbon group having 5 to 14 members which is monocyclic or bicyclic, or may be substituted with an oxo group, and having 0 to 4 nitrogen atoms, 0 to 2 sulfur atoms and 0 to 3 oxygen atoms as heteroatoms, and having at least 1 of nitrogen atom, sulfur atom and oxygen atom, and being an unsaturated heterocyclic group having 5 to 14 members which is monocyclic or bicyclic; R1 represents a nitro group or a cyano group; R2 represents a halogen atom; R3 represents an amino group, a mono- or di(C1-C6 alkyl)amino group, a (C3-C7 cycloalkyl)amino group or a C1-C6 alkyl group; R4 represents a halogen atom, a nitro group, a cyano group, a carboxy group, a C1-C8 alkyl group which may have a substituent, a C2-C6 alkenyl group which may have a substituent, a C1-C6 alkoxy group which may have a substituent, a C3-C7 cycloalkyl group which may have a substituent, a mono- or di(C1-C6 alkyl)amino group, or a carbamoyl group which may have a substituent. When at least 1 of R4 is a C1-C8 alkyl group having a substituent, a C2-C6 alkenyl group having a substituent, a C1-C6 alkoxy group having a substituent, a C3-C7 cycloalkyl group having a substituent or a carbamoyl group having a substituent, the substituent represents a halogen atom, a carboxy group, a C1-C6 alkoxy group, a hydroxyl group, a C1-C6 alkyl group which may have a hydroxyl group as a substituent, an unsaturated hydrocarbon group having 5 to 10 members which is monocyclic, a carbamoyl group which may have a C1-C6 alkyl group or an unsaturated hydrocarbon group having 5 to 10 members which is monocyclic as a substituent, a (C2-C7 acyl)oxy group, an amino group which may have a C1-C6 alkyl group or a C2-C7 acyl group as a substituent, a C3-C7 cycloalkyl group which may have a hydroxyl group as a substituent, or a (C1-C6 alkoxy)(C1-C6 alkyl) group. When a plurality of the substituents exist, they may be the same or different.R5 and R6 are the same or different and each represents a hydrogen atom or a C1-C6 alkyl group, or R5 and R6 may combine together to form an oxo group or a thioxo group. When R5 and R6 are the same or different and each represents a hydrogen atom or a C1-C6 alkyl group, at least one of R5 and R6 is a hydrogen atom. l represents an integer of 0 to 2, m represents an integer of 0 to 2, and n represents an integer of 0 to 5. When l is 2, the two R2s may be the same or different. When m is 2, the two R3s may be the same or different. When n is 2 to 5, the 2 to 5 R4s may be the same or different.], a biphenyl compound represented thereby or a salt thereof.

11. Use of a biphenyl compound or a salt thereof for enhancing the antitumor effect of another antitumor agent, the following general formula (I) [In the formula, ring A represents a nitrogen-containing saturated heterocyclic group having 1 to 3 nitrogen atoms, 0 to 1 sulfur atom, and 0 to 2 oxygen atoms as heteroatoms, and being a monocyclic, bridged cyclic or spirocyclic 4- to 14-membered ring; ring B represents an unsaturated hydrocarbon group having 5 to 14 members which is monocyclic or bicyclic, or may be substituted with an oxo group, and having 0 to 4 nitrogen atoms, 0 to 2 sulfur atoms, and 0 to 3 oxygen atoms as heteroatoms, and having at least 1 of nitrogen atom, sulfur atom and oxygen atom, and being an unsaturated heterocyclic group having 5 to 14 members which is monocyclic or bicyclic; R1 represents a nitro group or a cyano group; R2 represents a halogen atom; R3 represents an amino group, a mono- or di(C1-C6 alkyl)amino group, a (C3-C7 cycloalkyl)amino group, or a C1-C6 alkyl group; R4 represents a halogen atom, a nitro group, a cyano group, a carboxy group, a C1-C8 alkyl group which may have a substituent, a C2-C6 alkenyl group which may have a substituent, a C1-C6 alkoxy group which may have a substituent, a C3-C7 cycloalkyl group which may have a substituent, a mono- or di(C1-C6 alkyl)amino group, or a carbamoyl group which may have a substituent. When at least one of R4 is a C1-C8 alkyl group having a substituent, a C2-C6 alkenyl group having a substituent, a C1-C6 alkoxy group having a substituent, a C3-C7 cycloalkyl group having a substituent, or a carbamoyl group having a substituent, the substituent represents a halogen atom, a carboxy group, a C1-C6 alkoxy group, a hydroxyl group, a C1-C6 alkyl group which may have a hydroxyl group as a substituent, an unsaturated hydrocarbon group having 5 to 10 members which is monocyclic, a carbamoyl group which may have a C1-C6 alkyl group or an unsaturated hydrocarbon group having 5 to 10 members which is monocyclic as a substituent, a (C2-C7 acyl)oxy group, an amino group which may have a C1-C6 alkyl group or a C2-C7 acyl group as a substituent, a C3-C7 cycloalkyl group which may have a hydroxyl group as a substituent, or a (C1-C6 alkoxy)(C1-C6 alkyl) group. When there are a plurality of such substituents, they may be the same or different.R5 and R6 are the same or different and each represents a hydrogen atom or a C1-C6 alkyl group, or R5 and R6 may combine together to form an oxo group or a thioxo group. When R5 and R6 are the same or different and each represents a hydrogen atom or a C1-C6 alkyl group, at least one of R5 and R6 is a hydrogen atom. l represents an integer of 0 to 2, m represents an integer of 0 to 2, and n represents an integer of 0 to 5. When l is 2, the two R2 groups may be the same or different. When m is 2, the two R3 groups may be the same or different. When n is 2 to 5, the 2 to 5 R4 groups may be the same or different.], use of a biphenyl compound represented by the formula or a salt thereof.

12. Use of a biphenyl compound or a salt thereof for producing an antitumor effect enhancer of another antitumor agent, the following general formula (I) [In the formula, ring A represents a nitrogen-containing saturated heterocyclic group having 1 to 3 nitrogen atoms, 0 to 1 sulfur atom, and 0 to 2 oxygen atoms as heteroatoms, and being a monocyclic, bridged cyclic or spirocyclic 4- to 14-membered ring; ring B represents an unsaturated hydrocarbon group having 5 to 14 members which is monocyclic or bicyclic, or may be substituted with an oxo group, and having 0 to 4 nitrogen atoms, 0 to 2 sulfur atoms, and 0 to 3 oxygen atoms as heteroatoms, and having at least 1 of nitrogen atom, sulfur atom and oxygen atom, and representing an unsaturated heterocyclic group having 5 to 14 members which is monocyclic or bicyclic; R1 represents a nitro group or a cyano group; R2 represents a halogen atom; R3 represents an amino group, a mono- or di(C1-C6 alkyl)amino group, a (C3-C7 cycloalkyl)amino group, or a C1-C6 alkyl group; R4 represents a halogen atom, a nitro group, a cyano group, a carboxy group, a C1-C8 alkyl group which may have a substituent, a C2-C6 alkenyl group which may have a substituent, a C1-C6 alkoxy group which may have a substituent, a C3-C7 cycloalkyl group which may have a substituent, a mono- or di(C1-C6 alkyl)amino group, or a carbamoyl group which may have a substituent. When at least one of R4 is a C1-C8 alkyl group having a substituent, a C2-C6 alkenyl group having a substituent, a C1-C6 alkoxy group having a substituent, a C3-C7 cycloalkyl group having a substituent, or a carbamoyl group having a substituent, the substituent represents a halogen atom, a carboxy group, a C1-C6 alkoxy group, a hydroxyl group, a C1-C6 alkyl group which may have a hydroxyl group as a substituent, an unsaturated hydrocarbon group having 5 to 10 members which is monocyclic, a carbamoyl group which may have a C1-C6 alkyl group or an unsaturated hydrocarbon group having 5 to 10 members which is monocyclic as a substituent, a (C2-C7 acyl)oxy group, an amino group which may have a C1-C6 alkyl group or a C2-C7 acyl group as a substituent, a C3-C7 cycloalkyl group which may have a hydroxyl group as a substituent, or a (C1-C6 alkoxy)(C1-C6 alkyl) group. When a plurality of the substituents exist, they may be the same or different.R5 and R6 are the same or different and each represents a hydrogen atom or a C1-C6 alkyl group, or R5 and R6 may combine together to form an oxo group or a thioxo group. When R5 and R6 are the same or different and each represents a hydrogen atom or a C1-C6 alkyl group, at least one of R5 and R6 is a hydrogen atom. l represents an integer of 0 to 2, m represents an integer of 0 to 2, and n represents an integer of 0 to 5. When l is 2, the two R2s may be the same or different. When m is 2, the two R3s may be the same or different. When n is 2 to 5, the 2 to 5 R4s may be the same or different. ] Use of a biphenyl compound represented by the formula or a salt thereof.

13. The following general formula (I) [In the formula, ring A represents a nitrogen-containing saturated heterocyclic group having 1 to 3 nitrogen atoms, 0 to 1 sulfur atom, and 0 to 2 oxygen atoms as heteroatoms, and being a monocyclic, bridged cyclic or spirocyclic 4- to 14-membered ring; ring B represents a monocyclic or bicyclic unsaturated hydrocarbon group having 5 to 14 carbon atoms, which may be substituted with an oxo group, and having 0 to 4 nitrogen atoms, 0 to 2 sulfur atoms, and 0 to 3 oxygen atoms as heteroatoms, and having at least 1 of nitrogen atom, sulfur atom and oxygen atom, and being a monocyclic or bicyclic 5- to 14-membered unsaturated heterocyclic group; R1 represents a nitro group or a cyano group; R2 represents a halogen atom; R3 represents an amino group, a mono- or di-(C1-C6 alkyl)amino group, a (C3-C7 cycloalkyl)amino group, or a C1-C6 alkyl group; R4 represents a halogen atom, a nitro group, a cyano group, a carboxy group, a C1-C8 alkyl group which may have a substituent, a C2-C6 alkenyl group which may have a substituent, a C1-C6 alkoxy group which may have a substituent, a C3-C7 cycloalkyl group which may have a substituent, a mono- or di-(C1-C6 alkyl)amino group, or a carbamoyl group which may have a substituent. When at least one of R4 is a C1-C8 alkyl group having a substituent, a C2-C6 alkenyl group having a substituent, a C1-C6 alkoxy group having a substituent, a C3-C7 cycloalkyl group having a substituent, or a carbamoyl group having a substituent, the substituent represents a halogen atom, a carboxy group, a C1-C6 alkoxy group, a hydroxyl group, a C1-C6 alkyl group which may have a hydroxyl group as a substituent, a monocyclic 5- to 10-membered unsaturated hydrocarbon group, a carbamoyl group which may have a C1-C6 alkyl group or a monocyclic 5- to 10-membered unsaturated hydrocarbon group as a substituent, a (C2-C7 acyl)oxy group, an amino group which may have a C1-C6 alkyl group or a C2-C7 acyl group as a substituent, a C3-C7 cycloalkyl group which may have a hydroxyl group as a substituent, or a (C1-C6 alkoxy)(C1-C6 alkyl) group. When a plurality of the substituents exist, they may be the same or different.R5 and R6 are the same or different and each represents a hydrogen atom or a C1-C6 alkyl group, or R5 and R6 may combine together to form an oxo group or a thioxo group. When R5 and R6 are the same or different and each represents a hydrogen atom or a C1-C6 alkyl group, at least one of R5 and R6 is a hydrogen atom. l represents an integer of 0 to 2, m represents an integer of 0 to 2, and n represents an integer of 0 to 5. When l is 2, the two R2s may be the same or different. When m is 2, the two R3s may be the same or different. When n is 2 to 5, the 2 to 5 R4s may be the same or different. A method for preventing and / or treating a tumor, comprising the step of administering to a patient a therapeutically and / or prophylactically effective amount of a biphenyl compound represented by the following formula or a salt thereof in combination with another antitumor agent.

14. The following general formula (I) [wherein, ring A represents a nitrogen-containing saturated heterocyclic group having 1 to 3 nitrogen atoms, 0 to 1 sulfur atom and 0 to 2 oxygen atoms as heteroatoms, and being a 4- to 14-membered monocyclic, bridged cyclic or spirocyclic group; ring B represents an unsaturated hydrocarbon group having 5 to 14 members which is monocyclic or bicyclic, or may be substituted with an oxo group, having 0 to 4 nitrogen atoms, 0 to 2 sulfur atoms and 0 to 3 oxygen atoms as heteroatoms, and having at least 1 of nitrogen atom, sulfur atom and oxygen atom, and being an unsaturated heterocyclic group having 5 to 14 members which is monocyclic or bicyclic; R1 represents a nitro group or a cyano group; R2 represents a halogen atom; R3 represents an amino group, a mono- or di(C1-C6 alkyl)amino group, a (C3-C7 cycloalkyl)amino group or a C1-C6 alkyl group; R4 represents a halogen atom, a nitro group, a cyano group, a carboxy group, a C1-C8 alkyl group which may have a substituent, a C2-C6 alkenyl group which may have a substituent, a C1-C6 alkoxy group which may have a substituent, a C3-C7 cycloalkyl group which may have a substituent, a mono- or di(C1-C6 alkyl)amino group, or a carbamoyl group which may have a substituent; when at least one of R4 is a C1-C8 alkyl group having a substituent, a C2-C6 alkenyl group having a substituent, a C1-C6 alkoxy group having a substituent, a C3-C7 cycloalkyl group having a substituent or a carbamoyl group having a substituent, the substituent represents a halogen atom, a carboxy group, a C1-C6 alkoxy group, a hydroxyl group, a C1-C6 alkyl group which may have a hydroxyl group as a substituent, an unsaturated hydrocarbon group which is monocyclic and has 5 to 10 members, a carbamoyl group which may have a C1-C6 alkyl group or an unsaturated hydrocarbon group which is monocyclic and has 5 to 10 members as a substituent, a (C2-C7 acyl)oxy group, an amino group which may have a C1-C6 alkyl group or a C2-C7 acyl group as a substituent, a C3-C7 cycloalkyl group which may have a hydroxyl group as a substituent, or a (C1-C6 alkoxy)(C1-C6 alkyl) group. When a plurality of the substituents exist, they may be the same or different.R5 and R6 are the same or different and each represents a hydrogen atom or a C1-C6 alkyl group, or R5 and R6 may combine together to form an oxo group or a thioxo group. When R5 and R6 are the same or different and each represents a hydrogen atom or a C1-C6 alkyl group, at least one of R5 and R6 is a hydrogen atom. l represents an integer of 0 to 2, m represents an integer of 0 to 2, and n represents an integer of 0 to 5. When l is 2, the two R2s may be the same or different. When m is 2, the two R3s may be the same or different. When n is 2 to 5, the 2 to 5 R4s may be the same or different. A method for preventing and / or treating a tumor, comprising the step of administering to a cancer patient administered with another antitumor agent an effective amount for treating and / or preventing a biphenyl compound represented by the formula or a salt thereof.

15. The following general formula (I) [wherein, ring A represents a nitrogen-containing saturated heterocyclic group having 1 to 3 nitrogen atoms, 0 to 1 sulfur atom and 0 to 2 oxygen atoms as heteroatoms, and being a monocyclic, bridged cyclic or spiro cyclic 4- to 14-membered ring; ring B represents a monocyclic or bicyclic unsaturated hydrocarbon group having 5 to 14 members, or may be substituted with an oxo group, having 0 to 4 nitrogen atoms, 0 to 2 sulfur atoms and 0 to 3 oxygen atoms as heteroatoms, and having at least 1 of nitrogen atom, sulfur atom and oxygen atom, and representing a monocyclic or bicyclic unsaturated heterocyclic group having 5 to 14 members; R1 represents a nitro group or a cyano group; R2 represents a halogen atom; R3 represents an amino group, a mono- or di-(C1-C6 alkyl)amino group, a (C3-C7 cycloalkyl)amino group or a C1-C6 alkyl group; R4 represents a halogen atom, a nitro group, a cyano group, a carboxy group, a C1-C8 alkyl group which may have a substituent, a C2-C6 alkenyl group which may have a substituent, a C1-C6 alkoxy group which may have a substituent, a C3-C7 cycloalkyl group which may have a substituent, a mono- or di-(C1-C6 alkyl)amino group, or a carbamoyl group which may have a substituent; when at least 1 of R4 is a C1-C8 alkyl group having a substituent, a C2-C6 alkenyl group having a substituent, a C1-C6 alkoxy group having a substituent, a C3-C7 cycloalkyl group having a substituent or a carbamoyl group having a substituent, the substituent represents a halogen atom, a carboxy group, a C1-C6 alkoxy group, a hydroxyl group, a C1-C6 alkyl group which may have a hydroxyl group as a substituent, a monocyclic unsaturated hydrocarbon group having 5 to 10 members, a carbamoyl group which may have a C1-C6 alkyl group or a monocyclic unsaturated hydrocarbon group having 5 to 10 members as a substituent, a (C2-C7 acyl)oxy group, an amino group which may have a C1-C6 alkyl group or a C2-C7 acyl group as a substituent, a C3-C7 cycloalkyl group which may have a hydroxyl group as a substituent, or a (C1-C6 alkoxy)(C1-C6 alkyl) group. When a plurality of the substituents exist, they may be the same or different.R5 and R6 are the same or different and each represents a hydrogen atom or a C1-C6 alkyl group, or R5 and R6 may together form an oxo group or a thioxo group. When R5 and R6 are the same or different and each represents a hydrogen atom or a C1-C6 alkyl group, at least one of R5 and R6 is a hydrogen atom. l represents an integer of 0 to 2, m represents an integer of 0 to 2, and n represents an integer of 0 to 5. When l is 2, the two R2s may be the same or different. When m is 2, the two R3s may be the same or different. When n is 2 to 5, the 2 to 5 R4s may be the same or different. ] A method for enhancing antitumor effect, which comprises administering to a cancer patient administered with another antitumor agent an effective amount for treatment and / or prevention of a biphenyl compound represented by the formula or a salt thereof.

16. A product comprising a biphenyl compound or a salt thereof and another antitumor agent as a combined preparation for use simultaneously, sequentially, or at intervals when preventing and / or treating tumors, wherein the biphenyl compound has the following general formula (I) [In the formula, ring A represents a nitrogen-containing saturated heterocyclic group having 1 to 3 nitrogen atoms, 0 to 1 sulfur atom, and 0 to 2 oxygen atoms as heteroatoms, and being a monocyclic, bridged cyclic or spirocyclic 4- to 14-membered ring; ring B represents an unsaturated hydrocarbon group which is monocyclic or bicyclic and has 5 to 14 members, or may be substituted with an oxo group, and has 0 to 4 nitrogen atoms, 0 to 2 sulfur atoms, and 0 to 3 oxygen atoms as heteroatoms, and has at least 1 of nitrogen atom, sulfur atom and oxygen atom, and represents an unsaturated heterocyclic group which is monocyclic or bicyclic and has 5 to 14 members; R1 represents a nitro group or a cyano group; R2 represents a halogen atom; R3 represents an amino group, a mono- or di(C1-C6 alkyl)amino group, a (C3-C7 cycloalkyl)amino group, or a C1-C6 alkyl group; R4 represents a halogen atom, a nitro group, a cyano group, a carboxy group, a C1-C8 alkyl group which may have a substituent, a C2-C6 alkenyl group which may have a substituent, a C1-C6 alkoxy group which may have a substituent, a C3-C7 cycloalkyl group which may have a substituent, a mono- or di(C1-C6 alkyl)amino group, or a carbamoyl group which may have a substituent. When at least one of R4 is a C1-C8 alkyl group having a substituent, a C2-C6 alkenyl group having a substituent, a C1-C6 alkoxy group having a substituent, a C3-C7 cycloalkyl group having a substituent, or a carbamoyl group having a substituent, the substituent represents a halogen atom, a carboxy group, a C1-C6 alkoxy group, a hydroxyl group, a C1-C6 alkyl group which may have a hydroxyl group as a substituent, an unsaturated hydrocarbon group which is monocyclic and has 5 to 10 members, a carbamoyl group which may have a C1-C6 alkyl group or an unsaturated hydrocarbon group which is monocyclic and has 5 to 10 members as a substituent, a (C2-C7 acyl)oxy group, an amino group which may have a C1-C6 alkyl group or a C2-C7 acyl group as a substituent, a C3-C7 cycloalkyl group which may have a hydroxyl group as a substituent, or a (C1-C6 alkoxy)(C1-C6 alkyl) group. When a plurality of the substituents exist, they may be the same or different.R5 and R6 are the same or different and each represents a hydrogen atom or a C1-C6 alkyl group, or R5 and R6 may combine together to form an oxo group or a thioxo group. When R5 and R6 are the same or different and each represents a hydrogen atom or a C1-C6 alkyl group, at least one of R5 and R6 is a hydrogen atom. l represents an integer of 0 to 2, m represents an integer of 0 to 2, and n represents an integer of 0 to 5. When l is 2, the two R2s may be the same or different. When m is 2, the two R3s may be the same or different. When n is 2 to 5, the 2 to 5 R4s may be the same or different. ] A product which is a biphenyl compound represented by 17. The following general formula (I) [In the formula, ring A represents a nitrogen-containing saturated heterocyclic group having 1 to 3 nitrogen atoms, 0 to 1 sulfur atom and 0 to 2 oxygen atoms as heteroatoms, and being a monocyclic, bridged cyclic or spiro cyclic 4- to 14-membered ring; ring B represents an unsaturated hydrocarbon group which is monocyclic or bicyclic and has 5 to 14 members, or may be substituted with an oxo group, and has 0 to 4 nitrogen atoms, 0 to 2 sulfur atoms and 0 to 3 oxygen atoms as heteroatoms, and has at least 1 of nitrogen atom, sulfur atom and oxygen atom, and represents an unsaturated heterocyclic group which is monocyclic or bicyclic and has 5 to 14 members; R1 represents a nitro group or a cyano group; R2 represents a halogen atom; R3 represents an amino group, a mono- or di-(C1-C6 alkyl)amino group, a (C3-C7 cycloalkyl)amino group, or a C1-C6 alkyl group; R4 represents a halogen atom, a nitro group, a cyano group, a carboxy group, a C1-C8 alkyl group which may have a substituent, a C2-C6 alkenyl group which may have a substituent, a C1-C6 alkoxy group which may have a substituent, a C3-C7 cycloalkyl group which may have a substituent, a mono- or di-(C1-C6 alkyl)amino group, or a carbamoyl group which may have a substituent. When at least 1 of R4 is a C1-C8 alkyl group having a substituent, a C2-C6 alkenyl group having a substituent, a C1-C6 alkoxy group having a substituent, a C3-C7 cycloalkyl group having a substituent, or a carbamoyl group having a substituent, the substituent represents a halogen atom, a carboxy group, a C1-C6 alkoxy group, a hydroxyl group, a C1-C6 alkyl group which may have a hydroxyl group as a substituent, an unsaturated hydrocarbon group which is monocyclic and has 5 to 10 members, a carbamoyl group which may have a C1-C6 alkyl group or an unsaturated hydrocarbon group which is monocyclic and has 5 to 10 members as a substituent, a (C2-C7 acyl)oxy group, an amino group which may have a C1-C6 alkyl group or a C2-C7 acyl group as a substituent, a C3-C7 cycloalkyl group which may have a hydroxyl group as a substituent, or a (C1-C6 alkoxy)(C1-C6 alkyl) group. When a plurality of such substituents exist, they may be the same or different.R5 and R6 are the same or different and each represents a hydrogen atom or a C1-C6 alkyl group, or R5 and R6 may together form an oxo group or a thioxo group. When R5 and R6 are the same or different and each represents a hydrogen atom or a C1-C6 alkyl group, at least one of R5 and R6 is a hydrogen atom. l represents an integer of 0 to 2, m represents an integer of 0 to 2, and n represents an integer of 0 to 5. When l is 2, the two R2s may be the same or different. When m is 2, the two R3s may be the same or different. When n is 2 to 5, the 2 to 5 R4s may be the same or different. A combination of a biphenyl compound represented by the formula or a salt thereof and another antitumor agent.